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ABBREVIATIONS 
ACPA Anti-citrullinated protein antibodies 
ACR American College of Rheumatology 
AMOTL2 Angiomotin like 2 
Anti-CCP Anti-cyclic citrullinated protein 
APC Antigen presenting cell 
APS Ammonium persulfate 
bHLH Basic helix-loop-helix 
BLK B lymphoid tyrosine kinase 
bp Base pair 
BSA Bovine serum albumin 
bZIP Basic leucine zipper 
cAMP Cyclic adenosine monophosphate 
can Canonical 
CD Cluster of differentiation 
cDNA Complementary DNA 
cds Coding sequence 
ChIP Chromatin Immunoprecipitation 
CIA Collagen-induced arthritis 
CNS Conserved non-coding sequence 
Com Complementary 
CRP C-reactive protein 
CsA Cyclosporin A 
CTLA-4 Cytotoxic T lymphocyte-associated antigen 4 
DAS28 Disease activity score in 28 joints 
DC Dendritic cell 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferases 
dNTP Deoxyribonucleotide triphosphate 
ds Double-stranded 
DTT Dithiothreitol 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ESR Erythrocyte sedimentation rate 
EULAR European League Against Rheumatism 
FACS Fluorescence activated cell sorting 
FAM Fluorescein amidite 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FLS Fibroblast-like type B synoviocyte 
For Forward 
Foxp3 Forkhead box P3 
GARP Glycoprotein A repetitions predominant 
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GATA GATA-binding factor 
gDNA Genomic DNA 
GSP Gene specific primer 
H3ac Pan-acetylated histone H3 
H3K4me3 Trimethylated lysine 4 at histone H3 
H3K27me3 Trimethylated lysine 27 at histone H3 
HC Healthy control 
HEPES 4-(2-hydroxyethyl)piperazin-1-ethanesulfonic acid 
HLA Human leukocyte antigen 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
Ig Immunoglobulin 
IκB Inhibitor of NF-κB proteins 
IKK IκB kinase 
IL Interleukin 
Ion Ionomycin 
IPEX Immunodeficiency, polyendocrinopathy, and enteropathy, X-
linked syndrome 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IRAK IL-1 receptor associated kinase 
iTreg Induced regulatory T cell 
JAK Janus kinase 
kDa Kilo Dalton 
KDM5B Lysine-specific demethylase 5B 
KMT2A Lysine N-methyltransferase 2A 
LAG3 Lymphocyte activation protein 3 
LB Lysogeny broth 
LD Linkage disequilibrium 
LRR Leucine rich repeat 
LTBP Latent TGF-β binding protein 
MACS Magnetic activated cell sorting 
MafF V-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
MBD Methyl-CpG binding domain 
MFI Mean fluorescence intensity 
MGB Minor groove binder 
MHC Major histocompatibility complex 
MLL Mixed-lineage leukemia 
miRNA Micro RNA 
mRNA Messenger RNA 
n.a. Not applicable 
n.d. Not determined 
NFAT Nuclear factor of activated T cells 
NF-κB Nuclear factor kappa B 
NFQ Non-fluorescent quencher 
NHS Normal human serum 
NK cells Natural killer cells 
nt Nucleotide 
PAGE Polyacrylamide gel electrophoresis 
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PCR Polymerase chain reaction 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PFA Paraformaldehyde 
PIC Protease inhibitor cocktail 
PIPES Piperazine-N,N‘-bis-2-ethanesulfonicacid 
PMA Phorbol myristate acetate 
PMSF Phenylmethylsulfonylfluorid 
pTreg Peripheral regulatory T cell 
RA Rheumatoid arthritis 
RACE Rapid amplification of cDNA ends 
Rb1 Retinoblastoma 1 
RbBP5 Retinoblastoma binding protein 5 
Rev Reverse 
RF Rheumatoid factor 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RXR Retinoic X receptor 
SAM S-Adenosylmethionine 
scr Scrambled 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SH2 Src-homology 2 
SJC28 Swollen joint count on 28 joints 
SLE Systemic lupus erythematosus 
SNP Single nucleotide polymorphism 
S.O.C medium Super Optimal Broth medium 
STAT Signal transducer and activator of transcription 
TAE Tris-Acetate-EDTA 
Taq Thermus aquaticus 
Tconv Conventional T cell 
TCR T cell receptor 
TEMED Tetramethylethylenediamine 
TGF Transforming growth factor 
Th cell T helper cell 
TJC28 Tender joint count on 28 joints 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRAF TNF receptor associated factor 
Treg Regulatory T cell 
TSS Transcription start site 
tTreg thymic regulatory T cell 
UTR Untranslated region 
wt wildtype 
X-Gal 5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
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SUMMARY 
Regulatory T cells (Tregs) contribute to peripheral tolerance and prevent autoimmune diseases, 
such as rheumatoid arthritis (RA). Understanding the molecular mechanisms underlying Treg 
phenotype and function and delineating the factors that might lead to failure of Treg suppressive 
capacity may disclose important therapeutic strategies for autoimmune diseases. 
In the first part of my thesis, I focused on the characterization of molecular mechanisms 
regulating expression of a Treg-specific surface molecule, glycoprotein A repetitions 
predominant (GARP). Two alternative promoters regulate GARP expression. I could show that 
transcription from the strong up-stream promoter was attenuated by binding of transcription 
factors to the intragenic down-stream promoter. DNA demethylation of several CpGs in the 
intragenic promoter ensured Treg-specific binding of the transcription factors, Foxp3, NFAT, 
and NF-κB. GARP expression upon T cell receptor stimulation was regulated by permissive 
histone modifications caused by replacement of the H3K4-specific demethylase, PLU-1, by 
Foxp3. GARP serves as a transporter of latent TGF-β. TGF-β together with retinoic acid is a 
critical factor for the generation of induced Tregs (iTregs). Recently, the transcription factor 
MafF was reported to be specifically downregulated during iTreg generation and upregulated 
during effector T cell differentiation. In this regard, I could demonstrate that overexpression of 
MafF during Treg induction attenuated TGF-β/retinoic acid-mediated Foxp3 expression 
suggesting a negative function of MafF on the induction of iTregs. 
In the second part of my thesis, molecular mechanisms underlying impaired function of Tregs in 
RA were analyzed. In collaborative work with my colleagues, we found that GARP expression 
was decreased in Tregs from RA patients. Interestingly, the down-stream promoter was 
demethylated in Tregs from RA patients compared to healthy controls suggesting that 
attenuation of the up-stream promoter might be a mechanism leading to the decreased GARP 
expression in RA. In addition, I found that three nucleotides in the GARP gene locus are highly 
polymorphic in patients with RA as compared to healthy controls. Thus, polymorphisms in the 
GARP gene locus might also contribute to decreased GARP expression in RA. Considering 
GARP function as a TGF-β transporter, changes in the transcriptional control of the Treg-
specific molecule, GARP, might contribute to the altered phenotype of Tregs in RA. 
Beside Treg-specific GARP expression, miRNA has been reported to influence the Treg 
phenotype and function. It has been previously shown that miR-146a is highly expressed in 
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Tregs. We found that in Tregs from RA patients miR-146a expression was decreased. Decreased 
miR-146a expression coincided with altered expression of its target genes, STAT1, TRAF6, and 
IRAK1 which are involved in regulation of cytokine expression. When we analyzed the 
production of several cytokines by Tregs from RA patients we found an increase in the 
production of pro-inflammatory cytokines indicating a pro-inflammatory phenotype of Tregs in 
patients with RA. Thus, decreased miR-146a expression might also contribute to the altered 
phenotype of Tregs in RA. 
In summary, in my PhD thesis I characterized Treg-specific GARP expression, as well as the 
effect of the transcription factor MafF on iTreg induction. Furthermore, I described several 
molecular mechanisms that might contribute to the impaired Treg phenotype and function in RA. 
These data might have important implications for understanding the pathogenesis of autoimmune 
diseases and might provide potential therapeutic targets. 
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ZUSAMMENFASSUNG 
Regulatorische T-Zellen (Tregs) haben eine entscheidende Rolle bei der peripheren Toleranz und 
bei der Unterdrückung von Autoimmunerkrankungen, wie rheumatoide Arthritis (RA). Analyse 
der molekularen Mechanismen, welche dem Phänotyp und der Funktion von Tregs zugrunde 
liegen und die eventuell zur Beeinträchtigung der Suppressivität von Tregs führen, könnten neue 
Therapieansätze für Autoimmunerkrankungen offenbaren. 
Im ersten Teil meiner Doktorarbeit habe ich molekularen Mechanismen charakterisiert, welche 
die Expression des Treg-spezifische Oberflächenmoleküls glycoprotein A repetitions 
predominant (GARP) regulieren. Zwei alternative Promotoren regulieren die Expression von 
GARP. Ich konnte zeigen, dass die Transkription des starken vorgeschalteten Promotors, durch 
die Bindung von Transkriptionsfaktoren an den intragenischen Promotor, abgeschwächt wird. 
Die Demethylierung mehrerer CpGs im intragenischen Promotor gewährleistet die Treg-
spezifische Bindung der Transkriptionsfaktoren Foxp3, NFAT und NF-κB. Der Austausch der 
H3K4-spezifischen Demethylase PLU-1 durch Foxp3 führte vermehrt zu permissiven 
Histonmodifikationen nach Aktivierung des T-Zell Rezeptors und zur Expression von GARP. 
GARP wurde als ein Transporter für latentes TGF-β beschrieben. TGF-β und Retinolsäure sind 
wichtige Faktoren zur Erzeugung von „induced“ Tregs (iTregs). Der Transkriptionsfaktor MafF 
würde kürzlich untersucht und ist spezifisch während der Entwicklung von iTregs 
herunterreguliert und während der Effektor-T-Zell-Differenzierung hochreguliert. In diesem 
Zusammenhang konnte ich zeigen, dass die Überexpression von MafF während der iTreg-
Induktion die TGF-β/Retinolsäure-vermittelte Foxp3-Expression hemmt.  Diese Ergebnisse 
lassen vermuten, dass MafF die Differenzierung von iTregs negativ beeinflusst. 
Im zweiten Teil meiner Doktorarbeit habe ich molekulare Mechanismen untersucht, die zu einer 
Beeinträchtigung der Funktionalität von Tregs in RA führen. In Zusammenarbeit mit meinen 
Kollegen konnten wir zeigen, dass die Expression von GARP in Tregs von RA-Patienten 
vermindert ist. Der nachgeschaltete Promotor war interessanterweise in Tregs von RA-Patienten 
im Vergleich zu Tregs von gesunden Spendern demethyliert. Das deutet darauf hin, dass die 
Hemmung des vorgeschalteten Promotors eventuell einen Mechanismus darstellt, der zur 
Reduktion von GARP in RA führt. Außerdem habe ich drei Nukleotide im GARP-Genlokus 
gefunden, die hoch polymorph in Patienten mit RA im Vergleich zu gesunden Spendern sind. 
Diese Ergebnisse weisen darauf hin, dass Polymorphismen möglicherweise zur Verminderung 
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der GARP-Expression in RA beitragen. Da GARP ein TGF-β-Transporter ist, könnten 
Veränderungen in der Expression des Treg-spezifischen Moleküls am abgeänderten Treg-
Phänotyp in RA mitwirken. 
Außer der Expression von GARP beeinflusst auch die Regulation durch miRNAs den Phänotyp 
und die Funktion der Tregs. Für miR-146a konnte bereits gezeigt werden, dass sie in Tregs 
hochreguliert ist. In diesem Zusammenhang konnten wir zeigen, dass die Expression von miR-
146a in Tregs von RA-Patienten vermindert ist. Die Reduktion von miR-146a traten zusammen 
mit einer veränderten Expression ihrer Zielgene STAT1, TRAF6 und IRAK1 auf, welche alle in 
die Expression von Zytokinen involviert sind. Wir konnten zeigen, dass Tregs von RA-Patienten 
mehr Zytokine produzierten als die von gesunden Spendern. Tregs von RA-Patienten wiesen 
somit einen pro-inflammatorischen Phänotyp auf. Folglich beeinflusst die verminderte 
Expression von miR-146a auch den Phänotyp von Tregs in RA. 
Zusammenfassend konnte ich in meiner Doktorarbeit die Treg-spezifische GARP-Expression 
charakterisieren, sowie den Effekt des Transkriptionsfaktors MafF auf die iTreg-Induktion 
beschreiben. Außerdem habe ich mehrere molekulare Mechanismen beschrieben, die eventuell 
eine Rolle für die verminderte Funktion und den veränderten Phänotyp von Tregs in RA spielen. 
Diese Daten sind wichtige Erkenntnisse für das Verständnis der Pathogenese von 
Autoimmunerkrankungen und bieten möglicherweise neue therapeutische Ansätze. 
 
INTRODUCTION  10 
1 INTRODUCTION 
1.1 T cells in the immune system 
The immune system has evolved to provide rapid and specific means for protecting hosts against 
viral, bacterial, fungal, or parasitic pathogens experienced over a lifetime (Alberts et al. 2002). 
Two types of immune response, innate and adaptive, interact cooperatively to assure host 
defense. The innate immunity establishes the first line of defense that is based on the action of 
macrophages and granulocytes. It is non-specific and short-lasting, but acts immediately after 
pathogen invasion and activates the later-acting adaptive immune response mainly executed by 
lymphocytes providing specific and long-lasting protection against pathogens (Janeway et al. 
2001). Lymphocytes are found in the circulation, in central lymphoid organs and tissues, such as 
spleen, tonsils, and lymph nodes. Thymus-derived lymphocytes (T cells) react directly against a 
foreign antigen that is presented to them on the surface of antigen-presenting cells (APCs). 
Dendritic cells (DCs) are the most effective APCs that can activate naïve T cells. In addition, 
macrophages are not as effective in presenting antigens to naïve T cells, but they are able to 
activate memory T cells. Upon antigen recognition, naïve T cells mature into effector cells and 
induce either cell-mediated immune responses initiated by cytotoxic T cells or humoral immune 
responses mediated by bone marrow-derived lymphocytes (B cells). The primary lymphoid 
organ indispensable for T cell development is the thymus. It provides the suitable 
microenvironment with specific combination of stromal cells, cytokines and chemokines to 
generate functional T cells from precursor cells (thymocytes) (Luckheeram et al. 2012). The T 
cell receptor (TCR) gene rearrangement and thymocyte selection are the critical steps in the 
development of mature T cells capable of recognizing an infinite range of antigens. First, T cells 
that are capable of interacting with major histocompatibility complex (MHC) molecules are 
selected by positive selection. Only those thymocytes that interact with MHC appropriately (i.e. 
not too strongly or too weakly) will receive a "survival signal". Subsequently, negative 
selection removes thymocytes that are capable of strongly binding with "self" MHC peptides 
thereby removing potential autoreactive T cells (Daniels et al. 2006; Klein et al. 2009). 
TCR constitutes of αβ- or γδ-chains bonded with five CD3 (CD, cluster of differentiation) 
subunits (γ, δ, µ, π, and ε). The TCR interacts with antigen-MHC complexes and mediates T cell 
activation signals, such as nuclear factor of activated T cells (NFAT) signaling or nuclear factor 
kappa B (NF-κB) activation (Shaw et al. 1988; Thaker et al. 2015). T cells can be distinguished 
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according to specific surface molecules. The precursors are CD4 and CD8 double-positive and 
differentiate into mature T cell subtypes (Luckheeram et al. 2012). Based on the interaction of 
the TCR of double-positive cells with MHC class I or II molecules, two subtypes of T cells can 
develop. CD8 T cells recognize endogenously synthesized antigens (such as viruses or tumor 
peptides) presented by MHC class I molecules and differentiate into cytotoxic effector T cells 
that can kill infected cells. 
CD4 T helper (Th) cells interact with MHC class II molecules presenting extracellular antigen 
peptides captured by professional APCs. CD4 Th cells carry out a variety of functions, ranging 
from activation of the cells of the innate immune system, B cells, cytotoxic T cells, as well as 
non-immune cells, and also play a critical role in the suppression of the immune reaction (Zhu et 
al. 2010). Continuing studies identified several subtypes of CD4 Th cells, such as conventional T 
cells (Tconvs) and regulatory T cells (Tregs). The differentiation of the lineages depends on the 
complex network of cytokine milieu of the microenvironment, concentration of antigens, type of 
APCs, costimulatory molecules, and consequent transcription factor production and epigenetic 
modifications. The main co-stimulatory receptor is CD28 which is expressed on all naïve T cells. 
Ligands of CD28 on DCs are CD80 (B7-1) and CD86 (B7-2) which are upregulated upon 
activation (Acuto et al. 2003). The initial source of cytokines is from APCs and innate immune 
cells. Subsequently, some cytokines are produced by T cells in an autocrine or paracrine manner. 
Tconvs can be further subdivided. Th1 and Th2 cells are known since 1986 when they were 
firstly described by Coffman and Mosmann (Mosmann et al. 1986). Th1 cells play a critical role 
in the defense against intracellular pathogens such as bacteria or protozoa (Annunziato et al. 
2009). Th1 cells mainly produce high amounts of interferon (IFN)-γ, interleukin (IL)-2, 
lymphotoxin-α, and tumor necrosis factor (TNF). The master regulator of Th1 differentiation, the 
T-box transcription factor, was found to be mainly dependent on signal transducer and activator 
of transcription (STAT)-1, which is activated by IFN-γ (Afkarian et al. 2002; Lighvani et al. 
2001). Th2 cell function is important for humoral immune responses to infections with 
helminthes (Annunziato et al. 2009). Signature cytokines are IL-4, IL-5, and IL-13 (Abbas et al. 
1996; Annunziato et al. 2009; Mosmann et al. 1986). IL-4 upregulates the Th2 master 
transcription factor, GATA binding factor (GATA)-3 (Kaplan et al. 1996; Zhu et al. 2001). IL-6 
plays a role in Th2 differentiation by inhibiting the Th1 lineage through IL-6-induced 
upregulation of suppressor of cytokine signaling 1 expression which interferes with STAT-1 
activation downstream to IFN-γ signaling (Diehl et al. 2000; Diehl et al. 2002).  Th17 cells are 
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characterized by the production of the signature cytokines IL-17A and IL-17F (Wei et al. 2007; 
Wilson et al. 2007). IL-1β, IL-6, IL-21, IL-23, and transforming growth factor (TGF)-β are the 
major signaling cytokines involved in Th17 differentiation, and retinoic acid receptor-related 
orphan receptor gamma-t is the master regulator (Acosta-Rodriguez et al. 2007; Bettelli et al. 
2006; Volpe et al. 2009; Yang et al. 2008).  
1.2 Regulatory T cells 
Positive and negative selection of T cells in the thymus is necessary to eliminate harmful 
autoreactive T cells however this process is not error-free. Some cells escape selection in the 
thymus. Evading autoreactive cells in the periphery have the potential to induce autoimmune 
diseases, such as rheumatoid arthritis (RA). To circumvent autoimmune reactions, several 
additional mechanisms for peripheral tolerance developed, such as Treg-mediated suppression. 
In the eighties, Shimon Sakaguchi firstly demonstrated the existence of Tregs and described their 
pivotal role in maintaining peripheral tolerance and preventing autoimmune diseases (Sakaguchi 
et al. 1985). Tregs constitute 5-10% of the CD4 Th cell population in the peripheral blood of 
healthy individuals. They express several Treg-specific molecules, like the alpha-chain of the IL-
2 receptor (CD25) or the master transcription factor forkhead box P3 (Foxp3). Scurfy mice or 
patients with the immunodeficiency, polyendocrinopathy, and enteropathy, X-linked (IPEX) 
syndrome lack detectable Tregs. Both have mutations in the Foxp3 gene. Because Foxp3 is 
encoded on the X-chromosome, the affected population is mainly males. It was shown that the 
scurfy phenotype can be rescue by the transfer of CD25+ Tregs (Fontenot et al. 2003). Thus, they 
can ameliorate the symptoms of autoimmune or inflammatory reactions (Frey et al. 2005; Read 
et al. 2000). Furthermore, Treg suppress immune responses against allergens, tumor cells, and 
infections (Belkaid 2008; Chatila 2005; Knutson et al. 2007). Tregs can be discriminated 
according to the anatomical location of their differentiation (Abbas et al. 2013). Foxp3+ Tregs 
that differentiate in the thymus are called tTregs. They can differentiate in the periphery and are 
named pTregs. Additionally, Tregs that are induced in vitro are referred to induced Tregs 
(iTregs). In this regard, TGF-β plays an important role in inducing Tregs (Huter et al. 2008). 
Tregs can exert their suppressive function mainly on CD4 and CD8 T cells, but are also able to 
control B cells, natural killer (NK) cells, DCs and other APCs (Schmidt et al. 2012). Treg-
mediated suppression involves cell contact and soluble factors. For instance, the co-inhibitory 
molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is widely expressed on Tregs 
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and leads to downregulation of CD80/CD86 on APCs, thereby inhibiting Tconv activation by 
APCs (Takahashi et al. 2000; Wing et al. 2008). Additionally, Tregs can target DCs via CTLA-4 
or lymphocyte activation protein 3 (LAG3). CTLA-4-CD80/CD86 interaction increases 
indolamine 2,3-dioxygenase (IDO) expression in DCs (Puccetti et al. 2007). This enzyme 
catalyzes the degradation of tryptophan to kynurenine, leading to starvation of Tconvs and to 
direct cell cycle arrest. 
 
Figure 1 Mechanisms of Treg suppression. (A) CTLA-4 or LAG3 on Treg can bind to CD80/CD86 or MHCII on 
DCs, respectively. Thereby, the enzyme IDO gets expressed which upregulates immunosuppressive substances. (B) 
Expression of perforin and granzyme A or B by Tregs leads to cell lysis and apoptosis of the target cell. (C) Tregs 
express CD39/CD73 on the surface. This results in the production of extracellular adenosine. Gap junctions can 
transport cyclic adenosine monophosphate (cAMP) directly into the target cell. This disrupts the metabolism. 
Furthermore, CD25 can capture IL-2 on the surface of Tregs making it unavailable to other T cells. (D) Tregs can 
produce inhibitory cytokines like IL-35, IL-10, and TGF-β. Adapted from (Vignali et al. 2008). 
Moreover, Tregs can induce apoptosis of target cells by a cell-contact dependent mechanism. 
Upon activation, Tregs are able to induce the serine protease granzyme A or B and kill target 
cells in a perforin-dependent manner (Grossman et al. 2004). Additionally, granzyme B-deficient 
Tregs have impaired suppressive activity in vitro (Gondek et al. 2005). Furthermore, metabolic 
disruption of effector T cells is mediated by the expression of the ectoenzymes CD39 and CD73. 
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Those factors enable Tregs to catalyze pericellular adenosine triphosphate and adenosine 
diphosphate to anti-inflammatory adenosine (Bopp et al. 2007; Borsellino et al. 2007; Kobie et 
al. 2006). In contrast, importance of IL-2 deprivation by Tregs via their high CD25 expression 
remains controversial (Fontenot et al. 2005; Pandiyan et al. 2007). 
Another mechanism is the suppression via inhibitory cytokines, like IL-35, IL-10, and TGFβ. IL-
35 was recently implicated in Treg suppression and was shown to directly inhibit proliferation of 
Tconvs (Collison et al. 2007). There are several lines of evidence that IL-10 plays a role in Treg-
mediated suppression of intestinal and pulmonary inflammation (Asseman et al. 1999; Asseman 
et al. 2003; Rubtsov et al. 2008). Blocking IL-10 or usage of IL-10-deficient Tregs abrogates the 
protective effect in vivo. In contrast to this, in vitro studies using neutralizing antibodies to IL-10 
or TGF-β suggested that theses cytokines may not be essential for Treg suppression (Jonuleit et 
al. 2001). Interestingly, TGF-β receptor-deficient mice developed T cell-mediated autoimmunity 
within several weeks after birth (Li et al. 2006). The relevance of TGF-β-mediated suppression 
can be illustrated by different diseases. For instance, Tregs can inhibit NK cells and Tconvs via 
TGF-β in the tumor microenvironment (Li et al. 2007; Strauss et al. 2007). In addition, TGF-β is 
critical for Treg-mediated suppression of CD8 T cells in a model of type 1 diabetes (Green et al. 
2003). If TGF-β plays a pivotal role in Treg suppression, it is surprising that Treg function relies 
on cell-cell contact. TGF-β as a soluble and secreted cytokine should not depend on cell-cell 
contact. Remarkably, Th clones that were inhibited by Tregs showed the same transcriptional 
signature as those that were treated with recombinant TGF-β (Stockis et al. 2009b). However, it 
was not possible to detect active, soluble TGF-β in the supernatant of the co-cultures. One 
explanation is that TGF-β is secreted in a latent form from Tregs and is bound to the Treg 
membrane by the glycoprotein A repetitions predominant (GARP) (Stockis et al. 2009a). 
Interestingly, GARP is another Treg-specific surface molecule that is required for the expression 
of the TGF-β latency-associated peptide and both molecules bind to each other on the Treg 
surface (Stockis et al. 2009a; Tran et al. 2009). Furthermore, it represents a latent TGF-β binding 
protein (LTBP) that provides a cell surface platform for αv integrin-dependent TGF-β activation 
(Wang et al. 2012a). 
1.3 Glycoprotein A repetitions predominant 
Recently, a novel Treg-characteristic surface molecule, GARP or leucine rich repeat containing 
protein 32 (LRRC32), has been described (Tran et al. 2009). GARP was firstly defined in several 
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genetic alterations associated with different malignancies (Ollendorff et al. 1994; Ollendorff et 
al. 1992). The human GARP gene was mapped to the chromosomal region 11q13.5-14 and 
consists of three exons. The homologous mouse gene has been found in the 7F chromosomal 
region (Ollendorff et al. 1992; Roubin et al. 1996). The GARP gene locus possesses two 
alternative promoters which lead to the production of two different transcript variants. The 
protein is encoded in the last two exons and the coding sequence is highly conserved between 
species. The 80 kDa transmembrane protein consists of 662 amino acids and shares over 80% 
identity between human and mouse. The extracellular region contains 20 leucine rich repeats 
(LRRs), followed by a hydrophobic transmembrane domain and a 15-residue C-terminal 
cytoplasmic domain (Ollendorff et al. 1994). The extracellular LRRs form a horseshoe-like 
domain. The N-terminal signal peptide of the protein needs to be cleaved for efficient 
translocation of the mature protein to the cell surface (Chan et al. 2011). The LRR-family of 
proteins exhibits evolutionary similarities to Toll-like receptors (TLRs) (Bottcher et al. 2004). 
Expression of Garp was detected in various areas in the mid-gestation mouse embryo and in 
several adult tissues. More recently, GARP protein expression was detected in human 
megakaryocytes/platelets and activated Foxp3+ Tregs (Macaulay et al. 2007; Tran et al. 2009).  
The regulatory mechanisms controlling restricted GARP expression in Tregs are still not 
completely understood. GARP is upregulated in response to TCR stimulation on Tregs and lasts 
only a short time (Tran et al. 2009; Wang et al. 2009; Zhou et al. 2013b). Interestingly, murine 
Garp expression can also be induced by culture of Tregs only in the presence of IL-2 or IL-4 
(Edwards et al. 2013). Expression of GARP is not dependent on TGF-β since TGF-β-deficient 
Tregs retain their GARP expression. Furthermore, GARP expression is post-transcriptionally 
down-regulated by miR-142-3p despite sustained TCR signaling (Zhou et al. 2013b). It was 
shown that Foxp3 expression is necessary, but not sufficient to drive GARP expression (Tran et 
al. 2009; Wang et al. 2009). Moreover, epigenetic regulation was implicated in GARP expression 
since a Treg-specific hypomethylated region in intron 1 was identified (Schmidl et al. 2009). 
1.4 Transcriptional regulation of gene expression in T cells 
DNA is normally wrapped around a set of eight histone molecules in the nucleosome (Kornberg 
2007). Coiling of DNA into condensed chromatin leads to transcriptionally inactive chromatin. 
For active gene transcription, nucleosomes have to be removed from promoter regions to allow 
the binding of the components of the transcriptional machinery. The RNA polymerase II 
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transcriptional complex is responsible for all messenger RNA (mRNA) synthesis in eukaryotes 
(Kornberg 2007). This complex compromises six proteins: polymerase II and five general 
transcription factors known as transcription factor IIB, -D, -E, -F, and -H. Polymerase II is 
capable of unwinding DNA, synthesizing RNA, and rewinding DNA. However, it cannot 
recognize promoter regions or initiate transcription. Thus, general transcription factors are 
essential to fulfill these functions. Promoter-specific activator proteins are generally sequence-
specific DNA binding proteins that regulate specific gene expression by directing the pre-
initiation complex to the transcription start site (TSS) of the gene (Green 2005). RNA 
polymerase II is recruited and moves along DNA producing the RNA transcript (elongation). In 
addition, post-transcriptional events can regulate the abundancy of transcripts. 
Transcription factors are specific transcriptional activators or repressors. Binding of transcription 
factors is often cell type specific and modulates the transcription levels of the genes they act on. 
In this regard, the master transcription factor of Tregs, Foxp3, is necessary to develop the Treg-
specific gene expression signature. Additionally, changes in gene expression represent the 
culmination of the TCR signaling pathway which is necessary for differentiation and 
proliferation of the T cells and the ability to produce effector cytokines. Furthermore, interaction 
of cytokines with the respective receptor can induce gene expression in T cells. Transcription 
factors that have a particular role in TCR- or cytokine-stimulated changes in gene expression 
belong to the NFAT, NF-κB, or STAT families. Moreover, the V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog F (MafF) was also recently implicated in T cell signaling. 
1.4.1 Foxp3 
Foxp3 is known as the “master regulator” of the Treg lineage. Induction of the Foxp3 gene in 
normal naïve T cells converts them to Treg-like cells with some suppressive functions, indicating 
that Foxp3 is likely to play a key role in controlling expression of critical suppression-mediating 
molecules (Hori et al. 2003). Thus, Foxp3 was often described as the lineage-specification factor 
for Treg development. The Foxp3 gene consists of 11 coding and three non-coding exons 
(Lozano et al. 2013). Foxp3 can act as transcriptional repressor or activator. This dual function is 
possible mainly through interaction of Foxp3 with a variety of binding partners. The N-terminal 
domain with two proline-rich regions interacts with factors that are involved in transcriptional 
suppression. Factors that bind to this region are the Ikaros family member Eos, chromatin 
remodeling factors, and c-Rel. Foxp3 also contains a Zinc finger and a leucine zipper motif. The 
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latter can form homodimers or binds to histone H1.5 that is located in the IL-2 or CTLA-4 gene 
loci. The C-terminus of the protein contains a forkhead domain that is responsible for nuclear 
localization, DNA binding, and interaction with NFAT. It is plausible that the ability of Foxp3 to 
bind to this vast quantity of factors might guarantee its multifaceted way of regulation. 
1.4.2 NFAT family 
The NFAT family of transcription factors comprises five proteins that are evolutionary related to 
the Rel/NF-κB family, namely NFAT1, -2, -3, -4, and -5 (Chytil et al. 1996). The phosphorylated 
form of NFAT is usually localized in the cytoplasm (Hogan et al. 2003). Upon TCR stimulation 
intracellular calcium stores are depleted and calmodulin-dependent enzymes like calcineurin get 
activated. Calcineurin dephosphorylates NFAT proteins leading to their nuclear translocation and 
target gene transcription. Target genes of NFAT include Foxp3, CD25, and Ctla-4 (Wu et al. 
2006). Interestingly, NFAT can regulate the transcription of Foxp3 in Tregs however it has also 
been identified as interaction partner of Foxp3 (Bettelli et al. 2005; Tone et al. 2008; Wu et al. 
2006). 
1.4.3 NF-κB family 
The NF-κB family of proteins encompasses five members: p65, RelB, c-Rel, p50, and p52. They 
can form a variety of homo- and heterodimers that activate different genes (Li et al. 2002b). The 
most prevalent form is the heterodimer p65 and p50. Normally, NF-κB resides in its inactive 
form in the cytoplasm bound to the inhibitor of NF-κB proteins (IκB). Besides TCR stimulation, 
TNF, IL-17 or IL-1β can activate the IκB kinase (IKK) complex that phosphorylates IκB and 
leads to the degradation of IκB. Subsequently, NF-κB can translocate to the nucleus leading to 
the transcription of genes containing the consensus κB sequence. Genes with κB sites include 
cytokines and chemokines (TNF, IL-1β, IL-2, IL-6, macrophage inflammatory proteins), 
adhesion molecules, anti-apoptosis genes, cell proliferation associated genes, matrix 
metalloproteinases (Pahl 1999). The NF-κB subunit p65 can be inhibited by the NF-κB 
activation inhibitor, JSH-23, which prevents the binding to DNA (Shin et al. 2004). NF-κB is 
important for thymic Foxp3 induction and the subunit c-Rel directly binds to the Foxp3 locus 
thereby initiating chromatin opening (Isomura et al. 2009; Long et al. 2009). Furthermore, NF-
κB was found to interact with Foxp3 to regulate the transcriptional program of Tregs (Bettelli et 
al. 2005). 
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1.4.4 STAT family 
The STAT family of proteins includes STAT1, -2, -3, -4, -5, and -6. It has critical roles in 
cellular responses to cytokines. STAT proteins exhibit preference for specific cytokine receptors, 
for example STAT1 shows preference for interferons. Signaling through the cytokine receptor 
leads to activation of receptor-associated Janus kinases (JAKs) and the phosphorylation of 
residues on the receptor. This creates sites for interaction with proteins that 
contain phosphotyrosine-binding src-homolgy 2 (SH2) domains. STAT proteins contain SH2 
domains and bind to the receptor and are themselves tyrosine-phosphorylated by JAKs. Thus, 
STAT proteins can dimerize and translocated to the nucleus where they can activate target genes. 
STAT1-deficient mice showed reduced numbers and functional impairment of Tregs (Nishibori 
et al. 2004). In addition, STAT1-deficient Tregs failed to control allograft rejection in vivo (Wei 
et al. 2010). 
1.4.5 MafF 
The basic leucine zipper (bZIP) transcription factors of the Maf oncogene family have a variety 
of functions in T cell processes. The C-terminal bZIP domain mediates DNA binding and 
dimerization (Kataoka et al. 1996). Small Maf proteins include MafF, MafG, and MafK and they 
lack the N-terminal transactivation domain. Expression of MafF, has been recently reported to be 
down-regulated during the development of iTregs (Prots et al. 2011). Recent studies could show 
that pro-inflammatory cytokines like TNF and IL-1β induce MafF transcript levels (Massrieh et 
al. 2006). These results might suggest a role for MafF during effector T cell differentiation 
whereas it seems to negatively influence Treg induction. In addition, MafF was linked to type-1 
diabetes mellitus pathology suggesting that MafF could be a useful target for autoimmune 
therapy (Menegazzo et al. 2012). 
1.5 Chromatin structure and chromatin remodeling 
Apart from their role in DNA packaging, tightly condensed chromatin structures provide a 
barrier to active gene transcription (Roeder 2005). Histone modifications include acetylation, 
methylation, ubiquitination, and phosphorylation at different amino acids on the N-terminal 
histone tails. Histone tail modifications act dynamically and in combination to open up regions 
for active gene transcription by permitting binding of transcription factors or condensing 
chromatin to an inactive state (Grunstein 1997). Histone acetylases generally activate, whereas 
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histone deacetylases repress gene expression. In addition, histone methyltransferases or -
demethylases can be associated with both, repressive and permissive marks. Examples for 
permissive modifications are trimethylated lysine 4 at histone H3 (H3K4me3) or pan-acetylated 
histone H3 (H3ac) (Cervoni et al. 2001; Ooi et al. 2007). In contrast, trimethylated lysine 27 at 
histone H3 (H3K27me3) is often enriched at inactive chromatin regions (Wei et al. 2009). 
In humans there are at least eight histone lysine methyltransferases with specificity for H3K4. 
These include the mixed-lineage leukemia (MLL) genes, MLL1-5, hSET1a/b, and ASH1. One 
member, the MLL1 which is also called lysine N-methyltransferase 2A (KMT2A) mediates 
H3K4me3 and associates with histone acetyltransferases, thereby marking sites of active gene 
transcription (Milne et al. 2002; Zhao et al. 2013). Recently, MLL1 was found to associate with 
Foxp3 and regulates Foxp3-activated genes by inducing H3K4me3 (Katoh et al. 2011). 
Interestingly, Foxp3-binding sites were decorated with MLL1 and other complex members, such 
as retinoblastoma binding protein 5 (RbBP5), before Foxp3 induction. The JARID family 
member PLU-1, or lysine-specific demethylase 5B (KDM5B) is associated with MLL1 and 
facilitates steady-state demethylation of H3K4. It was demonstrated that Foxp3 replaces PLU-1, 
thereby shifting the balance in favor of H3K4 methylation. Another interesting aspect of MLL1 
is the fact that it contains a CpG-interacting CXXC domain that may couple the H3K4 
methylation reaction to un-methylated DNA (Cierpicki et al. 2010). 
1.6 DNA methylation 
DNA methylation is a process that involves the addition of a methyl group to the fifth carbon of 
a cytosine residue. DNA methylation represses transcription directly by inhibiting binding of 
transcription factors and indirectly by recruiting methyl-CpG-binding domain (MBD) protein 
family members with chromatin remodeling activities. Thus, the MBD protein family is the 
linkage between histone modifications and DNA methylation (Hashimoto et al. 2010). DNA 
methylation is established and maintained by two DNA methyltransferase (DNMT) families, the 
so-called ‘de novo’ methyltransferases of the Dnmt3 family and the ‘maintenance’ 
methyltransferase Dnmt1. Several lines of evidence indicate that members of the Dnmt3 family 
can act as a sensor for H3K4 methylation and induce de novo DNA methylation when H3K4 
methylation is absent. Genome-wide methylation analyses revealed hypomethylated regions in 
Treg-signature genes in Tregs. Additionally, those regions were associated with Foxp3 binding 
(Zhang et al. 2013). The Treg-specific hypomethylation pattern is involved in Treg-specific gene 
INTRODUCTION  20 
expression, lineage stability, and full suppressive activity (Morikawa et al. 2014; Ohkura et al. 
2012). 
1.7 Alternative promoter usage 
The usage of alternative promoters is a mechanism to create flexibility and diversity in the 
complex patterns of gene expression. Multiple promoters or TSS are apparently frequently used 
to influence transcription in diverse ways. The level of transcription initiation can vary between 
alternative promoters. Additionally, the turnover or translation efficiency of mRNA isoforms 
with different leader exons can differ. Alternative promoters were reported to have different 
tissue specificity and react differently to some signals. Finally, alternative promoter usage can 
lead to the generation of protein isoforms differing at the amino terminus (Ayoubi et al. 1996). 
Characteristic features of alternative promoters are CpG islands which are short genomic regions 
with approximately 10 times higher CpG frequencies and higher GC content than the genomic 
average (Bird 2011). Since CpG islands are associated with regulation of gene expression, it 
could be expected that they display tissue-specific DNA methylation patterns. Interestingly, CpG 
islands associated with TSS rarely show methylation (Maunakea et al. 2010). The gene body 
which is defined as the region past the first exon plays an important role in tissue- or cell-specific 
gene expression (Laurent et al. 2010). DNA methylation of intragenic promoters was found to be 
associated with higher levels of gene expression in rapid dividing cells such as hematopoietic 
cells (Aran et al. 2011; Ball et al. 2009). Most gene bodies are CpG-poor and alternative TSS 
located down-stream of the main promoter frequently lack CpG islands. However, methylation 
of CpGs of an intragenic, alternative TSS blocks initiation at this element, whereas it allows the 
transcriptional elongation of the transcript initiated by the up-stream promoter. Therefore, DNA 
methylation was suggested to be a mechanism for controlling alternative promoter usage 
(Maunakea et al. 2010). 
1.8 MicroRNAs in regulation of gene expression 
In contrast to the 5’ transcriptional regulation of expression, microRNAs (miRNAs) that bind to 
the 3’ untranslated region (UTR) represent a mechanism of post-transcriptional modulation. 
MiRNAs are endogenous approximately 22 nucleotide (nt) long RNAs that are involved in the 
posttranscriptional cleavage of mRNAs or translational repression (Bartel 2004). They are 
complementary to sites in the 3’ UTR of the respective mRNA. Moreover, about a quarter of all 
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miRNAs are encoded in introns, suggesting that they are not transcribed from their own 
promoters but are instead processed from the introns. This mechanism is a convenient system for 
coordinate expression of a miRNA and a protein. Other miRNAs are clustered and are 
transcribed as a multi-cistronic primary transcript. MiRNA maturation involves nuclear cleavage 
of the pri-miRNA, which liberates the 60-70 nt long pre-miRNA by the Drosha RNase III 
endonuclease. Next, the miRNA is processed in the cytoplasm by the RNase III endonuclease 
Dicer into around 22 nt long double-stranded (ds) fragments. After separation via helicases, the 
single-stranded RNAs become incorporated into the RNA-induced silencing complex (RISC). 
Subsequently, the RISC/miRNA complex can down-regulate gene expression by either mRNA 
cleavage or translational repression depending on the degree of complementarity of the miRNA 
and the mRNA. Furthermore, the involvement of miRNAs in fine-tuning of gene expression 
makes them promising new targets for disease treatment. 
1.9 Rheumatoid arthritis 
1.9.1 Disease characteristics, diagnostic criteria, and scoring of disease activity 
RA is a systemic autoimmune disease affecting approximately 1% of people in the developed 
world (Alamanos et al. 2005). The incidence is higher in women than in men, the ratio varies 
between 2:1 and 3:1. The age of disease onset peaks around the fifth decade of life. Furthermore, 
RA is described by synovial inflammation leading to joint damage and bone destruction. It can 
cause severe disability and increases mortality. Inflammatory cells such as T cells, B cells, and 
macrophages accumulate in the inflamed joints which can lead to persistent synovitis and 
cartilage destruction (Bettelli et al. 2007). The autoantigens are still not identified for RA 
however the main cause of the autoimmune condition seems to be the failure in the maintenance 
of immunological self-tolerance. Plasmatic cells infiltrating the joint produce autoantibodies 
recognizing the Fc portion of Immunoglobulin G (IgG). Those autoantibodies are named 
rheumatoid factor (RF). In some RA patients, lymphocytes infiltrating the synovial tissue can 
accumulate in follicular structures and form germinal centers (Weyand et al 2003). In addition, 
RF has been detected in germinal center cells (Mellors et al 1959). The IgM class is the most 
significant type of RF in regards to RA that emerges in around 70-80% of patients. It has been 
demonstrated that RA-specific autoantibodies recognize citrulline-containing peptides/proteins 
as common antigenic entity, and they are collectively termed as anti-citrullinated protein 
antibodies (ACPAs) (Girbal-Neuhauser et al. 1999; Schellekens et al. 1998; Sebbag et al. 1995). 
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In 2010, new classification criteria for patients with early RA were introduced by the American 
College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
(Aletaha et al. 2010). This classification aimed to allow earlier diagnosis, treatment and inclusion 
in clinical trials. Patients with at least one swollen joint and the presence of synovitis that cannot 
be explained by any other disorder such as systemic lupus erythematosus (SLE), psoriatic 
arthritis, gout etc., can be included. The 2010 criteria include tender and swollen joint count, 
acute phase reactants, ACPA, RF, and symptom duration. Acute phase reactants refer to the level 
of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The clinical and 
diagnostic parameters are then combined into a score ranging from zero to ten. Classification as 
definite RA is based on the achievement of a total score of at least six. 
The disease activity score in 28 joints (DAS28) has been developed as a quantitative index for 
the measurement of RA disease activity (Fransen et al. 2006; van Riel 2014). The DAS28 
combines information from tender and swollen joints, acute phase reactant, and patient self-
report of general health. The final score is calculated from all four parameters and can range 
from zero to ten. Cut points were developed to classify patients in remission, as well as low, 
moderate and high disease activity. A DAS28<2.6 corresponds with being in remission. 
Additionally, patients with low disease activity reached a DAS28 between 2.6 and 3.2. Patients 
who reached a score between 3.2 and 5.1 are termed as patients with moderate activity and a 
DAS28 higher than 5.1 indicates high disease activity. 
1.9.2 RA pathogenesis 
The etiology of RA is unknown, however many studies suggest that a combination of 
environmental and genetic factors is responsible. The structure of class II MHC molecules in 
APCs is associated with increased risk of RA. More than 80% of patients carry the epitope of the 
human leukocyte antigen (HLA)-DRB1*04 cluster (Smolen et al. 2007). Other RA-associated 
loci include protein tyrosine phosphatase non-receptor type 22, CD28, CTLA-4, REL, and B 
lymphoid tyrosine kinase (BLK). Despite genetic predisposition, smoking and infection might 
influence the development, rate of progression and severity of the disease (Getts et al. 2010; 
Klareskog et al. 2007). Epigenetic influences such as DNA hypomethylation or dysregulation of 
histone marks, abnormal signal transduction, as well as miRNA expression can increase pro-
inflammatory genes and contribute to the disease pathogenesis (Bottini et al. 2013). H3K4me3 
peaks were previously shown to overlap with RA risk loci in Tregs (Okada et al. 2014). In 
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addition, NFAT inhibitors such as Cyclosporin A (CsA) and tacrolimus have been studied for 
their efficacy as treatment for RA (Furst et al. 2002; Yocum et al. 2003). 
Several studies observed a variety of abnormalities in function and phenotype of Tregs in RA 
(Zhou and Haupt et al. 2015). CD25+ Tregs isolated from the peripheral blood of patients with 
RA are unable to control the production of inflammatory cytokines, such as TNF and IFN-γ, by 
effector cells while they are still capable of controlling Tconv cell proliferation (Ehrenstein et al. 
2004). Interestingly, TNF is able to down-modulate Treg function (Valencia et al. 2006). Anti-
TNF therapy can reverse impaired control of cytokine production (Ehrenstein et al. 2004). 
Furthermore, TNF inhibits the phosphorylation and function of Foxp3, indicating a critical role 
of TNF in the hampered Treg suppression (Nie et al. 2013). Another mechanism for defective 
Tregs in RA might be the reduction of CTLA-4 (Flores-Borja et al. 2008). In mice, CTLA-4-
deficient Tregs have impaired suppressive activity on Tconvs (Tivol et al. 1995). Interestingly, 
an altered DNA methylome was described for peripheral blood mononuclear cells (PBMCs) 
from patients with RA (Liu et al. 2011). One prominent example is the methylation of one CpG 
in the CTLA-4 promoter in Tregs from RA patients which lead to diminished binding of NFAT2 
thereby decreasing CTLA-4 expression and Treg function (Cribbs et al. 2014). In the context of 
RA two miRNAs, miR-146a and miR-155, have been reported to be associated with the disease 
and are highly expressed in Tregs (Leah 2011; Nakasa et al. 2008; Pauley et al. 2008). Several 
studies indicate that miR-155 deficiency does not lead to dysfunction of Tregs under non-
inflammatory conditions. However, in an inflammatory setting, the miR-155 deficient Tregs fail 
to respond correctly (Leng et al. 2011). MiR-146a limits TNF receptor associated factor 
(TRAF)6 and IL-1 receptor associated kinase (IRAK)1 expression in inflammatory settings (Hou 
et al. 2009; Taganov et al. 2006). Moreover, miR-146a-mediated down-regulation of STAT1, a 
key transcription factor of Th1 cells, was necessary for Treg ability to suppress Th1 responses 
(Lu et al. 2010). In an experimental disease model, the treatment of mice with miR-146a in the 
course of collagen-induced arthritis (CIA) prevented joint destruction, whereas miR-155-
deficient mice were completely resistant to CIA (Kurowska-Stolarska et al. 2011; Nakasa et al. 
2011). Furthermore, expression of miR-146a was lowered in autoimmune diseases such as SLE 
(Tang et al. 2009). 
It is still unclear if the number of Tregs is altered in RA, however there seems to be an increase 
of Tregs in the RA synovium (Cao et al. 2004; Sarkar et al. 2007). Additionally, the balance 
between Tregs and Th17 cells seems to be shifted towards an increased number of Th17 cells in 
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the presence of less functional Tregs (Nie et al. 2013). TGF-ß is crucial for extrathymic 
development of Tregs. Downstream of TGF-ß signaling, Foxp3 is induced after TCR 
stimulation. Small mothers against decapentaplegic-3 and NFAT, activated by TGF-β and TCR 
signaling, respectively, cooperate in Foxp3 gene remodeling and expression (Tone et al. 2008). 
However, TGF-β might also play a role in the differentiation of Th17 cells (Bettelli et al. 2006). 
Furthermore, it is known that cell surface-bound TGF-β plays an important role in 
immunosuppression by Tregs (Nakamura et al. 2004; Nakamura et al. 2001). Interestingly, anti-
TNF therapy gives rise to a distinct Treg population in patients with RA that mediates 
suppression via TGF-β and IL-10. This suggests that anti-TNF therapy generates a population 
that compensates for the defective RA-Treg function that relies on TGF-β-mediated suppression 
of target cells (Nadkarni et al. 2007). Additionally, a generated soluble human GARP was able to 
repress proliferation and cytokine production in Th cells (Hahn et al. 2013). It could stimulate 
the differentiation of naïve Th cells into induced Tregs and, in the presence of the pro-
inflammatory cytokines IL-6 and IL-23, soluble GARP promotes Th17 differentiation. TGF-β 
receptor blockage abrogated the activity of soluble GARP indicating that TGF-β is critical for 
these effects. Furthermore, Tregs expressing the latent TGF-β/GARP complex on their surface 
are potent inducers of both Th17 differentiation in the presence of IL-6 and Treg differentiation 
in the presence of IL-2 (Edwards et al. 2013). A more recent study could show that blocking 
antibodies against human GARP can inhibit the immunosuppressive function of Tregs in vitro 
and in vivo similar to anti-TGF-β antibodies (Cuende et al. 2015). However, anti-GARP 
antibodies inhibit only Treg-specific production of TGF-β which could have implications in 
tumor therapy because it might reduce side effects. All of these observations indicate that GARP 
might be a suitable target for the treatment of autoimmune disorders or cancer in order to restore 
the balance of Tregs and effector cells. 
The pathophysiology of RA is still not completely understood, however the existence of only one 
RA antigen is unlikely because several antigens are enriched in the joints of patients with RA 
(Snir et al. 2010). The antigens are loaded on MHC complexes on APCs and presented to T cells 
in the central lymphoid organs (Firestein 2005). Then, T cells can activate B cells. One of the 
earliest histopathological responses is the synovitis which is caused by the influx of mononuclear 
cells including T cells, B cells, plasma cells, DCs, macrophages, and mast cells into the synovial 
compartment and by angiogenesis. Production of pro-inflammatory cytokines such as IL-17, 
TNF, IL-1β, and IFN-γ promotes the infiltration. The synovial intimal lining is the interface 
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between the synovium and the synovial fluid space (Firestein et al. 2012). Two major cell types 
are found in the lining, macrophage-like type A synoviocytes and fibroblast-like type B 
synoviocytes (FLS). There is an absolute increase in both cell types in RA. FLS have a powerful 
capacity to invade connective tissue mediating the stimulation of osteoclasts and destruction of 
cartilage. The destruction of cartilage and bone in RA is initiated largely by matrix 
metallopeptidases. In response to inflammation bone resorption outweighs bone formation in the 
RA joint. Bone destruction is promoted by several factors, such as TNF and receptor activator of 
NF-κB ligand, which support osteoclast formation. Furthermore, the precise role of B cells in RA 
is uncertain, but antibody complexes can initiate and enhance joint inflammation. Complement 
activation and its interaction with immune complexes, as well as additional inflammatory 
mediators contribute to RA pathogenesis. In this regard, cytokines play a pivotal role in initiation 
of RA. IL-1β is mainly produced by synovial macrophages and it can induce fibroblast 
proliferation and can activate NF-κB, thereby promoting the production of pro-inflammatory 
cytokines. Moreover, TNF increases cell migration and inflammation (Choy 2012). CD4 Th cell 
cytokines like IFN-γ and IL-17 can drive T cell differentiation, recruit inflammatory cells, 
influence extracellular matrix synthesis, or enhance osteoclast formation (Firestein et al. 2012). 
1.10 Objective of the thesis 
Tregs play a critical role in controlling autoimmune diseases. Their suppressive function and 
phenotype are compromised in autoimmune diseases, such as RA. The underlying mechanisms 
of impaired function are not yet completely elucidated. This thesis will address several levels of 
regulation of Treg function and phenotype: 
 
- to analyze molecular mechanisms contributing to the characteristic phenotype of Tregs 
a) Transcriptional regulation of GARP expression 
b) Involvement of MafF in iTreg development 
- to characterize molecular mechanisms regulating GARP expression and Treg function in RA 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents and cytokines 
Reagent/Cytokine Origin 
Acetic acid (CH3COOH) Merck, Darmstadt, Germany 
Acetone (C3H6O) Merck 
Acrylamid/bis-acrylamid 30% (37.5:1) Merck 
Agarose Merck 
Ammonium chloride (NH4Cl) Sigma-Aldrich, St. Louis, MO, USA 
Ammonium persulfate (APS) Sigma-Aldrich 
Ampicillin, sodium salt Life technologies, Carlsbad, CA, USA 
β-mercaptoethanol Sigma-Aldrich 
Biotin Sigma-Aldrich 
Bovine serum albumin (BSA) Merck 
Bromophenol blue Merck 
Dimethylformamide Sigma-Aldrich 
Dimethylsulfoxid (DMSO) Merck 
Dipotassium hydrogen phosphate (K2HPO4) Merck 
Disodium hydrogen phosphate (Na2HPO4) Merck 
Dithiothreitol (DTT) Sigma-Aldrich 
DNA Gel Loading dye (6x) Life technologies 
Dulbecco's Modified Eagle Medium (DMEM) Life technologies 
dNTP set (100 mM solutions) Life technologies 
ECL Western Blotting Detection Reagent GE Healthcare, Munich, Germany 
Ethanol (C2H5OH) Merck 
Ethylendinitrotetraacetic acid (EDTA) Sigma-Aldrich 
Ficoll lymphoflot Biotest, Dreieich, Germany 
Formaldehyde 37% AppliChem GmbH, Darmstadt, Germany 
L-glutamine (C5H10N2O3) Life technologies 
Glycerol (C3H5(OH)3) Merck 
Glycine (NH2CH2COOH) Merck 
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Heparin-sodium salt Ratiopharm, Ulm, Germany 
4-(2-hydroxyethyl)piperazin-1-ethanesulfonic 
acid  (HEPES) 
Merck 
Hydrochloric acid 37% (HCl) Merck 
IL-2 (Proleukin, recombinant human) Novartis, Basel, Switzerland 
IL-4 (recombinant human) Perbio Science, Bonn, Germany 
Ionomycin Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Life technologies 
Isopropanol (C3H7OH) Merck 
Lysogeny Broth (LB) agar (Lennox L agar) Life technologies 
LB broth (1x) Life technologies 
Magnesium chloride (MgCl2) Merck 
Methanol (CH3OH) Sigma-Aldrich 
Monensin Sigma-Aldrich 
NP-40 Millipore, Billerica, MA, USA 
Nonfat dry milk powder Real 
Oligonucleotide-dT12-18 (Oligo(dT)) GE Healthcare 
Paraformaldehyde (PFA) Merck 
Penicillin G/streptomycin Life technologies 
Phenylmethylsulfonylfluorid (PMSF) Roche, Penzberg, Germany 
Phorbol myristate acetate (PMA) Sigma-Aldrich 
Phosphate buffered saline (PBS) Life technologies 
Piperazine-N,N‘-bis-2-ethanesulfonicacid 
(PIPES) 
Millipore 
Potassium chloride (KCl) Merck 
Potassium dihydrogen phosphate (KH2PO4) Merck 
Potassium bicarbonate (KHCO3) Merck 
Protease inhibitor cocktail (PIC) Roche 
RediLoad Loading buffer (10x) Life technologies 
Retinoic acid Sigma-Aldrich 
Roswell Park Memorial Institute (RPMI)1640 Life technologies 
Saponin Sigma-Aldrich 
Sheep erythrocytes Fiebig-Nährstofftechnik, Idstein, Germany 
Sodium acetate (CH3COONa) Merck 
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2.1.2 Antibodies 
Specificity Conjugate Clone Provider 
Antibodies for cell culture 
Anti-human CD3 non OKT3 LGC Standards Teddington, 
UK 
Anti-human CD28 non clone 28.2 BD Biosciences, San Diego, 
CA, USA 
Dynabeads Human T-
Activator CD3/CD28 
non not provided Life technologies 
Antibodies for flow cytometry 
Anti-human CD3  FITC UCHT1 Sigma-Aldrich 
Anti-human CD3/CD4 
dual tag 
FITC/PE UCHT1/Q4120 BD Biosciences 
Anti-human CD4 FITC Q4120 Sigma-Aldrich 
Anti-human CD14 FITC UCHM-1 Sigma-Aldrich 
Sodium azide (NaN3) Merck 
Sodium chloride (NaCl) Merck 
Sodium deoxycholat (Na-Deoxycholat) Merck 
Sodium dihydrogen phosphate (NaH2PO4) Merck 
Sodium dodecyl sulfate (SDS) Merck 
Sodium hydrogen phosphate (Na2HPO4) Merck 
Sodium hydroxide (NaOH) Merck 
Streptavidin-peroxidase Roche 
Sulphuric acid (H2SO4) Merck 
SYBR safe DNA gel stain (10,000x) Life technologies 
TaqMan Universal PCR mastermix 2x Life technologies 
Tetramethylethylenediamine (TEMED) Merck 
TGF-β (recombinant human) R&D Systems, Minneapolis, MN, USA 
Triton X-100 Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
X-Gal (5-Bromo-4-Chloro-3-Indolyl β-D-
Galactopyranoside) 
Life technologies 
Zeocin powder InvivoGen, San Diego, CA, USA 
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Anti-human CD16 PE 3G8 Biolegend, San Diego, CA 
Anti-human CD19 PE J3-119 Immunotech, Beckman-
Coulter, Brea, CA 
Anti-human CD20 FITC 2H7 BD Biosciences 
Anti-human CD25 PE M-A251 BD Biosciences 
Anti-human CD45RA FITC HI100 BD Biosciences 
Anti-human CD45RO PE UCHL1 BD Biosciences 
Anti-human CD127 AlexaFluor647 HL-7RM21 BD Biosciences 
Anti-human Foxp3 PE PCH101 ebioscience, San Diego, CA, 
USA 
Anti-human GARP 
hybridoma supernatant 
non 7H2 From our lab, Munich, 
Germany 
Anti-human MafF (C-
terminal) 
non polyclonal Sigma-Aldrich 
Anti-human STAT1 (N-
terminus) 
PE 1/Stat1 BD Biosciences 
Anti-human STAT1 
(pS727) 
AlexaFluor647 K51-856 BD Biosciences 
Anti-rat IgG2a, κ PE isotype control 
Foxp3 
BD Biosciences 
Anti-mouse IgG1 PE isotype control 
STAT1 
BD Biosciences 
Anti-mouse IgG1, κ APC isotype control 
STAT1 (pS727) 
BD Biosciences 
Anti-rat IgG (H+L) PE polyclonal 2nd 
antibody GARP 
Dianova, Hamburg, Germany 
Rat IgG non isotype control 
GARP 
Sigma-Aldrich 
Antibodies for Western Blot 
Anti-human MafF (C-
terminal) 
non polyclonal Sigma-Aldrich 
Anti-p38 MAP kinase non polyclonal Cell Signaling, Cambridge, UK 
MATERIALS AND METHODS   30 
Specificity Clone Provider 
Antibodies for Chromatin Immunoprecipitation (ChIP) 
Anti-trimethyl-Histone H3 
(Lysine4) 
polyclonal Merck 
anti-acetyl-Histone H3 polyclonal Merck 
anti-trimethyl-Histone H3 
(Lysine27) 
polyclonal Merck 
anti-human c-Rel D5G1A9 Cell Signaling 
anti-human Foxp3 polyclonal Thermo Scientific, Waltham, MA, 
USA 
anti-human NFAT1 25A10.D6.D2 Abcam, Cambridge, UK 
anti-human MLL/HRX N4.4 Active Motif, Carlsbad, CA, USA 
anti-human JARID1B (PLU-1) polyclonal Cell Signaling 
anti-human p65 D14E12 Cell Signaling 
anti-human p105/p50 D7H5M Cell Signaling 
anti-human RbBP5 polyclonal Bethyl laboratories, Montgomery, 
TX, USA 
Normal goat IgG isotype control Foxp3 R&D Systems 
Normal mouse IgG1 isotype control NFAT1 Sigma-Aldrich 
Normal rabbit IgG isotype control NF-κB, 
histone modifications 
Cell Signaling 
Antibodies for DNA-protein binding assay 
anti-human Foxp3 polyclonal R&D Systems 
anti-human NFAT1 D43B1 Cell Signaling 
anti-human p105/p50 D7H5M Cell Signaling 
Normal goat IgG isotype control Foxp3 R&D Systems 
Normal rabbit IgG isotype control p105/p50 
and NFAT1 
Cell Signaling 
2.1.3 Ladders/Markers 
Name Provider 
Biotinylated protein ladder Cell Signaling 
GeneRuler DNA ladder (100 bp) Fermentas, St. Leon-Rot, Germany 
GeneRuler DNA ladder (1 kb) Fermentas 
Prestained protein marker (broad range) Cell Signaling 
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2.1.4 Serum 
Name Provider 
Fetal calf serum (FCS) Life technologies 
Mouse serum Sigma-Aldrich 
Normal human serum (NHS) From our lab, Munich, Germany 
Rat serum Sigma-Aldrich 
2.1.5 Enzymes 
Enzyme Supplied Reaction Buffer Provider 
AmpliTaq DNA polymerase 10x PCR Buffer II Life technologies 
DpnI none Agilent Technologies, Santa 
Clara, CA, USA 
EcoRI 10x NEBuffer EcoRI New England Biolabs 
EcoRV 10x NEBuffer 3 New England Biolabs 
Epimark Hot Start Taq DNA 
Polymerase 
5x Epimark Hot Start Taq 
reaction buffer 
New England Biolabs 
GeneAmp High Fidelity PCR 
Enzyme Mix 
10x GeneAmp High Fidelity 
PCR buffer 
Life technologies 
Herculase II Fusion DNA 
Polymerase 
5x Herculase II reaction 
buffer 
Agilent Technologies 
HindIII 10x NEBuffer 2 New England Biolabs 
peqGOLD Proteinase K (20 
mg/ml) 
 Peqlab 
Quick T4 DNA Ligase 2x Quick ligation reaction 
buffer 
New England Biolabs 
RNase A, DNase and 
protease-free (10 mg/ml) 
 Life technologies 
SalI 10x NEBuffer 3 New England Biolabs 
XhoI 10x NEBuffer 2 New England Biolabs 
2.1.6 Single nucleotide polymorphism (SNP) genotyping assays 
SNP location SNP ID Probe Sequence 
GARP intergenic 
region 
rs7122065 A=VIC, 
G=FAM 
TCTGCACCCTACTCCAGCTCCATTC[A/G]
CTGGGCCCTACCTTGCAGCTGGTGA 
GARP intergenic 
region 
rs11236851 A=VIC, 
G=FAM 
CCTCCTTTAATGGCCTTCTTCCCGT[A/G]G
CACCTTGGAACACCCCCTCCTGGC 
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GARP intergenic 
region 
rs7342189 C=VIC, 
T=FAM 
ACTCACGAAAGCAACAAGCATGCAT[C/T]
GACCTCATACACGAATTTCACGTAG 
GARP 5’UTR rs947998 G=VIC, 
T=FAM 
TGAGTGCCCCACCTCCCACTCCCCC[G/T]
CCCCCAGAGGCTGTGGTTGTGGTTA 
GARP 5’UTR rs3814710 A=VIC, 
G=FAM 
GGCGGCGAAGCATCTTCACCACCCT[A/G]
GGACCTCGGCCGGGAAGGGGCGGGG 
GARP Intron 1 rs6592657 A=VIC, 
G=FAM 
CACTAAGGACATCAGCCAAGTGCTA[A/G]
GGATGTACAAATCCACCCATGAATT 
GARP Intron 1 rs4944115 G=VIC, 
T=FAM 
AGACCCCACCTGGCGGAAGACAGCC[G/T
]GGAGGGGATGCACAGAAGGCTGACA 
GARP Intron 2 rs7944357 A=VIC, 
G=FAM 
ATGCCATCCCCAACCAGATCCACAC[A/G]
TGAACTCTTCACACTGAGCTTCAGG 
GARP Intron 2 rs7944463 C=VIC, 
T=FAM 
CCAGCAGGGCCTTCGAGGCTGTTTG[C/T]
AGCCCCTGCCAACCTGTCCCCCACC 
2.1.7 TaqMan Gene Expression assays 
Gene Assay ID Probe Sequence (5‘ to 3‘) 
Cyclophilin A 4310x10783E VIC-probe not provided 
b-actin 4310x10781E VIC-probe not provided 
human GARP both 
transcript variants 
Hs00194136_m1 FAM-probe not provided 
human GARP 
transcript variant 2 
Hs00973758_m1 FAM-probe not provided 
human GARP 
transcript variant 1 
customed For primer 
Rev primer 
FAM-probe 
CCTTGATTTGGTATAGTGGGAAC 
CAGGGTCACGATCAGAATCCA 
TTGCTTTGGAGACAGATGA 
For - Forward; Rev - Reverse 
2.1.8 Oligonucleotides 
Gene/Region Oligonucleotide Sequence (5‘ to 3‘) 
Cloning primer 
human GARP promoter 
full-length 
For primer (EcoRV) 
Rev primer (HindIII) 
GAGATATCCAGAGTGGACGGCTT 
GATAAGCTTAGCCCTGCCAACG 
human GARP up-
stream P2 
For primer (EcoRV) 
Rev primer (HindIII) 
GAGATATCCAGAGTGGACGGCTT 
GATAAGCTTATGGCGGGAGGGGAG 
human GARP down-
stream P1 
For primer (EcoRV) 
Rev primer (HindIII) 
GAGATATCGACGCCCCCCAAACA 
GATAAGCTTAGCCCTGCCAACG 
mouse GARP promoter For primer 
Rev primer 
TGGCTCAAGTCCACAGGGATTC 
CCACTAACCTTCAACCTGGACTGG 
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human GARP 
conserved non-coding 
sequence (CNS) 
For primer 
Rev primer 
AACTTTCTAACGGGCGGTGG 
CGAAGATGGCTGCTCTGAATCC 
human MafF coding 
sequence (cds) 
For primer (Kozak) 
Rev primer 
CACCATGTCTGTGGATCCCCTATCC 
CTAGGAGCAGGAGGCCGGGCC 
Bisulfite sequencing primer 
human GARP up-
stream P2 
For primer 
Rev primer 
TTGTAGGAAATTTGAATTTAAATTT 
CTACCAAAACCCACCAAAATAAAC 
human GARP down-
stream P1 
For primer 
Rev primer 
TTTTTGTTTATGAAGAAAAGGAGGTT 
CTTACCCAAAAACACACAACTAAAC 
human GARP CNS For primer 
Rev primer 
GTGTTGGGAATTGGGAATTTAA 
AAAACAAAACAACTACAAAAACAAC 
ChIP assay realtime-polymerase chain reaction (PCR) primer 
human GARP up-
stream P2 
For primer 
Rev primer 
GACTTTGATGGTGCCGTTTC 
CAGGTCACTTTTCCTCTCCG 
human GARP down-
stream P1 
For primer 
Rev primer 
AATGTGGCTGTGATGGCGG 
TCTCCAAGGGGCTCTGAACC 
human GARP CNS For primer 
Rev primer 
TGCTAACTTTCTAACGGGCG 
GCATTACAGGTTGTGCTTTCAC 
Site-directed mutagenesis 
human GARP down-
stream P1 del311-317 
retinoic X receptor 
(RXR) 
For primer 
 
Rev primer 
CCATTTCTCGTAGTGGGCAAGGGG 
CGTCCCACCGCTCTCCAAGG 
CCTTGGAGAGCGGTGGACGCCCCT 
TGCCCACTACGAGAAATGG 
human GARP up-
stream P2 del101-102 
(Foxp3) 
For primer 
Rev primer 
TCACCTCGCCTGTGCCCCCGCGTT 
AACGCGGGGGCACAGGCGAGGTGA 
human GARP up-
stream P2 del402-403 
(Foxp3) 
For primer 
Rev primer 
CCGCCGGCTCCGGATACCGAGGC 
GCCTCGGTATCCGGAGCCGGCGG 
human GARP up-
stream P2 del751-752 
(Foxp3) 
For primer 
Rev primer 
GGGACGCCCCCCACACTCCCCTCC 
GGAGGGGAGTGTGGGGGGCGTCCC 
Can – Canonical; Scr – Scrambled; For - Forward; Rev - Reverse; Com - Complementary
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Gene/Region Oligonucleotide Sequence (5‘ to 3‘) 
DNA-protein binding assay 
Foxp3 can For oligo CAAGGTAAACAAGAGTAAACAAAGTGCGGTAAACAAG
AGTAAACAGTG 
 Com oligo GTTCCATTTGTTCTCATTTGTTTCACGCCATTTGTTCTCA
TTTGTCAC 
Foxp3 scr For oligo GTGACAGATAGAAGAAAGACACAGACATACGAGAAGA
CATAAGTAAGT 
 Com oligo CACTGTCTATCTTCTTTCTGTGTCTGTATGCTCTTCTGTA
TTCATTCA 
NFAT can For oligo CGCCCAAAGAGGAAAATTTGTTTCATACGCCCAGAGGA
AAATTTGTTTCATA 
 Com oligo GCGGGTTTCTCCTTTTAAACAAAGTATGCGGGTCTCCTT
TTAAACAAAGTAT 
NFAT scr For oligo GATAGACACCTATTCTGAATGGGACTAAAGATGTGCTA
CATACATACACTGT 
 Com oligo CTATCTGTGGATAAGACTTACCCTGATTTCTACACGATG
TATGTATGTGACA 
NF-κB can For oligo GAGATCCGGGGACTTTCCATGGATGGGGACTTTCCATG
GAG 
 Com oligo CTCTAGGCCCCTGAAAGGTACCTACCCCTGAAAGGTAC
CTC 
NF-κB scr For oligo GGCCAGGCGTCAGTCTATGTGTAGATGGTGCGCAGAGT
CAT 
 Com oligo CCGGTCCGCAGTCAGATACACATCTACCACGCGTCTCA
GTA 
GARP 
promoter 
For oligo GGCAAACCGGAATTTGAATTCAGGTTTCCTGCAACGCT
CCGA 
 Com oligo CCGTTTGGCCTTAAACTTAAGTCCAAAGGACGTTGCGA
GGCT 
GARP 
promoter scr 
For oligo ACATTCGTGCCTAAGAATCGCGTACATAAGCGTCGCTG
TGCA 
 Com oligo TGTAAGCACGGATTCTTAGCGCATGTATTCGCAGCGAC
ACG 
Can – Canonical; Scr – Scrambled; For - Forward; Rev - Reverse; Com - Complementary 
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2.1.9 Kits, devices, and software 
Kit name Origin 
ABI Prism 7000 Sequence Detection system Life technologies 
Affinity Script QPCR cDNA Synthesis kit Agilent technologies 
Amaxa Cell Line Nucleofector kit L Lonza, Cologne, Germany 
Amaxa Cell Line Nucleofector kit V Lonza 
Amaxa human T cell Nucleofector kit Lonza 
B Cell Isolation kit II, human Miltenyi Biotec, Bergisch Gladbach, Germany 
BioPhotometer Eppendorf, Hamburg, Germany 
Bioruptor® Plus (B01020001) Diagenode, Denville, NJ, USA 
CD4+ T Cell Isolation kit, human Miltenyi Biotec 
CD25 MicroBeads II, human Miltenyi Biotec 
CD127 MicroBead kit, human Miltenyi Biotec 
ChIP-IT High Sensitivity kit Active Motif 
EC-120 Mini Vertical Gel System E-C Apparatus, Holbrook, NY, USA 
EC-140 Mini Blot Module E-C Apparatus 
ELISA/ELISPOT Coating buffer powder ebioscience 
ELISA Wash buffer ebioscience 
EpiQuik General Protein-DNA Binding 
Assay Kit (Fluorometric) 
Epigentek, Farmingdale, NY, USA 
EpiQuik Nuclear Extraction Kit II Epigentek 
Dual-Glo Luciferase Assay System Promega, Madison, WI, USA 
FACS Cytomics FC500 Beckman Coulter 
FUJIFILM LAS-3000 Fujifilm, Tokyo, Japan 
Gel chamber Nautico 10x107 H. Hölzel Laborgeräte GmbH, Dorfen, Germany 
Human Foxp3 Buffer set BD Bioscienes 
Human IFN-gamma Quantikine ELISA kit R&D Systems 
Human IL-17 Quantikine ELISA kit R&D Systems 
Human TNF-α Quantikine ELISA kit R&D Systems 
MacVector Software MacVector, Inc., Cary, NC, USA 
MACSmix Tube rotator Miltenyi Biotec 
MethylDetectorTM Bisulfite Modification kit Active Motif 
Microcentrifuge 5415R Eppendorf 
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Monocyte Isolation kit II, human Miltenyi Biotec 
Naïve CD4+ T Cell Isolation kit II, human Miltenyi Biotec 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel, Düren, Germany 
Power Pac 1000 Bio-Rad Laboratories, München, Germany 
QIAamp DNA Blood Mini kit Qiagen, Hilden, Germany 
QIAGEN Plasmid Maxi kit Qiagen 
QIAprep Spin Miniprep kit Qiagen 
QIAquick Gel Extraction kit Qiagen 
QIAquick PCR Purification kit Qiagen 
QIAquick Nucleotide Removal kit Qiagen 
QuickChange Lightning Site-Directed 
Mutagenesis kit 
Agilent technologies 
Quick Ligation kit New England Biolabs 
5’RACE System for Rapid Amplification of 
cDNA Ends Version 2.0 
Life technologies 
RNeasy Plus Mini kit Qiagen 
Rotixa 50 RS centrifuge Hettich AG, Bäch, Switzerland 
Sigma GenElute PCR Clean-Up kit Sigma-Aldrich 
Tecan Spectra Microplate Reader Tecan Group, Männedorf, Switzerland 
TOPO TA Cloning kit Life technologies 
Tristar2 LB942 Multimode Microplate 
Reader 
Berthold technologies 
Unimax 1010 Orbital Shaker Heidolph GmbH, Schwabach, Germany 
UVT-28 MP transilluminator Herolab GmbH, Wiesloch, Germany 
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2.1.10 Buffers and solutions 
Buffers and solutions Composition 
Annealing buffer 10 µM oligonucleotide 
10 mM Tris, pH 7.5 
1 mM EDTA 
50 mM NaCl 
Cell Lysis buffer 5 mM PIPES, pH 8.0 
85 mM KCl 
0.5% NP-40 
1x PIC 
6x DNA Loading buffer 50 mM EDTA 
26.1% glycerol 
0.25% bromphenol blue 
FACS buffer PBS 
2% FCS 
0.01% NaN3 
MACS buffer PBS 
0.5% BSA 
2 mM EDTA 
10x NH4Cl 41.45 g NH4Cl 
5 g KHCO3 
1 mM EDTA 
H2O ad 0.5 l 
Nuclear Lysis buffer 50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
0.1% SDS 
1x PIC 
Resolving gel (15%) 380 mM Tris-HCl, pH 8.8 
15% acrylamide/bis-acrylamide 
0.2% SDS 
0.2% APS 
10 µl TEMED 
H2O ad 10 ml 
Stacking gel (4%) 126.6 mM Tris-HCl, pH 6.8 
4% acrylamide/bis-acrylamide 
0.1% SDS 
0.1% APS 
5 µl TEMED 
H2O ad 5 ml 
SDS Blot buffer 20 mM Tris-HCl, pH 7.6 
140 mM NaCl 
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0.1% Tween20 
SDS Running buffer 12.5 mM Tris-HCl, pH 6.8 
96 mM glycine 
0.05% SDS 
SDS Sample buffer 62.5 mM Tris-HCl, pH 6.8 
2% SDS 
10% glycerol 
50 mM DTT 
0.01% bromophenol blue 
SDS Transfer buffer 12.5 mM Tris-HCl, pH 8.3 
86 mM Glycine 
0.05% SDS 
20% Methanol 
Sonication buffer 50 mM HEPES, pH 7.8 
140 mM NaCl
 
1 mM EDTA 
1% Triton X-100 
0.1% Na-Deoxycholat 
0.1% SDS 
0.5 mM PMSF 
1x PIC 
Swelling buffer 25 mM HEPES, pH 7.8 
1.5 mM MgCl2 
10 mM KCl 
0.1% NP-40 
1 mM DTT 
0.5 mM PMSF 
1x PIC 
50x Tris-Acetate-EDTA (TAE) buffer 242 g Tris-HCl 
57.2 ml acetic acid 
50 mM EDTA (pH7.6) 
H2O ad 1 l 
TBST 20 mM Tris-HCl (pH7.6) 
140 mM NaCl 
0.1% Tween-20 
TE buffer 10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
0.5 mM PMSF 
1x PIC 
Wash buffer A 50 mM HEPES, pH 7.8 
500 mM NaCl
 
1 mM EDTA 
1% Triton X-100 
0.1% SDS 
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0.5 mM PMSF 
1x PIC 
Wash buffer B 20 mM HEPES, pH 8.0 
250 mM LiCl
 
1 mM EDTA 
0.5% NP-40 
0.5% Na-Deoxycholat 
0.5 mM PMSF 
1x PIC 
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2.2 Methods 
2.2.1 Cell purification 
2.2.1.1 Isolation of human rosette-positive and -negative cells 
Human peripheral CD4 Th cells from healthy donors and patients with RA were used in this 
work. Total populations of CD4 Th cells were isolated from heparinized peripheral blood. In the 
first step, PBMCs were isolated by centrifugation of the blood over a Ficoll (Biotest) layer. 10 
ml Ficoll were loaded under 20 ml blood diluted with 20 ml PBS and centrifuged at 400 xg for 
20 min at room temperature. PBMCs were harvested and washed once with PBS. 
In the second step (rosetting), PBMCs were incubated with sheep erythrocytes to isolate the so-
called rosette-positive cells. The CD58 homologue expressed on sheep erythrocytes binds to 
CD2 that is expressed on T cells and NK cells, but not on other PBMCs (e.g. monocytes and B 
cells) (Rosenberg et al. 1979). For rosetting, PBMCs were resuspended at 10x106 cells/ml in 
RPMI1640 and incubated with 1/2 volume of FCS and 1/2 volume of sheep erythrocytes (2x106 
cells/ml) at 37°C for 10 min. Afterwards, cells were centrifuged for 10 min at 255 xg and 
incubated at 4°C for 45 min to allow the rosette formation between sheep erythrocytes and CD2 
positive cells. Later, cells were carefully resuspended and centrifuged over a 10 ml Ficoll layer 
for 20 min at 400 xg. The rosettes of T cells bound to the erythrocytes sedimented through the 
Ficoll and were collected in the pellet, while the rosette-negative cells formed a cell ring above 
the Ficoll layer. The pellet of rosette-positive cells was resuspended with 5 ml/pellet of 155 mM 
NH4Cl to lyse the sheep erythrocytes and then washed twice with PBS. In the next step, CD4 T 
cells were isolated by negative selection from rosette-positive cells (see section 2.2.1.2). 
In some cases, rosette-negative cells (T cell-depleted PBMCs) were collected and used to isolate 
B cells or monocytes. Rosette-negative cells were harvested, incubated with 10 ml 155 mM 
NH4Cl for 2 min at room temperature to lyse contaminating sheep erythrocytes and washed with 
PBS. Afterwards, B cells or monocytes were isolated by negative selection from rosette-negative 
cells (see section 2.2.1.5 and 2.2.1.6). 
2.2.1.2  Isolation of CD4 T cells and naïve CD4 Th cells 
For isolation of total CD4 Th cells the human CD4 T Cell Isolation kit (Miltenyi Biotec) was 
used. The magnetic activated cell sorting (MACS) isolation procedure is a magnetic separation 
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of cells. First, rosette-positive cells were resuspended in MACS buffer and non-CD4 Th cells 
were labeled with biotin-conjugated antibodies against CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR γ/δ and Glycophorin A for 5 min at 4°C. Afterwards, antibodies were magnetically 
conjugated to anti-Biotin MicroBeads for 10 min at 4°C. Unbound beads were removed by 
washing the cells with PBS, and up to 10x107 cells were resuspended in 1 ml MACS buffer. The 
cell suspension was applied onto an LS MACS column (large separation column) placed in the 
magnetic field. When the LS column is placed in the magnetic field, labeled non-CD4 Th cells 
stack in the column. The column was washed three times with 3 ml MACS buffer to let all 
unlabeled CD4 Th cells run through. CD4 Th cells were then used for further MACS separation. 
For isolation of naïve CD4 Th cells the human CD4 Th Cell Isolation kit II (Miltenyi Biotec) 
was used. First, rosette-positive cells were resuspended in MACS buffer and non-naïve CD4 Th 
cells were labeled with biotin-conjugated antibodies against CD8, CD14, CD15, CD16, CD19, 
CD25, CD34, CD36, CD45RO, CD56, CD123, TCR γ/δ, HLA-DR, and Glycophorin A for 10 
min at 4°C. Unbound antibodies were removed by washing the cells with PBS, and up to 10x107 
cells were resuspended in 1 ml MACS buffer. Afterwards, antibodies were magnetically 
conjugated to anti-Biotin MicroBeads for 10 min at 4°C. Unbound beads were removed by 
washing the cells with PBS, and up to 10x107 cells were resuspended in 1 ml MACS buffer. The 
cell suspension was applied onto an LS MACS column placed in the magnetic field. When the 
LS column is placed in the magnetic field, labeled non-naïve CD4 Th cells stack in the column. 
The column was washed three times with 3 ml MACS buffer to let all unlabeled naïve CD4 Th 
cells run through. Naïve CD4 Th cells were then used for further MACS separation. 
2.2.1.3 Isolation of CD127- CD4 Th cells 
For isolation of CD127- CD4 Th cells the human CD127 MicroBead kit (Miltenyi Biotec) was 
used. First, CD4 Th cells were resuspended in MACS buffer and CD127+ cells were labeled 
with biotin-conjugated antibodies against CD127 for 10 min at 4°C. Afterwards, antibodies were 
magnetically conjugated to anti-Biotin MicroBeads for 15 min at 4°C. Unbound beads were 
removed by washing the cells with PBS, and up to 10x107 cells were resuspended in 1 ml MACS 
buffer. The cell suspension was applied onto an LS MACS column placed in the magnetic field. 
When the LS column is placed in the magnetic field, labeled CD127+ cells stack in the column. 
The column was washed three times with 3 ml MACS buffer to let all unlabeled CD127- CD4 
Th cells run through. CD127- CD4 Th cells were then used for further MACS separation. 
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2.2.1.4 MACS separation of CD25+ and CD25- T cells 
For isolation of CD25+ (Tregs) and CD25- (Tconvs) CD4 Th cells the human CD25 MicroBeads 
II (Miltenyi Biotec) were used. First, the Tregs were magnetically labeled with biotin-conjugated 
antibodies against CD25 incubated at 4°C for 15 min. Unbound beads were removed by washing 
the cells with PBS, and up to 10x107 cells were resuspended in 1 ml MACS buffer. The cell 
suspension was applied onto a MS MACS column (mini scale) placed in the magnetic field. 
When the MS column is placed in the magnetic field, labeled CD25+ cells stack in the column. 
The column was washed three times with 500 µl MACS buffer to let all unlabeled cells run 
through. After removal of the MS column from the magnetic field, the Tregs were eluted with 1 
ml MACS buffer. A part of the CD4 T cells were labeled with CD25 Microbeads as described 
above. Unlabeled Tconvs were applied onto an LD MACS column (large depletion column) to 
completely remove contaminating Tregs. The LD column was washed twice with 2 ml MACS 
buffer and Tconvs were collected as the flow through. Separated Tregs and Tconvs were washed 
once with PBS and used in further experiments. 
2.2.1.5 Isolation of B cells 
For isolation of B cells the human B cell Isolation kit II (Miltenyi Biotec) was used. First, 
rosette-negative cells were resuspended in MACS buffer and non-B cells were labeled with 
biotin-conjugated antibodies against CD2, CD14, CD16, CD36, CD43, Glycophorin A for 5 min 
at 4°C. Afterwards, antibodies were magnetically conjugated to anti-Biotin MicroBeads for 10 
min at 4°C. Unbound beads were removed by washing the cells with PBS, and up to 10x107 cells 
were resuspended in 1 ml MACS buffer. The cell suspension was applied onto an LS MACS 
column placed in the magnetic field. When the LS column is placed in the magnetic field, 
labeled non-B cells stack in the column. The column was washed three times with 3 ml MACS 
buffer to let all unlabeled B cells run through. B cells were then used for DNA methylation 
experiments. 
2.2.1.6 Isolation of monocytes 
For isolation of monocytes the human Monocyte Isolation kit II (Miltenyi Biotec) was used. 
First, rosette-negative cells were resuspended in MACS buffer, FcR Blocking reagent was added, 
and non-monocyte cells were labeled with biotin-conjugated antibodies against CD3, CD7, 
CD16, CD19, CD56, CD123 and Glycophorin A for 10 min at 4°C. Afterwards, antibodies were 
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magnetically conjugated to anti-Biotin MicroBeads for 15 min at 4°C. Unbound beads were 
removed by washing the cells with PBS, and up to 10x107 cells were resuspended in 1 ml MACS 
buffer. The cell suspension was applied onto an LS MACS column placed in the magnetic field. 
When the LS column is placed in the magnetic field, labeled cells stack in the column. The 
column was washed three times with 3 ml MACS buffer to let all unlabeled monocytes run 
through. Monocytes were then used for DNA methylation experiments. 
2.2.2 Cell culture 
Culturing of primary cells or cell lines was carried out in RPMI1640 medium or DMEM 
supplemented with penicillin G/streptomycin (50 units/ml), L-glutamine (2 mM) (all from Life 
technologies) and 10% NHS. Cell cultures were maintained at 37°C in a humidified atmosphere 
containing 5% CO2. 
2.2.2.1 Maintenance of cell lines 
Human HeLa, human embryonic kidney (HEK)293, T cell leukemia (Jurkat), human 
megakaryoblastic leukemia (MEG-01) cell lines and murine T cell leukemia line (EL-4) were 
obtained from the American Type Culture Collection (ATCC). HeLa, HEK293, and EL-4 cells 
were split 2-3 times a week in DMEM complete medium. Jurkat and MEG-01 cells were 
maintained in RPMI complete medium and split every 2-3 days. 
2.2.2.2 In vitro IL-4 stimulation 
The effect of IL-4 on MafF expression in effector T cells was assessed employing an in vitro 
culture. Freshly isolated naïve Tconvs (1.2x106/well in a 12-well plate) were stimulated with 
anti-CD3/CD28-Dynabeads (bead to cell ratio 1:4) in the presence of human recombinant IL-2 
(10 units/ml) and in the presence or absence of human recombinant IL-4 (31.25 ng/ml). After 5 
days of stimulation, the cells were harvested, washed, counted, and either used for intracellular 
staining for MafF or lysed for SDS-polyacrylamide gel electrophoresis (PAGE) and Western 
blotting for MafF according to sections 2.2.3.4 or 2.2.14, respectively. 
2.2.2.3 In vitro Treg induction 
Freshly isolated CD25- naïve Tconvs (1.2x106/well in a 12-well plate) were cultivated for a total 
of 4 days in RPMI1640 supplemented with human recombinant IL-2 (50 units/ml), 10% NHS, 
anti-CD3/CD28-Dynabeads (bead to cell ratio 1:4), in the presence or absence of human 
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recombinant TGF-β (5 ng/ml) and retinoic acid (100 nM). After 4 days of stimulation, the cells 
were harvested, counted, and stained for intracellular Foxp3-expression according to section 
2.2.3.4. 
2.2.2.4 Activation of primary human T cells 
To analyze the effect of TCR engagement on the transcriptional regulation of GARP, Tregs and 
Tconvs were stimulated with anti-CD3/CD28-Dynabeads (Life technologies) at a ratio of 1:1 in 
the presence of 100 units/ml recombinant human IL-2. After 1-4 days of stimulation, the cells 
were harvested, washed, counted, and prepared for the respective experiment. 
2.2.3 Flow cytometry 
Analysis of the expression of cell surface molecules or of intracellular cytokines and proteins on 
a single cell level was performed by fluorescence activated cell sorting (FACS) with a Cytomics 
FC500 flow cytometer (Beckman-Coulter). Fluorescence signals were determined using 
appropriate electronic compensation to exclude emission spectra overlap. All centrifugation steps 
were carried out at 3,000 xg for 2 min at room temperature. 
2.2.3.1 Flow cytometry of surface molecules 
For extracellular staining, 0.05-0.1x106 cells/staining were washed with 1 ml FACS buffer, 
resuspended in 50 μl FACS buffer and incubated with saturating amounts (2 µl) of directly 
fluorochrome-conjugated antibodies for 15 min at 4°C in the dark. Afterwards, cells were 
washed twice with 1 ml FACS buffer, resuspended in 300 μl FACS buffer and analyzed. The 
majority of the CD4 T cells (≥95 %) were positive for CD3 and CD4. Tregs were CD127 
negative and ∼90% CD25 positive. Tconvs were ∼80% positive for CD127 and ≥98% negative 
for CD25. B cells were ≥90% positive for CD19 and CD20. In addition, monocytes were ≥90% 
positive for CD14 and negative for CD16. 
2.2.3.2 Flow cytometry for GARP 
For surface staining of GARP, equal amounts of cells were stained with 25 µl of anti-GARP 
hybridoma supernatant (Clone 7H2) or 0.25 µl of 0.5 mg/ml rat IgG as isotype control for 15 
min at 4°C in the dark. Next, cells were washed with 1 ml FACS buffer, resuspended in 50 µl, 
and incubated with 0.25 µl of secondary antibody (PE-labeled anti-rat IgG) and 2 µl of FITC-
labeled anti-CD4 antibody for 15 min at 4°C in the dark. Finally, cells were washed, resuspended 
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in 300 µl FACS buffer and analyzed. 
2.2.3.3 Intracellular flow cytometry for STAT1 
For intracellular staining of total STAT1 or phosphorylated STAT1 (pS727), 1x106 cells/staining 
were fixed with 3% PFA for 10 min at 37°C, washed once with PBS and permeabilized with 
0.1% (w/v) saponin in FACS buffer (FACS-Saponin). All incubation and washing steps were 
performed with FACS-Saponin. Unspecific binding sites were blocked with 4% rat and mouse 
serum for 10 min at 4°C. After blocking, cells were washed once and incubated with saturating 
amounts of PE-anti-total STAT1 and APC-anti-STAT1 (pS727) antibodies for 30 min at 4°C. 
Afterwards, cells were washed twice, resuspended in 300 μl FACS buffer and analyzed. 
2.2.3.4 Intracellular flow cytometry for Foxp3 or MafF 
For intracellular staining of Foxp3 or MafF, the Human Foxp3 Buffer set (BD Biosciene) was 
used according to manufacturer's instructions. Briefly, 1x106 cells/staining were fixed with 1x 
Human Foxp3 buffer A for 10 min at room temperature, washed once with FACS buffer and 
permeabilized in 1x Permeabilization solution for 30 min at room temperature. Then, cells were 
centrifuged and unspecific binding sites were blocked with 4% rat and mouse serum in FACS 
buffer for 10 min at 4°C. After blocking, cells were split into two tubes and either incubated with 
saturating amounts of PE/APC-anti-Foxp3, anti-MafF antibodies or respective isotype controls 
for 30 min at 4°C. Afterwards, cells stained for Foxp3 were washed twice, resuspended in 300 μl 
FACS buffer and analyzed. The cells stained for MafF were washed twice with FACS buffer and 
incubated with a PE-labelled secondary antibody for 30 min at 4°C. Afterwards, cells were 
washed twice, resuspended in 300 μl FACS buffer and analyzed. 
2.2.4 Isolation of nucleic acids 
Total RNA isolation was performed using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. All centrifugation steps were performed at 16,000 xg at room 
temperature. In brief, 1-5x106 cells were lysed with 700 μl RTL buffer containing 1% β-
mercaptoethanol and centrifuged in a QIAShredder column for 2 min. One volume of 70% 
ethanol was added to the eluate and loaded onto an RNeasy column. After short centrifugation 
(30 sec), each column was washed with 700 μl RW1 buffer. After centrifugation, the columns 
were washed twice with 500 μl RW1 buffer. RNA was eluted with 32 μl of RNase-free 
water/column by centrifugation the columns for 1 min. The concentration of RNA was 
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determined by measuring the absorbance at 260 nm (A260). 
Genomic DNA (gDNA) isolation was performed using the QIAamp DNA Blood Mini kit 
(Qiagen) according to the manufacturer’s instructions. All centrifugations were performed at 300 
xg at room temperature. In brief, 0.5-5x106 cells were resuspended in 160 μl PBS containing 40 
µg RNase A and 20 µl QIAGEN Protease and 200 µl of buffer AL were added.  The reaction 
was incubated at 56°C for 10 min, 200 µl 100% ethanol was added, and the mixture was applied 
to a QIAamp Mini spin column. After centrifugation, the column was washed with 500 µl buffer 
AW1, followed by washing with 500 µl buffer AW2. After drying the column, the DNA was 
eluted into a new 1.5 ml tube with 32 µl of buffer AE. The concentration of DNA was 
determined by measuring the absorbance at 260 and 280 nm (A260/A280). 
2.2.5 Complementary DNA (cDNA) synthesis 
0.1-1 μg of total RNA was transcribed to cDNA using the Affinity Script QPCR cDNA 
Synthesis kit (Agilent Technologies) according to manufacturer’s protocol. Briefly, RNA was 
incubated for 5 min at 25°C, 5 min at 42°C, 30 min at 55°C and 5 min at 95°C in a total volume 
of 20 μl containing 1x First strand mastermix, 12.75 nM Oligo(dT), 2.25 nM random primer, and 
1 μl Affinity Script RT/RNase Block Enzyme mixture. 
2.2.6 Real-time PCR 
2.2.6.1 TaqMan Gene Expression assays 
Real-time PCR was performed with TaqMan Gene Expression assays in an ABI Prism 7000 
Sequence Detection System (Life technologies). The TaqMan assays contain two unlabeled 
primers (For and Rev) and one specific minor groove binder (MGB) probe. The 5’ end of the 
probe is linked to a reporter dye (FAM or VIC) and the 3’ end is linked to a non-fluorescent 
quencher (NFQ) and a MGB. During PCR, the probe anneals to the complementary sequence 
between For and Rev primers. However, the proximity of the NFQ and the reporter dye prevents 
the reporter fluorescence primarily by Förster-type energy transfer. During elongation of the 
PCR product the 5’ nuclease activity of the polymerase cleaves the probe, thereby releasing the 
reporter dye. This results in increased fluorescence of the reporter. Each sample was amplified in 
duplicates. PCR amplification was performed using 1 μl of cDNA in a final volume of 20 μl. The 
TaqMan Gene Expression reaction contained 1x TaqMan Universal PCR mastermix and 1x 
TaqMan Gene Expression Assay mix. The thermal cycling conditions were as follows: hot 
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enzyme activation at 95°C for 10 min followed by 40 cycles of amplification – DNA 
denaturation at 95°C for 10 sec and annealing of primers/DNA extension at 60°C for 1 min. The 
list of genes analyzed by real-time PCR and the respective assays are listed in “Materials”. 
Relative quantification was performed by calculating the difference in cross-threshold values 
(ΔCt) of the gene of interest and a housekeeping gene (Cyclophilin) according to the formula 2-
ΔCt
. 
2.2.6.2 SYBR Green detection 
Real-time PCR was performed with SYBR Green detection in an ABI Prism 7000 Sequence 
Detection System (Life technologies). Primers for ChIP analysis (For and Rev) for SYBR Green 
PCR were designed using the MacVector software to amplify fragments up to 120 base pair (bp) 
long. SYBR Green dye intercalates into ds DNA and emits fluorescence only when bound to 
DNA. During PCR, the polymerase amplifies the target sequence and the SYBR Green dye binds 
each new copy. The result is an increase in fluorescence intensity proportionate to the amount of 
PCR product produced. Each sample was amplified in duplicates or triplicates. PCR 
amplification was performed using 1 μl of DNA in a final volume of 20 μl. The SYBR Green 
PCR reaction included 1x Power SYBR Green PCR mastermix and 0.2 µM primermix. The 
thermal cycling conditions were as follows: hot enzyme activation at 95°C for 10 min followed 
by 40 cycles of amplification – DNA denaturation at 95°C for 10 sec and annealing of 
primers/DNA extension at 60°C for 1 min. For SYBR Green-based detection, a dissociation 
curve was carried out by one cycle following the last amplification cycle to control for the 
specificity of PCR amplification: 95°C for 15 sec, 60°C for 30 sec, 95°C for 15 sec. The list of 
genes analyzed by real-time PCR and SYBR Green primers are listed in “Materials”. Relative 
quantification was performed by calculating the difference in cross-threshold values (ΔCt) of the 
region of interest and the Input control (see section 2.2.11) according to the formula 2-ΔCt.  
2.2.6.3 Genotyping of SNPs 
Genotypes of the GARP gene locus were determined by TaqMan SNP Genotyping assays (Life 
technologies). SNP Genotyping assays contain two unlabeled PCR primers (For and Rev), one 
VIC dye-labeled probe that detects the allele 1 sequence and one FAM dye-labeled probe that 
detects the allele 2 sequence. The 5’ end of the probe is linked to the reporter dye (FAM or VIC) 
and the 3’ end is linked to a NFQ and a MGB. The principle of the PCR is the same as for 
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TaqMan Gene Expression assays. Each probe anneals specifically to a complementary sequence 
between the primers. The probes are designed so their off-target hybridization is highly reduced, 
thus, the fluorescence signal generated by the PCR amplification indicates which allele is in the 
sample. Signals of only one dye indicate homozygosity and signals of both dyes indicate 
heterozygosity. 
PCR amplification was performed using 10 ng of DNA in a final volume of 10 μl. The TaqMan 
SNP Genotyping reaction contained 1x TaqMan Universal PCR mastermix and 0.25 µM SNP 
Genotyping Assay mix. The thermal cycling conditions were as follows: hot enzyme activation 
at 95°C for 10 min followed by 40 cycles of amplification – DNA denaturation at 95°C for 15 
sec and annealing of primers/DNA extension at 60°C for 1 min. The list of SNPs analyzed by 
real-time PCR and the respective assays are listed in “Materials”. 
2.2.7 5’Rapid Amplification of cDNA Ends (RACE) 
The 5’RACE was performed using the 5’RACE System for Rapid Amplification of cDNA Ends 
Version 2.0 (Life technologies) according to manufacturer’s protocol. The method is used to 
amplify nucleic acid sequences from mRNA templates between a defined internal site and 
unknown sequences at the 5’ end of the mRNA. 4 µg total RNA from 4 different donors were 
used for each reaction. Reverse transcription with the gene-specific primer 1 (GSP1) was 
performed in a total volume of 25 µl. Therefore, 2.5 pmol GSP1, 1x PCR Buffer, 2.5 mM 
MgCl2, 0.4 mM dNTPs, 10 µM DTT, and 1 µl of Superscript II RT were added to the RNA. The 
reaction was carried out at 42°C for 50 min, followed by 70°C for 15 min. Then, 1 µl of the 
RNase Mix was added and incubated for 30 min at 37°C. The cDNA was purified with the 
S.N.A.P. column purification. The TdT-tailing of the cDNA was carried out in 25 µl by adding 
10 µl of purified cDNA, 1x tailing buffer, 0.2 mM dCTP, and 1 µl TdT. The reaction was 
incubated for 10 min at 37°C followed by 10 min at 65°C. The dT-tailed cDNA was then used in 
a PCR reaction with a total volume of 25 µl adding the following contents: 1x Reaction buffer, 
1.5 mM MgCl2, 0.2 mM dNTPs, 0.4 µM GSP2, 0.4 µM AAP, and 0.05 units Taq-DNA-
Polymerase. The cycling parameters were as follows: 35 cycles at 94°C for 1 min, 55°C for 30 
sec, 72°C for 2 min. The nested-PCR was carried out similar like above, except of the following 
changes: nested GSP and AUAP were used at the same concentrations. PCR products were then 
used in a real-time PCR with specific TaqMan Gene Expression assays for transcript variant 1 or 
2 (see section 2.2.6.1). 
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2.2.8 DNA amplification and purification 
2.2.8.1  AmpliTaq DNA Polymerase PCR (Life technologies) 
PCR amplification was performed using 1 μl of cDNA, gDNA or plasmid DNA in a final 
volume of 25 μl. The reaction contained 1x GeneAmp® PCR buffer I, 250 µM dNTPs, 0.5 µM 
Primermix, and 0.5 units AmpliTaq® DNA Polymerase. Cycling parameters were as follows: 
95°C 5 min, 35 cycles at 95°C 30 sec, 60°C 30 sec, 72°C 1-2 min, and a final extension at 72°C 
for 7 min. 
2.2.8.2 Herculase II Fusion DNA Polymerase PCR (Agilent Technologies) 
PCR amplification was performed using 1 μl of cDNA or gDNA in a final volume of 25 μl. The 
reaction contained 1x Herculase II reaction buffer, 250 µM dNTPs, 0.5 µM Primermix, 3% 
DMSO, and 0.25 µl Herculase II fusion DNA polymerase. Cycling parameters were as follows: 
98°C 4 min, 35 cycles at 98°C 20 sec, 60°C 20 sec, 68°C 1-2 min, and a final extension at 68°C 
for 3 min. 
2.2.8.3 GeneAmp High Fidelity PCR System (Life technologies) 
PCR amplification was performed using 1 μl of cDNA or gDNA in a final volume of 25 μl. The 
reaction contained 1x GeneAmp High Fidelity PCR buffer, 250 µM dNTPs, 0.5 µM Primermix, 
and 0.2 µl GeneAmp High Fidelity Enzyme mix. Cycling parameters were as follows: 95°C 5 
min, 35 cycles at 95°C 30 sec, 60°C 30 sec, 72°C 1-2 min, and a final extension at 72°C for 7 
min. 
2.2.8.4 EpiMark Hot Start Taq DNA Polymerase PCR (New England Biolabs) 
PCR amplification was performed using 1 μl of bisulfite treated DNA in a final volume of 25 μl. 
The reaction contained 1x EpiMark Hot Start Taq Reaction buffer, 200 µM dNTPs, 0.2 µM 
Primermix, and 1.25 units EpiMark Hot Start Taq DNA polymerase. Cycling parameters were as 
follows: 95°C 5 min, 35 cycles at 95°C 30 sec, 60°C 30 sec, 68°C 1-2 min, and a final extension 
at 68°C for 5 min. 
2.2.8.5 DNA fragment purification 
PCR products were purified with the QIAquick PCR Purification kit (Qiagen) according to 
manufacturer’s protocol to remove primers, nucleotides, enzymes, mineral oil, salts, and other 
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impurities from DNA samples. Briefly, 5 volumes of PB buffer were added to one volume of 
PCR reaction and transferred on a QIAquick column, centrifuged for 30 sec to bind DNA. The 
column was washed once with 750 µl PE buffer and eluted in 32 µl Elution buffer. 
PCR products were separated on a 1-2% agarose gel. Therefor, 1-2 g of agarose (1-2%) was 
boiled in 100 ml of 1x TAE buffer until the agarose was melted. The agarose solution was 
cooled to < 50°C, mixed with 5 μl of SYBR® Safe DNA Gel stain (Life technologies) and filled 
into the sealed gel tray. To perform DNA separation, the polymerized agarose gel was placed in 
the gel chamber Nautico 10x107 (H. Hölzel) filled with 1x TAE buffer to cover the gel. 5 μl of 
each PCR sample were mixed with 1x DNA loading buffer and transferred into a gel pocket. To 
control the size of the PCR products, a suitable molecular weight standard (100 bp or 1 kb DNA 
ladder, Fermentas) was included in each electrophoresis run. Electrophoresis was performed at 
100V for 30 min. The DNA bands were visualized and photographed on a UVT-28 MP 
transilluminator (Herolab). PCR fragments were excised from the gel with a scalpel and purified 
with the QIAquick Gel Extraction kit according to manufacturer’s protocol to removes primers, 
nucleotides, enzymes, mineral oil, salts, and other impurities from DNA samples. Briefly, one 
volume of agarose gel was diluted in 5 volumes of QG buffer and incubated at 50°C for 10 min 
until the gel was dissolved completely. Then, one gel volume of 100 % isopropanol was added, 
the solution was loaded on a QIAquick column, and centrifuged for 30 sec to bind DNA. The 
column was washed once with 500 µl QG buffer and once with 750 µl PE buffer. Afterwards the 
DNA was eluted in 32 µl Elution buffer. 
2.2.9 Cloning 
For and Rev primers (see section 2.1.8) were used for MafF cds amplification. The Kozak 
sequence was introduced in the For primer and is shown underlined, for consecutive cloning 
steps. The Herculase-PCR product for the MafF cds was cloned into pcDNA3.1D/V5-His-TOPO 
vector. Cloned sequences were confirmed by sequencing (Eurofins Genomics). The MafF cds 
was released from pcDNA3.1D/V5-His-TOPO by digestion with HindIII and XhoI restriction 
nucleases and inserted into pEGFP-N1 vector between HindIII and SalI sites. 
For and Rev primers (see section 2.1.8) were used for GARP promoter and CNS region 
amplification. Restriction sites of EcoRV and HindIII shown underlined were introduced into 
For and Rev primers, for consecutive cloning steps. The PCR products for the promoter regions 
were cloned into pCR2.1-TOPO vector. Cloned sequences were confirmed by sequencing 
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(Eurofins Genomics). The promoter or CNS sequences were released from pCR2.1 by digestion 
with EcoRV and HindIII restriction nucleases and inserted into pGL4.10[luc2] vector or pCpGL-
basic between EcoRV and HindIII sites. 
NFAT-, Foxp3-, NF-κB-, RXR, and Sp1-binding sites were described using several in silico-
prediction tools (Cartharius et al. 2005; Farre et al. 2003; Messeguer et al. 2002; Quandt et al. 
1995). The down-stream P1 NFAT/Foxp3-mutant sequences were synthesized (Eurofins 
Genomics), digested with EcoRV and HindIII restriction nucleases (New England Biolabs) and 
inserted into pGL4.10[luc2] vector between EcoRV and HindIII sites. The up-stream promoter 
P2 Foxp3 sequences and the down-stream promoter P1 RXR mutant sequences were generated 
using site-directed mutagenesis. pDEST12.2 (Promega) expression vector including human 
Foxp3 cds was kindly provided by Prof. Dr. Heissmeyer (Ludwig-Maximilians-Universität, 
Munich). 
2.2.9.1 Restriction enzyme digestion 
1 µg of DNA were digested in a total volume of 20 µl containing 2.5 units/µl suitable restriction 
enzymes with respective 1x supplied Reaction buffer as listed in section 5.1.5. The reaction was 
carried out at 37°C for 1 hour followed by an inactivation step at 65°C for 20 min. If gel 
extraction was necessary, 8 µg of DNA were digested in a total volume of 160 µl. 
2.2.9.2 TOPO TA Cloning 
TOPO TA Cloning was performed using the TOPO TA Cloning kit (Life technologies) 
according to manufacturer’s instructions. Briefly, 1-2 µl freshly purified PCR product were 
mixed with 10 ng pCR2.1-TOPO or pcDNA3.1D/V5-His-TOPO and 1x Salt solution (0.2 M 
NaCl, 0.01 M MgCl2) in a total volume of 6 µl. The ligation was carried out at room temperature 
for 30 min, transferred onto ice and 2 µl were subsequently used in a transformation reaction. 
2.2.9.3 Quick Ligase Reaction 
Purified PCR products or cut out and purified fragments (e.g. after restriction enzyme digest) 
from pcDNA3.1D/V5-His-TOPO or pCR2.1-TOPO were ligated into pEGFP-N1, 
pGL4.10[luc2] or pCpGL-basic (Klug et al. 2006) using the Quick Ligation kit (New England 
Biolabs) in a final volume of 20 µl. 50 ng of vector were combined with a 3-fold molar excess of 
insert, 1x Quick Ligation buffer and 1 μl of Quick T4 DNA ligase. The ligation was carried out 
at room temperature for 30 min. 
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2.2.9.4 Site-directed mutagenesis 
Up- or down-stream promoter plasmid inserts were mutated with the QuickChange® Lightning 
Site-Directed Mutagenesis kit (Agilent Technologies) according to manufacturer's protocol. 
Oligonucleotides listed in section 2.1.8 were used for mutation reactions. Oligonucleotide 
primers were designed that they include a restriction site to confirm mutagenesis with a 
restriction digest. The mutagenesis was performed in a total volume of 25 µl consisting of 1x 
Quick Change® Lightning buffer, 25 ng vector, 0.5 µl dNTP mix, 0.75 µl QuickSolution 
reagent, 62.5 ng oligonucleotide primers and 0.5 µl QuickChange® Lightning enzyme. The 
cycling parameters were as follows: 95°C 2 min, 18 cycles at 95°C 20 sec, 60°C 20 sec, 68°C 3 
min, and a final extension at 68°C for 5 min. Afterwards, 2 µl of the provided DpnI restriction 
enzyme was added directly to each amplification reaction and incubated for 5 min at 37°C to 
digest parental methylated DNA. Subsequently, transformation with XL10-Gold® 
Ultracompetent cells was performed. Cells were pre-chilled in a 13 ml polyprolene round-bottom 
tube on ice and 2 µl of ß-mercaptoethanol was added. After 2 min incubation, 2 µl of the DpnI-
treated DNA from each reaction was transferred into the bacteria tube. The reaction was 
incubated for 30 min on ice and heated for 30 sec to 42°C. After 2 min incubation on ice, 100 µl 
of each transformation reaction was plated on an ampicillin-containing LB agar plate and 
incubated for 16 hours at 37°C. 5-10 colonies were picked and transferred into a 13 ml falcon 
with 3 ml of LB broth (liquid) containing ampicillin. After overnight culture at 37°C plasmid 
DNA was isolated and control restriction digest was performed to check that mutagenesis was 
working. Positive clones were then sent out for sequencing (Eurofins Genomics) to control for 
the right sequence. 
2.2.9.5 LB plates 
16 g LB agar (Life technologies) was diluted in 500 ml MilliQ. The solution was stirred for 10 
min and autoclaved. After cooling to < 50°C, 50 mg ampicillin (Life technologies) or zeocin 
(InvivoGen) was added. 20 ml were transferred into each petri dish under the sterile bench. After 
polymerization, plates were stored at 4°C for a maximum of 2 weeks. Before use, plates were 
pre-warmed to 37°C and 30 µl of 20 mg/ml X-Gal (Life technologies) were spread onto one 
plate, if blue/white screening was performed (e.g. pCR2.1-TOPO). 
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2.2.9.6 Transformation 
2 µl of the ligation reaction were carefully added into one vial of One Shot TOP10 chemically 
competent Escherichia coli (E.coli) cells (Life technologies) and incubated for 30 min on ice. 
Then, cells were heat-shocked for 30 sec at 42°C, 250 µl S.O.C. medium was added and shaken 
horizontally at 200 rpm at 37°C for one hour. 100-200 µl from each transformation was spread 
on a pre-warmed selective plate. Plates were incubated at 37°C for 12 hours to ensure efficient 
blue/white selection and obtain visible colonies. 5-10 colonies were taken to be cultured 
overnight at 37°C and 225 rpm in 3 ml LB broth (liquid) containing ampicillin or kanamycin. 
2 µl of the ligation reaction with pCpGL luciferase vectors were carefully added into one vial of 
One Shot PIR1 chemically competent E.coli cells (Life technologies) because the vector includes 
a R6K origin. Cells were incubated for 30 min on ice, heat-shocked for 30 sec at 42°C, 250 µl 
S.O.C. medium was added and shaken horizontally at 200 rpm at 37°C for one hour. 100-200 µl 
from each transformation was spread on a pre-warmed selective plate with zeocin. Plates were 
incubated at 37°C for 12 hours to obtain visible colonies. 5-10 colonies were taken to be cultured 
overnight at 37°C and 225 rpm in 3 ml LB broth (liquid) containing zeocin. Plasmid DNA was 
isolated, checked by PCR with appropriate primers and digested with suitable restriction 
enzymes to confirm the presence and the correct orientation of the insert. DNA sequencing was 
performed using either the “value read tube” or the “prepaid plate kit” service from Eurofins 
Genomics. 750 ng of plasmid DNA in a total volume of 15 µl were used per sequencing. 2 µl of 
10 µM sequencing primer were enclosed if necessary. If “prepaid plate kits” were used (bisulfite 
sequencing), plasmid clones were send out as stab cultures in 96-well plates containing agar with 
ampicillin. 
2.2.9.7 Plasmid DNA miniprep 
Miniprep was performed with the QIAprep Spin Miniprep kit (Qiagen) following manufacturer’s 
instructions for a desired DNA yield lower than 20 µg. Briefly, 2 ml of overnight cultured 
bacteria were pelleted at 10,000 xg for 2 min and resuspended in 250 µl buffer P1. Next, 250 µl 
buffer P2 were added and tubes were inverted 4-6 times before the lysis was terminated with 350 
µl of buffer N3. After centrifugation at 16,000 xg for 10 min, the supernatants were decanted 
onto a QIAprep spin column to bind plasmid DNA. The columns were washed once with 500 µl 
PB and 750 µl PE buffer. After centrifugation, DNA was eluted with 32 µl Elution buffer. The 
concentration and purity of the plasmid DNA was determined by measuring the absorbance at 
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230 nm, 260 nm, and 280 nm (A260/A230, A260/A280). 
2.2.9.8 Plasmid DNA maxiprep 
Maxiprep was performed with the QIAGEN Plasmid Maxi kit (Qiagen) following 
manufacturer’s instructions for a desired DNA yield up to 500 µg. Briefly, 300 ml of overnight 
cultured bacteria were pelleted at 10,000 xg for 2 min and resuspended in 10 ml buffer P1. Next, 
10 ml buffer P2 was added and tubes were inverted 4-6 times and incubated for 5 min at room 
temperature. The lysis was terminated with 10 ml of buffer P3 on ice for 20 min. After 
centrifugation at 20,000 xg for 10 min, the supernatants were decanted onto an equilibrated 
column to bind plasmid DNA. The columns were washed twice with 30 ml buffer QC and DNA 
was eluted in pre-warmed 15 ml buffer QF. Then, DNA was precipitated with 10.5 ml 
isopropanol and centrifuged at 20,000 xg. After centrifugation, DNA was air-dried and 
redissolved in 500 µl. The concentration and purity of the plasmid DNA was determined by 
measuring the absorbance at 230 nm, 260 nm, and 280 nm (A260/A230, A260/A280). Afterwards, 
DNA concentration was adjusted to 0.5 µg/µl. 
2.2.9.9 Bacterial glycerol stock 
3 ml of overnight cultured bacteria in LB broth (liquid) were supplemented with 390 µl 100 % 
glycerol and split into three 1.5 ml Cryotubes (Greiner, Kremsmünster, Austria). The bacteria 
stock were frozen and stored at -80°C. 
2.2.10 Luciferase reporter assays 
Cell lines and primary T cells were transfected with reporter luciferase vectors using the 
appropriate Amaxa® Cell line or Human T Cell Nucleofector kit (Lonza). The Amaxa 
Nucleofector technology is based on the transient creation of small pores in cell membranes by 
electroporation in combination with cell-type specific reagents. The plasmid is directly 
transferred into the cytoplasm and nucleus. Luciferase reporter assays were carried out with the 
Dual-luciferase Reporter Assay system (Promega). The activities of firefly (Photinus pyralis) 
and renilla (Renilla reniformis) luciferases are measured sequentially from a single sample. 
Luciferases are enzymes that catalyze the oxidative carboxylation of a substrate in the presence 
of O2 to yield photo emission (bioluminescence). After detection of the firefly luminescence the 
reaction is quenched and the renilla reaction is initiated by adding the renilla-specific substrate. 
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2.2.10.1 Transfection of the EL-4 cell line 
EL-4 cells were transfected with the Amaxa Cell Line Nucleofector kit L (Lonza) according to 
manufacturer's instructions. Briefly, 9.6x106 cells were resuspended in 656 µl Cell Line 
Nucleofector solution L + 144 µl supplement and divided into 8 transfections. 5 µg promoter-
luciferase reporter vectors, 0.25 µg renilla control vector and 2.5 µg pDEST12.2-hFoxp3 
expression vector or pcDNA3.1-CTGFP control vector were used per transfection. The 
appropriate program C-009 was selected and 550 µl 10% FCS/DMEM was added after 
transfection. Cells were transferred to a 48 well plate and incubated at 37°C for 2 hours. Then, 
50 µl of the cell suspension was divided into 12 wells of a 96 well plate (100,000 cells per well). 
Treatment of cells with different stimuli was performed in triplets in a total volume of 75 µl per 
well. 10 ng/ml PMA, 1 µM ionomycin, 5 ng/µl TGF-β, 10 µM retinoic acid, 1 µg/ml CsA, and 
160 µM JSH-23 was used, respectively. Cells were incubated overnight at 37°C and 17 hours 
after transfection the dual-luciferase reporter assay was started. 
2.2.10.2 Methylation analysis with luciferase reporter assays 
Promoter sequences were cloned into the CpG-free vector, pCpGL-basic, as described above. 
Thus, upon methylation only the insert gets methylated. 1 µg of the vector was methylated in a 
total volume of 20 µl containing 1x NEBuffer 2, 3.2 mM S-Adenosylmethionine (SAM), and 4 
units of SssI methylase (New England Biolabs). The reaction was carried out at 37°C for 1 hour, 
followed by heating at 65°C for 20 min to stop the reaction. The methylated vector was purified 
using the QIAquick PCR purification kit (Qiagen). EL-4 cells were transfected with the Amaxa 
Cell Line Nucleofector kit L (Lonza) according to manufacturer's instructions. Briefly, 9.6x106 
cells were resuspended in 656 µl Cell Line Nucleofector solution L + 144 µl supplement and 
divided into 8 transfections. 5 µg methylated and non-methylated promoter-luciferase reporter 
vectors, 0.25 µg renilla control vector and 2.5 µg pDEST12.2-hFoxp3 expression vector or 
pcDNA3.1-CTGFP control vector were used per transfection. The appropriate program C-009 
was selected and 550 µl 10% FCS/DMEM was added after transfection. Cells were transferred to 
a 48 well plate and incubated at 37°C for 2 hours. Then, 50 µl of the cell suspension was divided 
into 12 wells of a 96 well plate (100,000 cells per well). Treatment of cells with different stimuli 
was performed in triplets in a total volume of 75 µl per well. 10 ng/ml PMA and 1 µM 
ionomycin were used, respectively. Cells were incubated overnight at 37°C and 17 hours after 
transfection the dual-luciferase reporter assay was started. 
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In some experiments inserts of the pGL4.10 vector were cut out and methylated separately. 1 µg 
of the insert was methylated in a total volume of 20 µl containing 1x NEBuffer 2, 3.2 mM SAM, 
1, 0.1, or 0.01 units of SssI methylase (New England Biolabs), respectively. The reaction was 
carried out at 37°C for 1 hour, followed by heating at 65°C for 20 min to stop the reaction. The 
methylated insert was purified using the QIAquick PCR purification kit (Qiagen) and ligated via 
the Rapid Ligation system back into the cut pGL4.10 vector. EL-4 cells were transfected with the 
Amaxa Cell Line Nucleofector kit L (Lonza) according to manufacturer's instructions. Briefly, 
3.6x106 cells were resuspended in 492 µl Cell Line Nucleofector solution L + 10x107 µl 
supplement and divided into 6 transfections. 1 µg methylated and non-methylated promoter-
luciferase reporter vectors, 0.05 µg renilla control vector and 0.5 µg pDEST12.2-hFoxp3 
expression vector or pcDNA3.1-CTGFP control vector were used per transfection. The 
appropriate program C-009 was selected and 250 µl 10% FCS/DMEM was added after 
transfection. Cells were transferred to a 48 well plate and incubated at 37°C for 2 hours. Then, 
50 µl of the cell suspension was divided into 6 wells of a 96 well plate (100,000 cells per well). 
Treatment of cells with different stimuli was performed in triplets in a total volume of 75 µl per 
well. 10 ng/ml PMA and 1 µM ionomycin were used, respectively. Cells were incubated 
overnight at 37°C and 17 hours after transfection the dual-luciferase reporter assay was started. 
2.2.10.3 Transfection of primary human T cells 
After isolation of primary human Tregs or Tconvs, cells were transfected with the Amaxa 
Human T Cell Nucleofector kit (Lonza) according to manufacturer's instructions. Briefly, 
approximately 5.4x106 cells were resuspended in 328 µl Human T Cell Nucleofector® Solution 
+ 72 µl Supplement and divided into 4 transfections. 2.5 µg promoter-luciferase reporter vectors, 
0.125 µg renilla control vector were used per transfection. The appropriate program U-014 was 
selected and 400 µl 10% NHS/RPMI was added after transfection. Cells were transferred to a 48 
well plate and incubated at 37°C for 2 hours. Then, 50 µl of the cell suspension was divided into 
9 wells of a 96 well plate (150,000 cells per well). Treatment of cells with different stimuli was 
performed in triplets in a total volume of 75 µl per well. Anti-CD3/CD28-Dynabeads (cell to 
bead ratio 1:1) in the presence of 100 units/ml human recombinant IL-2 or 10 ng/ml PMA and 1 
µM ionomycin were used, respectively. Cells were incubated overnight at 37°C and 17 hours 
after transfection the dual-luciferase reporter assay was started. 
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2.2.10.4 Dual-Luciferase Reporter assay 
After transfection and overnight-incubation of the cells 75 µl of the Luciferase Assay reagent II 
was added to each well and the suspension was transferred into a 96-well plate appropriate for 
luciferase measurement. After 10 min incubation at room temperature in the dark, the firefly 
luminescence was measured at an emission wavelength of 560 nm. Next, 75 µl of the 
Stop&Glo® reagent was added and after 10 min incubation at room temperature in the dark, the 
renilla luminescence was measured at an emission wavelength of 480 nm. The ratio of luciferase 
and renilla luminescence was calculated and those values were normalized to the empty control 
vector pGL4.10[luc2] and displayed as relative luciferase units. 
2.2.11 ChIP 
ChIP assay can be used to determine whether transcription factors or histone modifying 
complexes interact with a candidate gene sequence. Additionally, it is used to monitor the 
presence of histones with post-transcriptional modifications at specific genomic locations. Thus, 
targets of histone modifiers and transcription factors can be analyzed, the transcriptional state of 
the region can be detected, and regulatory regions (e.g. promoters, enhancers, or repressors) can 
be described. 
2.2.11.1 Histone modifications 
2-3x106 cells were resuspended in 10 ml RPMI complete medium and 1% formaldehyde was 
added to crosslink the chromatin for 10 min at room temperature. The reaction was stopped with 
125 mM glycine for 5 min at room temperature. All centrifugation steps were performed at 723 
xg at 15°C for 5 min. After centrifugation, the cell pellet was washed twice with ice-cold PBS. 
Then, the cells were resuspended in 250 µl Swelling buffer and incubated for 10 min at room 
temperature with iterated vortexing every 2 min. After centrifugation, cells were resuspended in 
250 µl Sonication buffer. The suspension was frozen at -80°C for at least 1 hour. Then, the 
sample was sonicated in a Bioruptor® Plus (Diagenode) for 25 cycles with 30 sec intervals. To 
sediment cell debris the sheared chromatin was centrifuged for 10 min at 16,000 xg at 4°C and 
supernatant was transferred to a new 1.5 ml tube. Afterwards, 34 µl of the sheared chromatin was 
re-crosslinked by adding 250 mM NaCl, 40 µg of Proteinase K and 20 µg of RNase A and digest 
for 2 hours at 55°C followed by stopping the reaction for 30 min at 95°C. The DNA was isolated 
using the GenElute PCR Clean-Up kit (Sigma-Aldrich) according to manufacturer’s protocol. 
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Briefly, 500 µl Column Preparation solution was added to each column. Then, 170 µl Binding 
solution (5 volumes) were added to the chromatin and transferred to the column. Centrifugation 
steps were performed at 13,000 xg for 1 min. The DNA was bound to the column by 
centrifugation and washed once with 500 µl Wash solution. The column was dried and DNA was 
eluted in 32 µl Elution solution. 15 µl were loaded with 2.2 µl of 6x Loading dye on a 2% 
agarose gel to check the fragment size that should range from 200 bp to 1000 bp. The other 15 µl 
were filled up to 30 µl with MilliQ and used as Input control. 
Next, Nunc Maxisorp 96 well plates (Thermo Scientific) were coated with antibodies. 100 µl 
ELISA/ELISPOT Coating buffer (ebioscience) were prepared per well and 2 µg of anti-
H3K4me3, anti-H3ac, anti-H3K27me3 or rabbit IgG control were added per well. Plate was 
closed with an adhesive foil and incubated at 4°C overnight. The next morning, the plate was 
washed three times with 200 µl of ELISA Wash buffer (ebioscience). To immunoprecipitate the 
fragmented DNA 100 µl per IP was used. The sheared chromatin was filled up to 400 µl with 
Sonication buffer and 100 µl was transferred into each well. The plate was shaken on an Orbital 
Shaker (Heidolph) at 300 rpm at room temperature for 90 min. The plate was washed twice with 
Sonication buffer, Wash buffer A, Wash buffer B, and TE buffer. To re-crosslink the precipitated 
chromatin 75 µl TE buffer, 250 mM NaCl, 40 µg of Proteinase K, 20 µg of RNase A and 0.5% 
SDS was added to each well in a total volume of 100 µl. The plate was incubated for 2 hours at 
65°C and 500 rpm. Then, 500 µl Binding solution of the GeneElute PCR Clean-up kit (Sigma-
Aldrich) was added to each sample and DNA purification was proceeded as stated above. The 
chromatin was stored at -20°C until real-time PCR analysis was performed with ChIP assay real-
time PCR primers (see section 2.1.8). 
2.2.11.2 Transcription factors and chromatin remodeling complexes 
For ChIP with antibodies against Foxp3, NFAT1, p50, c-Rel, p65, MLL1, RbBP5, and PLU-1 
the ChIP-IT High Sensitivity kit (Active Motif) was used with the following changes. For 4 IPs 
12x106 Tregs and Tconvs were isolated from 8-10 donors and resuspended in 10 ml 10% 
NHS/RPMI and 1% formaldehyde was added to crosslink the chromatin for 10 min at room 
temperature. The reaction was stopped with 125 mM glycine for 5 min at room temperature. All 
centrifugation steps were performed at 723 xg at room temperature for 5 min. After 
centrifugation, the cell pellet was washed three times with ice-cold PBS and 1 ml Cell Lysis 
buffer was added. After 10 min lysis on ice, cells were centrifuged and cell pellet was frozen for 
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at least 1 hour at -80°C. The pellet was resuspended in 1 ml Nuclear Lysis buffer and sheared 
with a dounce homogenizer. The chromatin was sonicated in a Bioruptor® Plus (Diagenode) 
twice for 25 cycles with 30 sec intervals. To sediment cell debris the sheared chromatin was 
centrifuged for 10 min at 16,000 xg at 4°C and the supernatant was transferred to a new 1.5 ml 
tube. The sample was filled up with ChIP buffer (Active Motif) supplemented with 1x PIC and 
1:100 PMSF to 930 µl. 30 µl were re-crosslinked by adding 144 µl TE buffer, 250 mM NaCl, 80 
µg Proteinase K, and 20 µg RNase A and incubate for 2 hours at 55°C followed by stopping the 
reaction at 95°C for 30 min. To purify the DNA, the MN PCR Purification kit (Macherey-Nagel) 
with the NTB buffer was used. Briefly, 60 µl of NTB buffer were added to the sheared chromatin 
and transferred to a column to bind DNA. The centrifugation steps were performed at 11,000 xg 
for 1 min at room temperature. Membrane was washed with 700 µl NT3 buffer and then dried by 
centrifugation. The DNA was eluted with 30 µl NE buffer and 15 µl were loaded with 2.2 µl of 
6x Loading dye on a 2% agarose gel to check the fragment size that should range from 200 bp to 
1000 bp. The other 15 µl were filled up to 30 µl with MilliQ and used as Input control. 
To immunoprecipitate, 220 µl the chromatin was supplemented with 10 µg of anti-human Foxp3, 
anti-human NFAT1, anti-human p50, anti-human c-Rel, anti-human p65, anti-human MLL1, 
anti-human RbBP5, anti-human PLU-1 antibodies, or 2 µg IgG controls, 5 µl Blocker solution, 
and 5 µl PIC, respectively. The mixture was incubated at 4°C in a MACSmix Tube rotator 
(Miltenyi Biotec) overnight. Next morning, the Protein G agarose beads were washed twice with 
an equal volume of TE buffer. 30 µl of beads were added to the antibody-chromatin mixture and 
incubated for 3 hours at 4°C in a MACSmix Tube rotator. To wash the beads with the bound 
antibodies and chromatin, an appropriate number of ChIP Filtration Columns was prepared by 
removing the tap from the bottom and put in a rack to allow gravity flow-through. After addition 
of 600 µl ChIP buffer, the precipitation reaction with the beads was transferred to the columns. 
The columns were washed four times with 900 µl Wash Buffer AM1. Next, columns were 
transferred into 1.5 ml tubes and 50 µl 37°C pre-warmed Elution Buffer AM4 was loaded on 
each column and incubated for 5 min at room temperature. After centrifugation at 1250 xg for 3 
min, the elution was repeated with another 50 µl Elution Buffer AM4. The flow-through (100 µl) 
was supplemented with 2 µl Proteinase K and re-crosslinked for 30 min at 55°C followed by 2 
hours at 80°C. To clean up the precipitated DNA, 5 volumes of DNA Purification Binding buffer 
were added, adjusted with 25 mM NaAcetate, and transferred onto a DNA Purification column. 
Centrifugations were performed at 13,000 xg for 2 min. The columns were washed with 750 µl 
MATERIALS AND METHODS   60 
DNA Purification Wash Buffer, dried, and DNA was eluted in 36 µl 37°C pre-warmed Elution 
buffer. The chromatin was stored at -20°C until real-time PCR analysis was performed with 
ChIP assay real-time PCR primers (see section 2.1.8). 
2.2.12 Bisulfite DNA sequencing 
DNA methylation describes the addition of methyl groups to the carbon-5 position of cytosine 
residues of the dinucleotide CpG, and is often associated with the repression of transcriptional 
activity. Bisulfite sequencing is based on the use of bisulfite treatment of DNA to determine the 
pattern and level of methylation of specific gene loci. During bisulfite treatment unmethylated 
cytosine residues are deaminated to uracil, while methylated cytosine residues are unaffected. 
PCR amplification of regions of interest and subsequent cloning of amplicons into vectors allows 
analysis of the methylation status of these regions by sequencing. Bisulfite sequencing primers 
were designed using an online tool (Li et al. 2002a) and are listed in the section 2.1.8. 
2.2.12.1 Bisulfite conversion reaction 
After isolation of gDNA (see section 2.2.4), 0.5-1 µg gDNA was converted using the 
MethylDetectorTM Bisulfite Modification kit (Active Motif) according to manufacturer’s 
protocol. Briefly, the conversion reaction was performed in a final volume of 140 µl containing 7 
µl hydroquinone and 120 µl Conversion buffer. The reaction was initiated at 94°C for 3 min, 
followed by incubation at 50°C for 5 hours, and by a hold at 4°C. The on-column desulfonation 
was performed by mixing the conversion reaction with 500 µl DNA Binding buffer and loading 
it a DNA purification column. After spinning at 10,000 rpm for 30 sec, the column was washed 
with 200 µl DNA Wash buffer. Then, 200 µl Desulfonation buffer was added and incubated for 
20 min at room temperature. After centrifugation, the column was washed again with 200 µl 
DNA Wash buffer and dried by spinning for 2 min. The converted DNA was eluted with 52 µl 
DNA Elution buffer. The DNA was stored at -20°C until the control PCR and the PCR with the 
bisulfite sequencing primers were performed. 
2.2.12.2 PCR with bisulfite-converted DNA 
1 µl of the converted DNA was used in each PCR reaction. For positive control of the conversion 
reaction p16 outer and inner primers (Active Motif) were used. For the region-specific PCRs, 
bisulfite sequencing primers were used. The PCR amplification was performed according to 
EpiMark Hot Start Polymerase PCR in section 2.2.8.4. 5 µl of the reaction were used for control 
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agarose gel electrophoresis, the remaining 20 µl were used for agarose gel extraction of the right 
fragment size band. After isolation of the PCR product of interest, 2 µl were used for ligation 
into pCR2.1-TOPO, followed by transformation into E.coli (see section 2.2.9). 12-24 clones 
were picked for each fragment and AmpliTaq PCR was performed to control for the right insert. 
12-24 clones were send out for sequencing (Eurofins Genomics). The sequencing results were 
analyzed with the MacVector Software and the percentage of methylation of each CpG was 
calculated and displayed in a heat map format. 
2.2.13 DNA-protein binding assay 
To assess the binding ability of transcription factors to methylated and non-methylated ds 
oligonucleotides that span parts of the differentially methylated down-stream P1 promoter, 
DNA-protein binding assays were carried out. Oligonucleotides were designed by using the in 
silico-prediction tool (Farre et al. 2003; Messeguer et al. 2002). The ds oligonucleotides 
contained canonical binding sites for Foxp3, NFAT, or NF-κB. Scr oligonucleotides were 
generated using an online tool1 and then tested for absence of respective binding sites using the 
above mentioned in silico-prediction tool. Additionally, oligonucleotides located within the 
differentially methylated region of the down-stream P1 promoter were tested for binding of 
Foxp3, NFAT1, or NF-κBp50. 
2.2.13.1 Annealing and methylation of ds oligonucleotides 
Single-stranded oligonucleotides were annealed in Annealing buffer at 95°C for 10 min, 
followed by cooling down the reaction gradually to 25°C. The methylation of the ds 
oligonucleotide were performed at 37°C for 1 hour in a total volume of 50 µl by adding 1.5 µg 
ds oligonucleotide, 1x NEBuffer 2, 160 µM SAM, and 10 units of SssI methylase. The reaction 
was stopped at 65°C for 20 min. The ds oligonucleotides were purified with the Qiaquick 
Nucleotide Removal kit (Qiagen) following manufacturer’s protocol. 
2.2.13.2 Transfection and stimulation 
Jurkat cells were transfected with the Amaxa Cell Line Nucleofector kit V (Lonza) according to 
manufacturer's instructions. Briefly, 5x106 cells were resuspended in 328 µl Cell Line 
Nucleofector® solution V + 72 µl supplement and divided into 4 transfections.  
 
1
 https://www.genscript.com/ssl-bin/app/scramble 
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2.5 µg pDEST12.2-hFoxp3 expression vector was used per transfection. The appropriate 
program X-001 was selected and 1 ml 10% FCS/RPMI was added after transfection. Cells were 
transferred to a 6 well plate and incubated at 37°C overnight. For the assay with anti-NFAT1 or 
p50, 20x106 Jurkat cells were stimulated overnight with 10 ng/ml PMA and 1 µM ionomycin, 
respectively. The nuclear extracts were isolated from a total of 20x106 Jurkat cells. 
2.2.13.3 Nuclear extraction 
The nuclear extracts were isolated with the EpiQuik Nuclear Extraction Kit II (Epigentek) 
following the manufacturer’s protocol. Briefly, cells were harvested and centrifuged for 5 min at 
723 xg. The pellet was resuspended in 2 ml 1x NP1 supplemented with 1:1000 DTT and 1:1000 
PIC and incubated on ice for 10 min. After vortexing for 10 sec, they were centrifuged for 1 min 
at 13,400 xg and the cytoplasmic extract was carefully removed from nuclear pellet. The pellet 
was resuspended in 200 µl NP2 supplemented with 1:1000 DTT and 1:10 NP3. After incubation 
for 15 min on ice with iterative vortexing for 3 sec, the extract was centrifuged for 10 min at 
16,100 xg and 4°C. The supernatant was transferred into a new tube and 1:100 NP4 was added 
and incubated at room temperature for 20 min. After centrifugation for 1 min at 16,100 xg and 
4°C, the supernatant was transferred into a new tube and the protein concentration was 
measured. 
2.2.13.4 Measurement of protein concentration 
Protein concentration in nuclear extracts was determined by Bio-Rad Protein Assay kit (Bio-
Rad) based on the manufacturer’s instructions. This measurement is based on the method of 
Bradford (Bradford 1976). The Coomassie brilliant blue G-250 dye binds primarily basic 
(especially arginine) and aromatic amino acid residues. By comparing the color change of a 
sample to a standard curve a relative measurement of protein concentration is provided. Briefly, 
10 µl of the nuclear lysates were incubated with 200 µl of 1x protein assay dye reagent (freshly 
diluted 5x protein assay dye reagent concentrate) for 5 min at room temperature. The quality and 
quantity of protein were determined by analyzing the absorbance at 595 nm (A595) using a 
BioPhotometer (Eppendorf). Lysates were kept on ice or used immediately in the assay. 
2.2.13.5 DNA-protein binding 
The DNA-protein binding assay was performed with the EpiQuik DNA-protein Binding assay 
(Fluorometric, Epigentek) according to the manufacturer’s instructions with some modifications. 
MATERIALS AND METHODS   63 
Briefly, nuclear extracts were washed with 1x PF1. Then, the antibodies were diluted in PF2 to a 
final concentration of 10 µg/ml. 50 µl antibody dilution were added per well and incubated for 
1.5 hours at room temperature. Meanwhile, nuclear extracts were cleaned with a 1:10 dilution of 
NP3 and incubated on ice for 5 min. After centrifugation, the supernatant was collected. The 
antibody-solution was aspirated from the wells and the wells were washed three times with 1x 
PF1. Approximately 20 µg of cleaned nuclear extracts were then added to each well, except the 
negative control where only 1x PF1 was added. The strips were incubated for 1 hour at room 
temperature at 100 rpm. Afterwards, the extracts were aspirated and the wells were washed three 
times with 1x PF1. To test the binding ability of the methylated or non-methylated ds 
oligonucleotide, 400 ng were added in 50 µl Complete PF4 and incubated for 1 hour at 37°C. 
Next, the wells were washed five times with 1x PF1 and 100 µl PF5 Oligonucleotide Release 
solution was added. After 30 min of incubation at 55°C, the solution was transferred into a 96-
well plate (Microplate 96 well, black, Berthold technologies) and 2 µl PF6 was added. After 
additional incubation of 30 min, the fluorescence was measured in a TriStar2 LB 942 Multimode 
Plate Reader (Berthold technologies) with an extinction filter of 495 nm and an emission filter of 
520 nm. 
2.2.14 SDS-PAGE and Western blotting 
To determine MafF protein expression in different CD4 T cell subsets under different treatment, 
Western blot analysis of cell lysates with anti-human MafF antibody was performed. Cells were 
lysed at 1x106 cells/20 μl with SDS sample buffer and boiled at 95°C for 5 min or stored at -
20°C until use. Gel electrophoresis was performed using the EC120 Mini Vertical Gel System 
(E-C Apparatus corporation). 3.5 ml of a 15% Resolving gel was first poured. After 
polymerization, 1.5 – 2 ml of a 4% Stacking gel was poured The gel electrophoresis was carried 
out in SDS Running buffer. Boiled cell lysates were centrifuged at 16,000 xg for 5 min and 
loaded onto the gel. To identify the molecular weight of the bands protein molecular markers 
were included to each gel (see section 2.1.3). Cell lysates of human MafF-transfected cells were 
included to MafF detecting gels to control the specificity of the anti-MafF antibody (molecular 
weight: 18 kDa). The gel was run at a constant current for 30 min (100 V) and a constant 200 V 
for 1.5 hours. Following electrophoresis, proteins were transferred on a nitrocellulose membrane 
using the EC140 Mini Blot Module (E-C Apparatus corporation) in the SDS Transfer buffer. The 
transfer was performed at 150 mA for 1.5 hours. Afterwards, the membrane was blocked with 
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5% milk powder in SDS Blot buffer for 5 min at room temperature. Afterwards, the membrane 
was incubated with rabbit anti-human MafF antibodies (1:1000 diluted in SDS Blot buffer 
containing 5% BSA) for 1 hour at room temperature or overnight at 4°C. The membrane was 
then washed with SDS Blot buffer three times for 15 min each and incubated with peroxidase-
conjugated anti-rabbit antibody diluted 1:1000 in SDS Blot buffer containing 5% milk powder 
for 1 hour at room temperature. After three washing steps for 15 min with SDS Blot buffer, the 
membrane was incubated for 1 min with 2 ml of the ECL Western Blotting Detection reagent 
(1:1 mixture of reagent 1 and reagent 2; all from GE Healthcare) and developed 1-5 min using a 
FUJIFILM LAS-3000 (Fujifilm, Tokyo, Japan). 
2.2.15 Enzyme-linked immunosorbent assay (ELISA) 
Human Quantikine ELISA kits (R&D Systems) were used to quantify cytokine levels in the 
serum and cell culture supernatants according to the manufacturer’s protocol. First, 100 µl 
sample were applied to each well to allow the binding of cytokine molecules to plate-bound 
specific primary antibodies. After 3 hours incubation at room temperature, the plate was washed 
carefully with wash buffer to remove any remaining samples. The cytokine conjugate was 
applied to each well and incubated for 1 hour at room temperature to allow binding of the 
specific secondary antibody. The plate was washed again before adding the substrate solution. 
After 30 min in the dark, 50 µl stop solution was added and the absorption was determined at 
450 nm with a wavelength correction at 620 nm with the Tecan Spectra Microplate Reader 
(Tecan Group). 
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3 RESULTS 
3.1 Characterization of molecular mechanisms contributing to the characteristic 
phenotype of Tregs 
3.1.1 Analysis of GARP transcription 
3.1.1.1 Expression of two GARP transcript variants 
Two transcript variants transcribed from two alternative promoters are provided for the GARP 
gene by the NCBI Gene database2. Those variants differ in the 5’UTR however since the 
translation start site (ATG) is located in the second exon E2 both transcripts encode the same 
protein isoform (Figure 2A). Usage of alternative promoters with no variation in the resulting 
protein has been reported for many genes (Landry et al. 2003). Initially, I tested whether both 
transcripts account for GARP expression in human Tregs. Expression upon TCR/CD28 signaling 
was carried out by transcript-specific real-time PCR analysis on mRNA isolated from three 
healthy individuals. Both variants were expressed in freshly isolated CD25+ Tregs and none 
were detected in CD25- Tconvs (Figure 2B). Expression levels were significantly increased in 
Tregs after TCR/CD28 stimulation for 24 h and down-regulated after 48 h. Strikingly, the 
expression of the transcript variant from the P2 promoter located up-stream of P1 promoter was 
markedly higher compared to transcription from the intragenic P1 promoter. The real-time PCR 
data on the expression pattern of both transcript variants in Tregs were confirmed by 5’ RACE 
analysis on mRNA pooled from Tregs of four individuals (Figure 2C). These data indicate that 
both promoters are active in human Tregs however this results in different expression levels. 
3.1.1.2 Transcriptional activity of the alternative GARP promoters 
To analyze transcriptional activity of GARP, the non-overlapping 770 bp long up-stream P2 
promoter and the 616 bp long down-stream P1 promoter sequences were inserted in front of the 
luciferase gene into pGL4.10 vector. Treg-specific stimuli, TCR/CD28 stimulation mimicked by 
PMA and ionomycin and ectopic Foxp3, were used to measure transcriptional activity in 
luciferase reporter assays. Both promoters were responsive to Treg-specific stimuli in a similar 
fashion (Figure 3A).  
2
 http://www.ncbi.nlm.nih.gov/gene
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Figure 2 GARP transcript variants are expressed at different levels in human Tregs. (A) Schematic overview of 
the GARP gene locus with indication of two promoters (arrows), non-coding (empty boxes) and coding (black boxes) 
exons. Two differentially spliced transcript variants are indicated by dashed lines. Transcript variant 2 is initiated 
from the up-stream promoter 2 (P2) and transcript variant 1 from the down-stream promoter 1 (P1). The translation 
start site (ATG) is located in the second exon. Both transcript variants encode the same protein isoform. (B, C) Tregs 
and Tconvs were isolated from healthy individuals and stimulated with anti-CD3/CD28-beads for a total of three 
days. The GARP transcript variant 2 and 1 expression was assessed in freshly isolated (d0) and in stimulated cells at 
day one (d1), two (d2), and three (d3). (B) Results of real-time PCR analysis using TaqMan gene expression assays 
specific for each transcript variant are shown as mean ± SD of three independent donors. Relative mRNA expression 
was normalized to the expression levels of Cyclophilin A mRNA. (C) Data of 5’RACE assay on RNA pooled from 
four different donors and subsequent transcript-specific realtime-PCR are depicted as mean ± SD of triplet 
measurements. Statistical analysis was performed using Student’s T-test * p<0.05, *** p<0.001. 
In both cases, treatment with PMA/ionomycin only slightly increased the luciferase activity 
whereas ectopic Foxp3-expression was able to increase promoter activity significantly. Of note, 
the combination of Treg-specific stimuli was able to up-regulate the luciferase activity 
synergistically. In accordance with a higher abundance of transcript 2, the up-stream P2 promoter 
activity was prominently stronger than the P1 promoter activity. Next, I investigated the 
transcriptional activity of the GARP promoters in primary human T cells. It was induced from 
both promoters in response to TCR/CD28 or PMA/ionomycin stimulation only in Foxp3-
expressing Tregs and not in Tconvs confirming the Treg-specificity of both promoters (Figure 
3B). Also in primary Tregs, luciferase activity induced from up-stream P2 promoter was more 
pronounced than that from the down-stream P1 promoter. Thus, both promoters were responsive 
to the Treg-specific stimulation. The up-stream P2 promoter possessed much stronger 
transcriptional activity compared to the down-stream P1 promoter. Both promoters are 
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responsible for GARP expression in human Tregs upon activation however the stronger 
responsiveness of the up-stream P2 promoter suggests that this is the main promoter of GARP. 
 
Figure 3 Two interfering alternative promoters initiate GARP transcription in a Treg-specific manner. (A, B) 
Up-stream P2 or down-stream P1 promoter sequences were amplified and cloned into pGL4.10 vector. 
Transcriptional activity was analyzed in a luciferase assay (A) after cotransfection of EL-4 cells with a Foxp3-
encoding vector and/or treatment with PMA and ionomycin (ion.) or (B) in primary Tregs and Tconvs in response to 
stimulation with PMA/ionomycin or with anti-CD3/CD28 for one day. Means ± SD of three to six independent 
experiments are shown. (C) The full-length promoter spanning over both alternative promoters was cloned into 
pGL4.10 vector. EL-4 cells were treated with PMA and ionomycin or left untreated as a control. Comparison of the 
transcriptional activity by the three promoter sequences was carried out with luciferase reporter assays after 
cotransfection of EL-4 cells with a Foxp3-encoding vector and/or treatment with PMA and ionomycin. Means ± SD 
of six independent experiments are shown. Statistical analysis was performed using Student’s T-test * p<0.05, ** 
p<0.01, *** p<0.001, n.s. not significant. 
3.1.1.3 Transcriptional activity of the full-length GARP promoter region 
The transcriptional activity of the full-length promoter region was analyzed by inserting the 1432 
bp long region encompassing P2 and P1 promoters in front of the luciferase gene into pGL4.10 
vector. Transcriptional activity was investigated in a luciferase reporter assay in response to 
Treg-specific stimuli (Figure 3C). Again, stimulation of the full-length region with Treg-specific 
stimuli resulted in a significant increase of the promoter activity. Interestingly, the luciferase 
activity of the full-length promoter region was decidedly lower than the transcriptional activity of 
the up-stream P2 promoter and only slightly higher than that by the down-stream P1 promoter. 
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This observation indicates that the interaction of the alternative promoters leads to inhibition of 
the up-stream P1 promoter by the down-stream P2 promoter. 
3.1.1.4 DNA methylation of the GARP gene locus 
Since DNA methylation has been proposed to be involved in the regulation of alternative 
promoter usage (Cheong et al. 2006), I next analyzed the methylation status of the GARP 
promoter regions and a highly conserved CNS. The up-stream P2 promoter represents a CpG 
island with 93 CpGs, whereas the down-stream P1 promoter contains 15 individual CpGs. The 
CNS located in the first intron consists of 16 individual CpGs and was recently reported to be 
specifically hypomethylated in Tregs (Schmidl et al. 2009) (Figure 4A). Bisulfite sequencing 
revealed that the up-stream P2 promoter was completely demethylated (< 10% methylation) in all 
analyzed cell subsets of the hematopoietic system, namely T cells, B cells, monocytes, and the 
megakaryoblastic cell line MEG-01 (Figure 4B, 4C, 4D, 4E). TCR/CD28 stimulation of Tregs or 
Tconvs for 24 h did not change the P2 promoter methylation pattern (Figure 4B and 4C). In the 
epithelial cell lines, HeLa and HEK293, the CpG island of P2 promoter was found to be fully 
methylated (> 90% methylation) (Figure 4E).  
CpGs of the down-stream P1 promoter showed around 50% methylation in either freshly isolated 
or activated Tconvs (Figure 4B and 4C). In contrast, in freshly isolated or activated Tregs the 
average methylation of the P1 promoter was around 30%. Again, TCR/CD28 stimulation did not 
alter the DNA methylation of the GARP P1 promoter in the analyzed T cell subsets. The CpGs of 
the down-stream P1 promoter were methylated in monocytes up to 55% and in B cells up to 38% 
(Figure 4D). In all cell lines this region was highly methylated (> 70%) (Figure 4E). 
Additionally, the CNS region was almost completely methylated in all cells (>80 %), with the 
exception of Tregs in which the methylation level averaged 55%. In MEG-01 cells, the P1 
promoter and the CNS were highly methylated similar to the other analyzed cell lines (Figure 
4E). It appears that the downstream P1 promoter and the intronic CNS get specifically 
hypomethylated in Tregs, but not in all the other cells analyzed. In contrast, the strong up-stream 
P2 promoter undergoes demethylation and gets prepared for transcriptional initiation early in 
hematopoietic development. Given the Foxp3-dependency of both promoters (Figure 3A and 
3B), the data suggests that Treg-specificity is rather ensured by Foxp3 and not through Treg-
specific demethylation. It seems that Treg-specific demethylation of the P1 promoter is 
apparently necessary to generate a Treg-specific attenuation of the GARP expression level. In this 
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regard, Treg-specific demethylation of the intronic CNS might also play an important regulatory 
function. 
 
Figure 4 Down-stream P1 promoter and the intronic CNS undergo a Treg-specific DNA demethylation. (A) 
Schematic overview of the GARP gene locus with indication of the up-stream P2, the down-stream P1 promoter 
(arrows), and an intronic CNS (grey box) analyzed by bisulfite sequencing. Pins indicate individual CpGs. Open 
boxes represent non-coding, black boxes coding exons. (B to E) Genomic DNA from (B) freshly isolated or (C) 
activated human Tregs and Tconvs, (D) B cells and monocytes, (E) HeLa, HEK293, and MEG-01 cell lines was 
extracted and subjected to bisulfite conversion. The up- and down-stream promoter regions, as well as the CNS were 
amplified, cloned, and sequenced. Heat maps depict the aggregate methylation levels (yellow, 0% to blue, 100%) at 
each CpG from at least 12 clones from nine (B), three (C), two (D), or one (E) independent experiment(s). Statistical 
analysis was performed using Student’s T-test * p<0.05, ** p<0.01, *** p<0.001. 
3.1.1.5 Regulation of the down-stream P1 promoter by DNA methylation 
Differential intragenic DNA methylation is a common mechanism regulating the usage of 
alternative promoters embedded in gene bodies (Kulis et al. 2013). The weak GARP P1 promoter 
is located intragenically down-stream of the strong distal promoter. Binding of transcription 
factors and the transcription initiation complex to the demethylated P1 promoter might inhibit the 
elongation from the up-stream P2 promoter influencing the overall transcriptional activity of the 
full-length promoter region. To test whether DNA methylation modifies the binding of 
transcription factors to the P1 promoter, I conducted several DNA-protein binding assays. A 
number of putative binding sites for Foxp3, NFAT, or NF-κB were predicted in silico in the 
down-stream P1 promoter (Figure 5A). Several CpGs are located within transcription factor 
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binding sites. Two oligonucleotides were designed: One spanning over binding sites for NFAT 
and/or Foxp3 and a second one spanning over a binding site for NF-κB. Both oligonucleotides 
are located within the differentially methylated region of the proximal P1 promoter. The selected 
transcription factor binding sites include CpGs. The oligonucleotides were used in methylated 
and non-methylated form and their binding capacity to NFAT1, Foxp3 and the NF-κB subunit, 
p50, were compared in fluorometric DNA-protein binding assay. As controls, oligonucleotides 
with respective canonical binding sequences or the scrambled versions were used. All three 
transcription factors were found to bind to the non-methylated oligonucleotides in an extent 
comparable to the binding to the respective canonical oligonucleotides (Figure 5B). 
 
Figure 5 Methylation of CpGs in the down-stream P1 promoter prevents transcription factor binding. (A) 
Schematic presentation of the downstream P1 promoter with indication of putative transcription factor binding sites 
(boxes), CpGs (black pins) and oligonucleotide sequences used for DNA-protein binding analysis. NFAT/Foxp3 
stands for overlapping NFAT/Foxp3 binding sites capable to bind both; Foxp3 binding sites only bind Foxp3; NF-κB 
binding sites bind to various NF-κB subunits. Arrows mark the TSS. (B) The oligonucleotides were synthesized and 
methylated by SssI methylase. NFAT1, Foxp3, or p50 binding to the methylated (meth.) or non-methylated (non-
meth.) oligonucleotides was analyzed by DNA-protein binding assay in nuclear extracts of Jurkat cells. As negative 
controls, scrambled oligonucleotides (scr.) were used. For positive control, oligonucleotides encoding the respective 
canonical sequence (can.) were used. Means ± SD of one representative of two independent experiments measured in 
triplicates are shown. 
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In contrast, methylation of the oligonucleotides led to pronounced diminution of binding of all 
three transcription factors in the range of binding to the scrambled oligonucleotides. Therefore, 
DNA methylation within binding sites is able to inhibit binding of the respective transcription 
factor. 
3.1.1.6 Transcription initiated by the up- and down-stream promoter is regulated by Foxp3, 
NFAT, and NF-κB 
Since methylation was able to regulate the binding of transcription factors to the GARP promoter 
region, I investigated the molecular mechanisms underlying GARP expression. 
 
Figure 6 Foxp3, NFAT, and NF-κB binding to the demethylated up-stream P2 promoter initiates 
transcription. (A-C) Transcriptional activity of the up-stream P2 promoter cloned into the pGL4.10 vector was 
analyzed after transfection with the Foxp3-encoding vector and/or treatment with PMA and ionomycin by luciferase 
reporter assays. (A) Transcriptional activity was investigated in the presence or absence of CsA. Means ± SD of 
three independent experiments are shown. (B) Vector containing a mutated promoter variant was generated by site 
mutations of three Foxp3 binding sites (Foxp3). Transcriptional activity of the mutated promoter in comparison to 
wild-type (wt) promoter was analyzed. Means ± SD of three independent experiments are shown. (C) Transcriptional 
activity was analyzed in the presence or absence of JSH-23. Means ± SD of three independent experiments are 
shown. (D) Transcriptional activity in response to methylation was determined. The up-stream promoter sequence 
was inserted into a CpG-free luciferase vector, pCpGL. The construct was treated with different concentrations of 
SssI methylase and measured in a luciferase reporter assay. Means ± SD of three independent experiments are 
shown. Statistical analysis was performed using Student’s T-test * p<0.05, ** p<0.01, n.s. not significant. 
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Signaling pathways and transcription factors down-stream of TCR/CD28 activation were 
analyzed by transfection of EL-4 cells with the pGL4.10 vector containing the up- or down-
stream promoter sequences and treatment with the NFAT signaling inhibitor, CsA, in the 
presence of Treg-specific stimuli (PMA/ionomycin and ectopic Foxp3 expression). Additional 
treatment with CsA repressed the up-stream P2 promoter activity after PMA/ionomycin 
stimulation and ectopic Foxp3-expression (Figure 6A). Furthermore, P2 promoter activity in the 
presence of ectopic Foxp3 was almost reduced to background levels upon deletion of putative 
Foxp3 binding sites, indicating the strong Foxp3 dependency of this promoter (Figure 6B). The 
p65 activation inhibitor, JSH-23, also reduced the transcriptional activity of the up-stream P2 
promoter when the cells were stimulated with PMA/ionomycin with or without addition of 
ectopic Foxp3, respectively (Figure 6C). 
Moreover, treatment with CsA resulted in significant decrease of P1 promoter activity in the 
presence of PMA/ionomycin and ectopic Foxp3 (Figure 7A). However, CsA had no effect on P1 
promoter activity in the presence of only PMA/ionomycin or only Foxp3. These results indicate 
that NFAT signaling is involved in the regulation of P1 promoter activity. To verify that NFAT is 
necessary, four overlapping NFAT/Foxp3 binding sites were deleted in the down-stream P1 
promoter (NFAT/Foxp3, Figure 7B). The deletion led to a significant decrease of the promoter 
activity in the presence of PMA/ionomycin and Foxp3, confirming the results with CsA. 
Additional deletion of all putative Foxp3 and NFAT binding sites in the P1 promoter led to 
further, but not complete loss of activity (complete, Figure 7B). The remaining transcriptional 
activity of the completely mutated P1 promoter was inhibited by JSH-23 (Figure 7C). 
In complementary experiments, the transcriptional activity of the alternative promoters upon 
methylation was tested. Remarkably, methylation of both promoter regions abrogated 
transcriptional activity in a concentration-dependent manner (Figure 6D and 7D). Taken together, 
it seems that demethylation of both promoters enables binding of Foxp3, NFAT, and NF-κB. The 
results indicate that both promoters are regulated in a similar fashion by transcription factor 
binding which in turn initiates the transcription. 
3.1.1.7 Chromatin configuration of the GARP gene locus in Tregs 
Gene transcription is associated with the presence of permissive histone modifications, such as 
H3ac and H3K4me3, or the absence of repressive chromatin marks, such as H3K27me3, in 
promoter or enhancer regions. Since TCR signaling is frequently reported to induce changes in 
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histone modifications, I examined the chromatin configuration of the GARP gene locus in 
response to TCR/CD28 stimulation. 
 
Figure 7 Foxp3, NFAT, and NF-κB binding to the demethylated down-stream P1 promoter initiates 
transcription. (A-C) Transcriptional activity of the down-stream P1 promoter cloned into the pGL4.10 vector was 
analyzed after transfection with the Foxp3-encoding vector and/or treatment with PMA and ionomycin by luciferase 
reporter assays. (A) Transcriptional activity was investigated in the presence or absence of CsA. Means ± SD of four 
independent experiments are shown. (B) Vectors containing mutated promoter variants were generated by site 
mutations of either four overlapping NFAT/Foxp3 binding sites (NFAT/Foxp3) or of NFAT/Foxp3 binding sites 
along with only Foxp3 binding sites (complete). Activity of the mutated promoters in comparison to wild-type (wt) 
promoter was analyzed. Means ± SD of three independent experiments are shown. (C) Transcriptional activity was 
analyzed in the presence or absence of JSH-23. Means ± SD of three independent experiments are shown. (D) 
Transcriptional activity in response to methylation was determined. The down-stream promoter sequence was 
inserted into a CpG-free luciferase vector, pCpGL. The construct was treated with different concentrations of SssI 
methylase and measured in a luciferase reporter assay. Means ± SD of three independent experiments are shown. 
Statistical analysis was performed using Student’s T-test * p<0.05, ** p<0.01, *** p<0.001, n.s. not significant. 
Therefore, freshly isolated or activated Tregs and Tconvs were used in ChIP assays. Permissive 
histone modifications were enriched in the GARP promoter regions, as well as the intragenic 
CNS in Tregs upon TCR/CD28 stimulation (Figure 8). No enrichment of these modifications was 
detected in unstimulated Tregs or Tconvs. The suppressive H3K27me3 showed no enrichment at 
all gene locations in the analyzed cells, suggesting a regulation of GARP gene expression rather 
by the presence of permissive marks than by the absence of repressive marks. 
The MLL complex is involved in Foxp3-dependent changes of histone modifications and gene 
transcription by displacing the H3K4-specific demethylase PLU-1 (Katoh et al. 2011). This 
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complex catalyzes H3K4 methylation and is often associated with H3ac (Ruthenburg et al. 2007). 
Thus, enrichment of components of the MLL core complex at the GARP gene locus was analyzed 
by ChIP assay. 
  
Figure 8 GARP gene locus changes towards an open, transcriptionally active chromatin upon TCR 
stimulation in Tregs. Tregs and Tconvs were isolated and stimulated with anti-CD3/CD28 for one day. Chromatin 
was immunoprecipitated with antibodies against H3K4me3, H3ac, or H3K27me3. Presence of GARP sequences in 
immunoprecipitates was detected by real-time PCR. Results were normalized to DNA input and are depicted as 
means ± SD of five independent experiments. 
Interestingly, the H3K4-specific methyltransferase MLL1, as well as RbBP5, another member of 
the complex, showed a constant level of enrichment at all three GARP locations (Figure 9). In 
accordance with higher amounts of permissive H3K4me3 in Tregs upon activation, H3K4-
specific demethylase PLU-1 was reduced in the GARP promoter regions and the CNS after 
TCR/CD28 activation. 
The MLL1 core complex has been reported to interact with various transcription factors, such as 
Foxp3 and the NF-κB subunit, p65 (Katoh et al. 2011; Wang et al. 2012b). Since Foxp3, NFAT, 
and NF-κB are involved in GARP regulation, I decided to analyze the enrichment of these 
transcription factors in the GARP gene locus. NFAT1 and Foxp3 were increased at the GARP 
promoters and the CNS only in Tregs upon TCR/CD28 stimulation for 24 h (Figure 10). The NF-
κB subunits, p50, p65, and c-Rel were only bound to the GARP promoter regions, but not to the 
CNS in activated Tregs. In unstimulated Tregs and Tconvs the transcription factors were not 
enriched in the analyzed regions. 
In summary, the GARP gene locus is accessible for the transcriptional regulatory complex only in 
activated Tregs, but not in unstimulated Tregs, unstimulated Tconvs, or activated Tconvs. The 
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open chromatin configuration at the GARP gene locus in activated Tregs might be mediated by 
binding of Foxp3, NFAT, and NF-κB, as well as the dissociation of H3K4-specific demethylase 
PLU-1. 
 
Figure 9 H3K4-specific demethylase PLU-1 is reduced at the GARP gene locus upon TCR stimulation in 
Tregs. Tregs and Tconvs were isolated and stimulated with anti-CD3/CD28 for one day. Chromatin was 
immunoprecipitated with antibodies against the H3K4-specific methyltransferase (MLL1), a core component of the 
MLL-complex (RbBP5), and the H3K4-specific demethylase (PLU-1). Presence of GARP sequences in 
immunoprecipitates was detected by realtime-PCR. Results were normalized to DNA input and are depicted as 
means ± SD of triplet measurements of one of two independent experiments performed on cells pooled from five to 
ten individuals. 
3.1.1.8 Analysis of Treg-specific inducing factors on human and murine GARP promoter 
activity 
To determine the GARP promoter activity in iTregs, I tested several stimulatory factors that are 
reported to generate Tregs. Tregs can be induced from CD25- naïve T cells in vitro. For human 
cells, TCR/CD28 stimulation in the presence of TGF-β and retinoic acid is used. I determined the 
influence of the inducing conditions on GARP transcription by measuring the P2 and P1 promoter 
activity in the presence of Treg-specific stimuli and in the presence or absence of TGF-β or 
retinoic acid, respectively. Up-stream P2 promoter activity was not influenced by TGF-β or 
retinoic acid when stimulated only with PMA/ionomycin (Figure 11). However, under Treg-
specific simulating conditions (PMA/ionomycin and ectopic Foxp3), TGF-β or retinoic acid 
reduced promoter activity significantly. 
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Figure 10 Foxp3, NFAT1, and NF-κB are enriched at the GARP gene locus upon activation in Tregs. Tregs and 
Tconvs were isolated and stimulated with anti-CD3/CD28 for one day. Chromatin was immunoprecipitated with 
antibodies against the transcription factors NFAT1, Foxp3, and the NF-κB subunits, p50, p65, and c-Rel. Presence of 
GARP sequences in immunoprecipitates was detected by real-time PCR. Results were normalized to DNA input and 
are depicted as means ± SD of triplet measurements of one of two independent experiments performed on cells 
pooled from five to ten individuals. 
Down-stream promoter P1 activity was not influenced by TGF-β (Figure 12A). Interestingly, 
retinoic acid decreased the promoter activity in the presence of ectopic Foxp3 expression 
independently of the presence or absence of PMA/ionomycin (Figure 12B). To test whether 
GARP promoter activity is negatively regulated by RXR signaling, a putative RXR binding site 
in the P1 promoter was deleted (Figure 12C). This deletion resulted in a reduction of promoter 
activity below background levels irrespective of the stimulation. Another in silico prediction of 
this region revealed a putative Sp1 binding site, possibly explaining the marked decrease. 
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Figure 11 Up-stream P2 promoter is negatively regulated by TGF-β and retinoic acid. Up-stream P2 promoter 
sequence was amplified and cloned into pGL4.10 vector. Transcriptional activity was analyzed in a luciferase 
reporter assay. (A) Transcriptional activity was measured in the presence or absence of TGF-β. Means ± SD of three 
independent experiments are shown. (B) Transcriptional activity was measured in the presence or absence of retinoic 
acid. Means ± SD of three independent experiments are shown. Statistical analysis was performed using Student’s T-
test * p<0.05, n.s. not significant. 
Taken together, transcriptional activity of GARP is negatively influenced by TGF-β and retinoic 
acid in the presence of Treg-specific stimuli. However, these Treg-inducing factors had no 
influence on GARP transcriptional activity in the presence of PMA and ionomycin indicating that 
the widely used in vitro inducing conditions for Tregs are not sufficient to upregulate GARP 
expression. 
 
Figure 12 Down-stream P1 promoter is negatively regulated by retinoic acid. Down-stream P1 promoter 
sequence was amplified and cloned into pGL4.10 vector. Transcriptional activity was analyzed in a luciferase 
reporter assay. (A) Transcriptional activity was measured in the presence or absence of TGF-β. Means ± SD of three 
independent experiments are shown. (B) Transcriptional activity was measured in the presence or absence of retinoic 
acid. Means ± SD of three independent experiments are shown. (C) Vector containing a mutated promoter variant 
was generated by site mutation of a putative RXR binding site (RXR). Transcriptional activity of the mutated 
promoter in comparison to wild-type (wt) promoter was analyzed. Means ± SD of three independent experiments are 
shown. Statistical analysis was performed using Student’s T-test * p<0.05, ** p<0.01, n.s. not significant. 
In order to determine whether transcription of the murine Garp promoter differs from the human 
system, the murine promoter sequence was cloned into pGL4.10 vector. 
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Figure 13 Transcriptional regulation of murine Garp. Murine Garp promoter sequence was amplified and cloned 
into pGL4.10 vector. (A) Transcriptional activity was analyzed in a luciferase assay after cotransfection of EL-4 cells 
with a Foxp3-encoding vector and/or treatment with PMA and ionomycin. Means ± SD of five independent 
experiments are shown. (B) Transcriptional activity in the presence or absence of CsA was assessed. Means ± SD of 
four independent experiments are shown. (C) Transcriptional activity in the presence or absence of JSH-23 was 
assessed. Means ± SD of three independent experiments are shown. Statistical analysis was performed using 
Student’s T-test * p<0.05, ** p<0.01, n.s. not significant. 
I analyzed the transcriptional activity in luciferase reporter assays in response to Treg-specific 
stimulation. Murine Garp promoter activity was markedly upregulated by treatment with 
PMA/ionomycin (Figure 13A). Ectopic Foxp3 expression also increased promoter activity, 
although to a lower extent than PMA/ionomycin treatment. Combination of PMA/ionomycin and 
Foxp3 led to the most pronounced transcriptional activity. Similar to the human promoters, 
murine Garp promoter activity is negatively influenced by the NFAT signaling inhibitor, CsA 
(Figure 13B) and the NF-κB subunit, p65, activation inhibitor, JSH-23 (Figure 13C). 
 
Figure 14 Murine Garp promoter is negatively regulated by TGF-β and retinoic acid. Murine Garp promoter 
sequence was amplified and cloned into pGL4.10 vector. Transcriptional activity was analyzed in a luciferase 
reporter assay. (A) Transcriptional activity was measured in the presence or absence of TGF-β. Means ± SD of three 
independent experiments are shown. (B) Transcriptional activity was measured in the presence or absence of retinoic 
acid. Means ± SD of four independent experiments are shown. Statistical analysis was performed using Student’s T-
test * p<0.05, ** p<0.01, n.s. not significant. 
Murine Garp promoter regulation by Treg-inducing factors resembles that of the human 
promoters. These observations indicate certain parallels between transcriptional regulation of 
human GARP and murine Garp gene. Both inhibitors reduced the luciferase activity in the 
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presence of PMA/ionomycin alone or in combination with ectopic Foxp3 expression. When 
murine promoter activity was tested in the presence of TGF-β or retinoic acid, 
PMA/ionomycin/ectopic Foxp3-induced transcriptional activity was significantly decreased 
(Figure 14A and 14B). 
3.1.2 Analysis of MafF expression in Tconvs and MafF-mediated regulation of Foxp3 
3.1.2.1 MafF protein expression in Tconvs can be inhibited by IL-4 
Recently, down-regulation of the expression of the transcription factor MafF was associated with 
the generation of iTregs (Prots et al. 2011). In this study, microarray and real-time PCR analyses 
were performed with functionally competent iTregs generated in vitro from CD25- naïve T cells 
in the presence of autologous feeder cells and IL-4 and in effector T cells generated in the same 
system without IL-4. MafF mRNA was specifically upregulated at early developmental stages 
(day 3 to 5) in T cells activated in the absence of IL-4, whereas MafF expression seemed to be 
downregulated in Tregs induced in the presence of IL-4. To confirm these results on protein 
level, I analyzed the MafF protein expression in naïve CD25- T cells activated with anti-
CD3/CD28 in the presence and absence of exogenous IL-4. TCR/CD28 stimulated T cells in the 
presence of exogenous IL-4 showed no upregulation of MafF protein during the five days of 
culture (Figure 15A and 15B). However, T cells stimulated without exogenous IL-4 expressed 
constant levels of MafF protein during the first two days and then showed an increase on day 
three and four followed by a decrease on day five. Intracellular staining of MafF and subsequent 
flow cytometry analysis confirmed the upregulation of MafF in Tconvs stimulated without 
exogenous IL-4 on day four (Figure 15C). This data indicates that MafF might be a regulator of 
effector T cell function and can be downregulated by addition of exogenous IL-4. 
3.1.2.2 Overexpression of MafF attenuates induction of Foxp3+ Tregs 
MafF is expressed in Tconvs upon TCR/CD28 expression, whereas this transcription factor is 
rather downregulated during the induction of Tregs (Prots et al. 2011). Thus, I next analyzed the 
influence of enforced MafF expression during the in vitro generation of Tregs. MafF was 
overexpressed in iTregs generated by TCR/CD28 stimulation in the presence of TGF-β or in the 
presence of TGF-β in combination with retinoic acid (Figure 15D). 
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Figure 15 MafF expression in Tconvs is constrained by IL-4 and overexpression of MafF attenuates induction 
of Foxp3+ Tregs. (A,B,C) Naïve CD25- Tconvs were stimulated with anti-CD3/CD28 and IL-2, in the presence or 
absence of IL-4 for a total of five days. (A) Western blot of MafF and p38 expression was performed. (B) Relative 
units of densitometry from one representative experiment are displayed. (C) Intracellular staining and FACS analysis 
of MafF was performed and one representative of three independent experiments is shown. (D) Tregs were generated 
by treatment of naïve CD25- Tconvs with anti-CD3/CD28 in the presence of IL-2 and TGF-β, and in the presence or 
absence of retinoic acid for a total of 4 days. Intracellular staining of Foxp3 was performed and cells were analyzed 
by flow cytometry. Mean fluorescence intensity (MFI) from three independent experiments is depicted. 
Interestingly, MafF overexpression in Tregs resulted in significant lower Foxp3 expression levels 
during the four days of culture when compared to iTregs induced only with endogenous MafF 
levels. Foxp3 expression in iTregs overexpressing MafF was similar to T cells that where 
activated without addition of TGF-β. Taken together, these data suggests that MafF is only 
upregulated in effector T cells and negatively regulates Foxp3 induction and therefore in vitro 
generation of Tregs. However, further analyses are necessary to understand underlying molecular 
mechanisms.
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3.2 Characterization of molecular mechanisms regulating GARP expression and 
Treg function in RA 
3.2.1 Influence of DNA methylation on GARP expression in RA 
Recently, profound alterations in the Treg phenotype in RA were reported (Zhou and Haupt et al. 
2015). The surface marker and TGF-β transporter, GARP, might be implicated in these 
alterations. In this regard, I analyzed in a cooperative work with Dr. Qihui Zhou and the medical 
students, Viktoria Söntgerath and Johannes Kreuzer, GARP expression and DNA methylation in 
34 patients with RA and 37 age- and gender-matched healthy controls (HCs). All patients 
fulfilled the 2010 ACR/EULAR or the ACR 1987 classification criteria for RA (Aletaha et al. 
2010; Arnett et al. 1988). Demographic and clinical parameters were collected and recorded at 
the Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, 
Ludwig-Maximilians-Universität München and summarized in Table 1. 
Table 1 Clinical and demographic characteristics of the study population* 
 RA patients (n=34) HC (n=37) 
Age, years 60.0±12.7 51.7±8.1 
Female/male (n) 26/8 29/8 
Disease duration, years 3.4±6.5 n.a.§ 
RF positive, % 80.0 n.d.a 
Anti-CCP positive, % 68.6 n.d. 
DAS28 4.0±1.8 n.a. 
TJC28 (n) 5.3±6.4 n.a. 
SJC28 (n) 4.4±5.6 n.a. 
CRP, mg/dL 1.4±2.4 n.d. 
ESR, mm/hour 21.6±14.3 n.d. 
Erosions, % 51.5 n.a. 
*Data are shown as means ± SD or absolute numbers. 
§n.a., not applicable. 
an.d., not determined. 
Abbreviations: RA, rheumatoid arthritis; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 
disease activity score in 28 joints; TJC28, tender joint count on 28 joints; SJC28, swollen joint count on 28 joints; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. 
GARP mRNA was significantly lowered in Tregs isolated from patients with RA and activated 
for 24 or 48 h compared to activated Tregs from HCs (Figure 16A). The decreased GARP 
expression upon TCR stimulation correlated inversely with the disease activity (Figure 16B) and 
was reflected by the diminished GARP protein expression at the cell surface (Figure 16C). 
Furthermore, DNA methylation levels of the down-stream P1 promoter and the intragenic CNS 
were analyzed in 10 patients with RA and HCs, respectively. Both regions were demethylated to 
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a greater extent in RA-Tregs than in Tregs from HCs (Figure 17A). There was no difference in 
DNA methylation observed in Tconvs from RA patients and HCs. The higher degree of 
demethylation at the GARP gene locus coincided with lower GARP mRNA expression upon Treg 
activation and with higher disease activity. This observation strongly supports the hypothesis that 
transcription initiation from the down-stream P1 promoter hinders the transcription from the up-
stream P2 promoter and attenuates the overall transcriptional activity. 
 
Figure 16 GARP expression is reduced in Tregs from patients with RA and contributes to disease activity. 
(adapted from Haupt et al., 2015) Tregs were isolated from peripheral blood of patients with RA and of age- and 
gender-matched healthy controls (HCs). GARP expression was assessed at mRNA (A, B) and protein (C) levels in 
freshly isolated (d0) and in anti-CD3/CD28-stimulated Tregs at day one (d1) and day two (d2). (A) GARP mRNA 
expression was assessed by real-time PCR in Tregs from 19 RA patients and 21 HCs. Relative mRNA expression 
normalized to the expression levels of Cyclophilin A mRNA is shown. (B) Correlation between GARP mRNA 
expression on day one in Tregs and disease activity reflected by DAS28 was assessed by Spearman’s rank 
correlation coefficient. (C) Surface GARP expression was evaluated by flow cytometry. Representative staining 
histograms with indications of frequencies of GARP positive Tregs are shown in the left panel. The right panel 
summarizes results from 23 RA patients and 26 controls. Statistical analysis was performed using Student’s T-test. * 
p<0.05, ** p<0.01, *** p<0.001, n.s. not significant. 
It is possible that binding of transcription factors to the intragenic promoter further impedes 
transcriptional elongation. To prove this hypothesis, a region spanning the P1 promoter was 
methylated separately with increasing amounts of SssI methylase (Figure 17B). I analyzed the 
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activity of the full-length promoter with the partially methylated P1 region in a luciferase reporter 
assay. Indeed, the lower the methylation of the down-stream P1 promoter was, the lower was the 
transcriptional activity of the full-length GARP promoter region. 
 
Figure 17 GARP expression in Tregs is regulated by DNA methylation at the down-stream P1 promoter and 
the intragenic CNS. (A) DNA methylation of the down-stream P1 promoter and the intragenic CNS was assessed in 
10 patients with RA and 10 age- and gender-matched HCs. gDNA from Tregs and Tconvs was purified and 
subjected to bisulfite conversion. The down-stream promoter region and the CNS were amplified, cloned, and 
sequenced. Heat maps depict the aggregate methylation levels at each CpG from at least 12 clones for each 
individual patient or control. Summarized results are depicted in the graph on the right. (B) A sequence spanning the 
differentially methylated region of the down-stream P1 was released by enzymatic digestion from the pGL4.10 
vector containing the full-length GARP promoter, subjected to DNA methylation with increasing amounts of SssI 
methylase and ligated back into the origin vector. Purified ligations were used to transfect EL-4 cells. Transcriptional 
activity of the full-length promoter, containing the down-stream promoter methylated to different degrees, was 
analyzed in a luciferase reporter assay. Means ± SD of one representative of two independent experiments performed 
in triplicates are shown. (C) The demethylated CNS sequence was inserted down-stream of the full-length promoter 
sequence and in front of the luciferase gene into pGL4.10 vector. Transcriptional activity of the full-length promoter 
together with the CNS was analyzed in a luciferase reporter assay. Means ± SD of three independent experiments are 
shown. Statistical analysis was performed using Student’s T-test * p<0.05, ** p<0.01, *** p<0.001, n.s. not 
significant. 
Additionally, the CNS was inserted behind the demethylated full-length promoter construct and 
assessed in a luciferase assay. The promoter activity was markedly decreased by inserting the 
CNS behind the full-length construct (Figure 17C). These observations suggest that the 
recruitment of transcription factors and accessory proteins to the demethylated down-stream 
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promoter and the CNS attenuates the transcription from the up-stream P2 promoter specifically in 
Tregs. The methylation of the proximal P1 promoter prevents binding of the transcriptional 
machinery and therefore favors transcription from the strong up-stream P2 promoter. Hence, it 
seems as if the demethylation-induced transcriptional attenuation of GARP expression in RA 
Tregs facilitate disease activity. 
3.2.2 SNP frequencies in the GARP gene locus in patients with RA and HCs 
Several polymorphisms are associated with altered gene expression and susceptibility to RA. 
SNPs located in the GARP gene locus might influence the gene expression in Tregs of RA 
patients. Therefore, I chose nine SNP sites distributed over the GARP gene locus (Figure 18 and 
table 2). 
  
Figure 18 SNP locations in the GARP gene locus. Schematic overview of the GARP gene locus with indication of 
two promoters (arrows), non-coding (empty boxes) and coding (black boxes) exons. The translation start site (ATG) 
is located in the second exon. The analyzed SNPs one to nine are indicated by red lines. 
Table 2 Location, minor and major alleles of the analyzed GARP SNPs 
Name SNP ID Location Allele 
  (genome) (major/minor) 
SNP1 rs7122065 intergenic G/A 
SNP2 rs11236851 intergenic G/A 
SNP3 rs7342189 intergenic C/T 
SNP4 rs947998 5’UTR G/T 
SNP5 rs3814710 5’UTR G/A 
SNP6 rs6592657 intron 1 G/A 
SNP7 rs4944115 intron 1 T/G 
SNP8 rs7944357 intron 2 G/A 
SNP9 rs7944463 intron 2 T/C 
Demographic and clinical parameters of the RA patients were collected and recorded at the 
Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, 
Ludwig-Maximilians-Universität München and summarized in Table 3. 623 RA patients and 430 
HCs were included in the study and analyzed for the selected SNPs by using Taqman SNP 
genotyping assays. Allele and genotype frequencies were calculated (Table 4 and 5). 
Significantly lower frequencies of the minor allele of SNP 2 (A) and 8 (A) were found in RA 
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(Table 4). Additionally, for SNP 7 significantly higher frequencies of the minor allele (G) in RA 
were observed. These polymorphisms were located in the intergenic region and the intron 1 and 2 
of the GARP gene locus. None of the SNPs located in the 5’UTR showed significant differences 
in the allele frequencies in HCs compared to patients with RA. 
Table 3 Clinical and demographic characteristics of the study population* 
 RA patients (n=623) HC (n=430) 
Age, years 57.4±15.0 52.1±16.4 
Female/male (%) 73/27 68/32 
Disease duration, years 7.8±12.7 n.a.§ 
RF positive, % 81.0 n.d.a 
Anti-CCP positive, % 55.0 n.d. 
DAS28 n.d. n.a. 
TJC28 (n) n.d. n.a. 
SJC28 (n) n.d. n.a. 
CRP, mg/dL 2.4±3.4 n.d. 
ESR, mm/hour 27.2±25.4 n.d. 
Erosions, % 35.2 n.a. 
*Data are shown as means ± SD or absolute numbers. 
§n.a., not applicable. 
an.d., not determined. 
Abbreviations: RA, rheumatoid arthritis; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 
disease activity score in 28 joints; TJC28, tender joint count on 28 joints; SJC28, swollen joint count on 28 joints; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. 
In line with the observed differences of allele frequencies, significantly higher frequencies of the 
major (GG) and the heterozygote (GA) genotypes were found for SNP 2 in RA (Table 5). For 
SNP8 the major (GG) genotype was increased and the minor (AA) genotype was decreased. 
Additionally, for SNP 7 significantly higher frequencies of the minor (GG) and significantly 
lower frequencies of the major (TT) genotype were observed. 
Table 4 Allele counts in analyzed GARP SNPs in RA patients and HCs 
Name Allele Allele count (major/minor) and frequencies (%) P* 
 (major/minor) HC (n=430) RA (n=623)  
SNP1 G/A 542/318 (63/37) 763/485 (61//39) 0.4063 
SNP2 G/A 746/114 (87/13) 1160/98 (93/7) <0.0001 
SNP3 C/T 745/115 (87/13) 1108/150 (89/11) 0.3562 
SNP4 G/T 744/116 (87/13) 1104/152 (89/11) 0.3814 
SNP5 G/A 561/299 (66/34) 784/474 (63/37) 0.1866 
SNP6 G/A 481/379 (56/44) 715/531 (57/43) 0.5372 
SNP7 T/G 671/189 (78/22) 878/368 (70/30) 0.0001 
SNP8 G/A 595/265 (69/31) 930/316 (75/25) 0.0069 
SNP9 T/C 466/394 (54/46) 673/573 (54/46) 0.9729 
*P-values were calculated based on the individual numbers, using Fisher’s exact test. 
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Table 5 Individual numbers and frequencies of genotypes in analyzed GARP SNPs in RA patients and HCs 
Name Genotypes Genotypes AA/AB/BB§, frequencies (%) χ2* P* 
 AA/AB/BB§ HC (n=430) RA (n=623)   
SNP1 GG/GA/AA 171/200/59 
(39/47/14) 
236/291/97 
(38/47/15) 
0.8229 0.6627 
SNP2 GG/GA/AA 320/106/4    
(74/25/1) 
537/86/6   
(85/14/1) 
20.768 <0.0001 
SNP3 CC/CT/TT 320/105/5    
(74/25/1) 
484/140/5 
(77/22/1) 
1.097 0.5779 
SNP4 GG/GT/TT 319/106/5    
(74/25/1) 
482/140/6 
(77/22/1) 
0.9379 0.6257 
SNP5 GG/GA/AA 191/179/60 
(44/42/14) 
242/300/87 
(38/48/14) 
4.289 0.1172 
SNP6 GG/GA/AA 132/217/81 
(31/50/19) 
202/311/110 
(32/50/18) 
0.4496 0.7987 
SNP7 TT/TG/GG 263/145/22  
(61/34/5) 
332/214/77 
(54/34/12) 
17.017 0.0002 
SNP8 GG/GA/AA 222/151/57 
(52/35/13) 
357/216/50 
(57/35/8) 
8.353 0.0153 
SNP9 TT/TC/CC 121/224/85 
(28/52/20) 
180/313/130 
(29/50/21) 
0.3722 0.5536 
*χ2 and P-values were calculated based on the individual numbers, using Chi-square test. 
§
 AA: major allele homozygote; AB: heterozygote; BB: minor allele homozygote. 
3.2.3 Haplotype distribution in patients with RA and HCs 
Analysis of the haplotype using Haploview defined three different blocks of haplotypes that were 
distributed along the GARP gene locus and termed as block 1, 2, and 3 (Figure 19) (Barrett et al. 
2005).  Linkage disequilibrium (LD) was calculated from the estimates of haplotypic frequencies 
and very high LDs are displayed in red. Block 1 comprises SNP 1 to 5 and is mainly located in 
the intergenic region and the 5’UTR. 
Block 2 consist of SNP 6 and 7, block 3 consists of SNP 8 and 9. These blocks are located in the 
intragenic regions 1 and 2, respectively. The haplotype distributions are summarized in Table 6. 
The haplotypes AGCGA and GGTTG of block 1, GG of block 2, and GT of block 3 were 
significantly increased in RA. The haplotypes GATTG and AGCGG of block 1, GT of block 2, 
and AT of block 3 showed lower frequencies in RA. In summary, these results suggest that the 
haplotype distribution of SNPs located in the GARP gene is altered in patients with RA. 
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Figure 19 Haplotype of SNPs in the GARP gene locus. The schematic overview of the GARP gene locus with 
indication of SNP1 to 9 is shown in the upper panel. Haplotype block structure on the basis of the strength of 
pairwise LD, which is presented as a 2x2 matrix is depicted in the lower panel. Red represents very high LD, white 
indicates absence of correlation between SNPs. The numbers in the boxes also indicate the degree of LD with 100 
being the highest and 0 being the lowest. 
Table 6 Haplotype distribution in the GARP gene locus 
Haplotype Count (RA/HC) Frequency (RA/HC) Global P* P§ 
Haplotype block 1 
GGCGG 602:634/427:433 0.487/0.496 
<0.0001 
0.6701 
AGCGA 461:775/292:568 0.373/0.339 0.1165 
GATTG 94:1142/113:747 0.076/0.131 <0.0001 
AGCGG 18:1218/20:840 0.014/0.023 0.1423 
GGTTG 52:1184/0:860 0.042/0.000 <0.0001 
Haplotype block 2 
AT 524:718/368:492 0.422/0.428 
0.0001 
0.7841 
GT 352:890/303:557 0.283/0.352 0.0008 
GG 362:880/189:671 0.291/0.220 0.0002 
Haplotype block 3 
GC 559:683/391:469 0.450/0.455 
0.0020 
0.8360 
AT 305:937/262:598 0.246/0.305 0.0027 
GT 368:874/204:656 0.296/0.237 0.0028 
*Global p-values were calculated based on the individual numbers, using Chi-square test. 
§P-values were calculated based on the individual numbers, using Fisher’s exact test. 
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3.2.4 NF-κB activity and STAT1 expression and phosphorylation in Tregs from patients 
with RA 
Several miRNAs were reported to be highly expressed in Tregs and are involved in the post-
transcriptional regulation of mRNAs. 
 
Figure 20 NF-κB activity and STAT1 expression in patients with RA. (A) Tregs and Tconvs were isolated from 
eight RA patients with active disease and nine age- and gender-matched HCs. Cells were transfected with an NF-κB 
reporter luciferase vector. After anti-CD3/CD28 or PMA/ionomycin stimulation, luciferase activity was measured. 
Relative luciferase activity was normalized to untreated cells (no stimulation). (B) Expression of total STAT1 and 
phosphorylated STAT1 (pSTAT1 S727) was assessed as mean fluorescence activity (MFI). Representative stainings 
are shown in the upper panel. In the lower panel the results from eight RA patients with low disease activity, nine 
RA patients with active disease, and nine HCs are summarized. DAS28>3.2 – active disease; DAS28≤3.2 – low 
disease activity. Statistical analysis was performed using Student’s T-test *p<0.05, **p<0.01, **p<0.001. 
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I, in cooperation with Dr. Qihui Zhou, analyzed the expression and function of the Treg-specific 
miRNA-146a. The expression of miR-146a was decreased in RA patients with active disease 
(Zhou and Haupt et al. 2015). MiR-146a is involved in the regulation of the NF-κB pathway by a 
negative feedback loop (Ma et al. 2011). Therefore, the NF-κB activity was tested in eight RA 
patients with active disease (DAS28>3.2) and nine age- and gender-matched HCs (Figure 20A). 
The NF-κB reporter luciferase vector was transfected into Tregs. After TCR/CD28 or 
PMA/ionomycin stimulation, no differences in the NF-κB activity were observed. Thus, no 
correlation between the expression levels of mir-146a and NF-κB activity was observed. Since 
STAT1 is another target of miR-146a, we measured the expression and phosphorylation of 
STAT1 in Tregs from patients with RA and HCs. Interestingly, higher levels of STAT1 were 
detected in Tregs from patients with active disease, when compared to HCs or patients with low 
disease activity (Figure 20B). Given the fact that miR-146a levels in Tregs from patients with 
active disease are lowered, the STAT1 expression correlated with the levels of miR-146a. 
3.2.5 Increased expression of pro-inflammatory cytokines in Tregs from patients with RA 
In order to analyze the meaning of lower miR-146a expression in Tregs from RA patients, levels 
of the pro-inflammatory cytokines IFN-γ, TNF, and IL-17 were measured in the cell culture 
supernatants of activated Tregs from 24 patients with RA and 14 HCs (Figure 21). The Tregs 
from RA patients with active disease produced significantly higher levels of all measured 
cytokines when compared to RA patients with low disease activity or HCs. Thus, the expression 
of pro-inflammatory cytokines by Tregs correlated with higher STAT1 protein expression and 
phosphorylation and lower abundance of miR-146a. 
 
Figure 21 IFN-γ, TNF, and IL-17 expression in Tregs from patients with RA. Protein levels of IFN-γ, TNF, and 
IL-17 were measured in the cell culture supernatants of Tregs after anti-CD3/CD28 stimulation for one day (d1) by 
ELISA. Results from 16 RA patients with active disease, eight RA patients with low disease activity, and 14 age- 
and gender-matched HCs are displayed. DAS28>3.2 – active disease; DAS28≤3.2 – low disease activity. Statistical 
analysis was performed using Student’s T-test *p<0.05, **p<0.01. 
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These data indicate that changes in the expression of miR-146a might lead to alterations in the 
STAT1 expression and phosphorylation, thereby influencing the production of pro-inflammatory 
cytokines. To test this hypothesis, the STAT1 expression, phosphorylation and the cytokine 
production of Tregs were measured after transfection of the cells with either mimics or 
antagomirs of miR-146a, respectively (Figure 22). Indeed, treatment of the cells with mimics led 
to a significant decrease of STAT1 expression and phosphorylation in comparison to the control 
(scr). However, the treatment of the cells with antagomirs resulted in a significant increase of 
STAT1 expression and phosphorylation (Figure 22A). Consistently, Tregs treated with mimics 
showed lower expression of pro-inflammatory cytokines, whereas treatment with antagomirs 
resulted in significant increase (Figure 22B). Taken together, these data provide evidence for 
miR-146a-mediated changes in Tregs from patients with RA that might explain some alterations 
of the Treg phenotype. 
 
Figure 22 Effect of miR-146a on STAT1 expression and cytokine production in Tregs (adapted from Zhou 
and Haupt et al. 2015). Tregs were isolated and transfected with mimics or antagomirs of miR-146a. After anti-
CD3/28 stimulation for one day, (A) STAT1 protein expression and phosphorylation, as well as (B) cytokine 
production in the cell culture supernatants were assessed. Means ± SD of ten independent experiments are shown. 
Statistical analysis was performed using Student’s T-test *p<0.05, **p<0.01, ***p<0.001. 
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4 DISCUSSION 
4.1 DNA methylation of alternative promoters and Foxp3 regulate GARP 
expression 
4.1.1 Molecular mechanisms underlying GARP transcriptional regulation 
Phenotypic complexity of higher eukaryotes is achieved by complex gene regulation in order to 
get larger protein diversity. This protein variety is ensured by regulatory mechanisms, such as 
alternative splicing and existence of alternative promoters and TSS (Kelemen et al. 2013; 
Kornblihtt 2005). Alternative promoters have different tissue specificities, developmental 
activities, transcriptional or translational efficiencies (Landry et al. 2003). In the first part of the 
study, I analyzed transcriptional interference between two alternative GARP promoters. These 
promoters control GARP transcription in combination with the Treg-specific transcription factor, 
Foxp3, and the TCR-mediated transcription factors, NFAT and NF-κB. 
DNA methylation often regulates usage of alternative promoters. Up to 70 % of genes that are 
regulated by alternative promoter usage possess one promoter containing a CpG-island (Kimura 
et al. 2006). Surprisingly, CpG-island containing promoters are in most cases completely 
demethylated regardless of whether the gene is expressed or not. In addition, those promoters 
often possess stronger transcriptional activity acting as the major promoter of the gene (Cheong 
et al. 2006). This is in line with the result that the up-stream GARP promoter contains a CpG-
island which is completely demethylated in all analyzed cells, independently of GARP expression 
and acts as the strong major promoter. In contrast, alternative promoters with lower CpG content 
often demonstrate a correlation between tissue-specific demethylation and gene expression. 
Consistent with this, the weaker down-stream promoter of GARP contains only several CpGs that 
once methylated inhibit accessibility and transcriptional activity (Figure 5). Tissue- and cell type-
specific demethylation occurs across gene bodies, often coinciding with highly conserved 
sequences (Maunakea et al. 2010). In line with this, demethylation of the intragenic GARP 
promoter and the intragenic CNS only occurs in Tregs. Intragenic methylation is paradoxically 
often associated with enhanced elongation efficiency from the up-stream TSS. One example is 
the angiomotin like 2 (AMOTL2) gene which is involved in angiogenesis. Hypomethylation 
within the gene body of AMOTL2 is associated with reduced transcription (Movassagh et al. 
2010). In addition, the human retinoblastoma (Rb1) gene contains a weak imprinted promoter in 
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the second intron. The methylation of this promoter is associated with high levels of the main 
transcript, whereas demethylation of this promoter correlates with high expression of the 
alternative transcript and low expression of the main Rb1 transcript (Kanber et al. 2009). It has 
been proposed that the transcription initiation complex bound to the un-methylated alternative 
promoter acts like a roadblock and reduces the elongation speed from the up-stream promoter 
(Kulis et al. 2013). Here, I observed that the usage of the down-stream GARP promoter 
attenuated the transcriptional activity of the up-stream P2 promoter. Moreover, transcriptional 
activity regulated by DNA methylation of the down-stream P1 promoter region influenced the 
overall activity of the GARP promoter region.  
In addition, the Treg-specific transcription factor, Foxp3, and the TCR/CD28-mediated factors, 
NFAT and NF-κB, bind to the GARP gene locus (Figure 10). Putative binding sites were 
predicted and their close vicinity might indicate a cooperation of the transcription factors in 
GARP regulation. In this regard, inhibition of NFAT or NF-κB signaling and impaired binding of 
Foxp3 decreased GARP promoter activity (Figure 6 and 7). Genome-wide analyses of Foxp3 
targets have revealed that Foxp3 induces both activation and repression of its target genes (Gavin 
et al. 2007; Marson et al. 2007; Zheng et al. 2007). Thus, it is conceivable that the final outcome 
of the Foxp3-mediated gene regulation is strongly influenced by cofactors and multimerization. 
NFAT cooperates with Foxp3 via the C-terminal forkhead domain, whereas NF-κB was reported 
to bind to the N-terminal part (Bandukwala et al. 2011; Bettelli et al. 2005; Loizou et al. 2011; 
Wu et al. 2006). Thus, it is possible that the interaction of Foxp3 with NFAT and NF-κB is 
necessary for Treg-specific and TCR-dependent GARP expression. 
Furthermore, Foxp3, NFAT1, and NF-κB binding to GARP were accompanied by permissive 
histone modifications indicating chromatin remodeling of GARP upon TCR/CD28 stimulation 
(Figure 8). In addition, Foxp3 binding and chromatin remodeling towards an open chromatin 
configuration was accompanied by displacement of the H3K4-specific demethylase, PLU-1 
(Katoh et al. 2011). PLU-1 is a histone demethylase whose presence in chromatin leads to 
continuous demethylation of H3K4me3 (Yamane et al. 2007). Steady-state methylation of H3K4 
might be maintained on the other hand by the H3K4-specific methyltransferase, MLL1 (Katoh et 
al. 2011; Milne et al. 2002). Furthermore, the MLL1 complex was found to bind to Foxp3 and the 
NF-κB subunit, p65 (Katoh et al. 2011; Wang et al. 2012b). Binding sites for PLU-1 could be 
predicted adjacent to Foxp3 binding sites in the GARP promoter regions and the intronic CNS. 
Thus, it is possible that binding of Foxp3 to the GARP locus replaces PLU-1 from the MLL-1 
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complex which in turn leads to permissive H3K4me3. In addition, the MLL-1 complex associates 
with histone acetyltransferases which might explain the presence of H3ac marks (Zhao et al. 
2013). Indeed, upon TCR/CD28 stimulation PLU-1 binding to the GARP gene locus was 
decreased while MLL-1 and other members of the complex remained unchanged (Figure 9). 
Foxp3 expression alone is not sufficient for the regulatory activity of Tregs, since they also need 
TCR activation for their suppressive functions. Foxp3 binding to DNA and stability is promoted 
post-translationally by phosphorylation in response TCR stimulation (Chen et al. 2006; Nie et al. 
2013). Additionally, the subcellular localization of Foxp3 from a cytoplasmic to a nuclear pattern 
is regulated by TCR stimulation (Chen et al. 2006). This might provide the basis for the TCR-
mediated upregulation of GARP expression. Upon TCR stimulation of Tregs, Foxp3 gets 
phosphorylated and shuttles to the nucleus (Figure 23). Furthermore, TCR/CD28 stimulation 
promotes phosphorylation and nuclear localization of NFAT and degradation of IκB and 
translocation of NF-κB to the nucleus (Hogan et al. 2003; Schmitz et al. 2003). In Tregs, Foxp3 
replaces PLU-1 and enables the permissive H3K4me3 at both regions by the MLL1 complex. 
Then, other transcription factors activated by TCR stimulation can bind to the demethylated P2 
and P1 promoters in order to up-regulate GARP expression. The strong transcription from the up-
stream P2 promoter is attenuated by the binding of the transcriptional machinery to the down-
stream P1 promoter and the CNS region. This mechanism might be necessary for fine-tuning 
GARP expression. 
 
Figure 23 GARP expression is regulated by DNA methylation, Foxp3, NFAT and NF-κB. A proposed model by 
which DNA methylation of GARP and binding of Foxp3 regulate expression of GARP in Tregs by displacement of 
H3K4 demethylase, PLU-1, and recruitment of TCR-induced transcription factors.  
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In Tconvs, the P1 promoter is methylated and the GARP gene locus is closed, since they lack 
stable Foxp3 expression. This mechanism does not exclude other transcription factors that might 
be involved in regulating GARP expression in humans. 
GARP is implicated in anchoring TGF-β to the surface of Tregs (Stockis et al. 2009a; Tran et al. 
2009). TGF-β is a pleiotropic cytokine involved in many biological processes, such as 
proliferation, apoptosis, cell differentiation, and regulation of the immune system. It can act as a 
potent immune suppressor, however depending on the context it also displays pro-inflammatory 
properties (Mantel et al. 2011). Additionally, TGF-β is known to inhibit the cell cycle in benign 
cells, but promotes progression and metastasis in cancer cells (Inman 2011; Principe et al. 2014). 
LTBPs are secreted multidomain glycoproteins central to TGF-β regulation. GARP was recently 
described as a new LTBP that regulates TGF-β bioavailability (Wang et al. 2012a). Interestingly, 
other latent LTBPs were reported to be regulated by differential promoter usage facilitating tissue 
specificity and abundance of transcripts (Bultmann et al. 2013; Davis et al. 2014; Koski et al. 
1999). Since TGF-β has potential harmful implications and contributes to tumor progression or 
tissue fibrosis, it is conceivable that bioavailability is tightly regulated. In this regard, GARP 
expression has been linked to various cancers, such as squamous cell carcinoma, colorectal 
cancer, breast cancer, ovarian carcinoma, and prostate cancer (Bekri et al. 1997; Edwards et al. 
2003; Goode et al. 2013; Lassmann et al. 2007; Liu et al. 2006; Ollendorff et al. 1992). TGF-β 
producing Tregs could be isolated from hepatocellular carcinoma patients (Han et al. 2014). 
These cells suppressed Th cell response via membrane bound TGF-β in vitro. High surface 
expression of GARP and subsequently high membrane bound or local TGF-β concentrations 
might suppress tumor immunity through TGF-β signals, which at least partly contribute to iTreg 
generation (Chen et al. 2005; Li et al. 2007; Liu et al. 2007). In addition, presence and 
accumulation of TGF-β and/or GARP positive Tregs at tumor sites and in the circulation of 
cancer patients have been reported (Kalathil et al. 2013; Schuler et al. 2013; Schuler et al. 2012). 
In contrast, mouse Tregs that express latent TGF-β/GARP complexes on their surface are able to 
induce Th17 cells in the presence of IL-6 (Edwards et al. 2013). Thus, it is possible that 
uncontrolled TGF-β production at sites of inflammation might lead to production of pro-
inflammatory Th17 responses known as major contributors to autoimmune conditions, such as 
RA (Leipe et al. 2010; Leipe et al. 2014). Therefore, considering the versatile potential 
pathologic effects of immoderate GARP expression, tight regulation of the surface molecule 
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through the observed transcriptional attenuation by the down-stream P1 promoter on Tregs is 
essential. 
4.1.2 Effect of TGF-β on GARP expression 
No alternative promoter could be predicted for Garp in the mouse. Although murine Garp 
promoter activity was more dependent on TCR stimulation, the presence of Foxp3 was still 
necessary for induction (Figure 16). This is consistent with previous findings which show the 
necessity of Foxp3 for stable GARP expression in the mouse (Edwards et al. 2013). However, in 
this study cytokines like IL-2 and IL-4 were sufficient to induce murine GARP expression on 
Foxp3+ Tregs. This can be explained by the fact that IL-2, IL-4 and TCR/CD28 signaling share 
some pathways, such as those that activate NFAT and NF-κB. Therefore, IL-2 or IL-4 could also 
induce NFAT/NF-κB signaling in Foxp3+ Tregs, thereby mediating GARP expression. However, 
influence of these cytokines on GARP promoter activity remains to be elucidated. In contrast to 
human iTregs, in vitro and in vivo induced mouse Tregs express GARP on their surface (Edwards 
et al. 2013; Tran et al. 2009). This is in line with the finding that PMA/ionomycin stimulation in 
the presence of TGF-β is not able to increase human GARP promoter activity. However, the 
mouse Garp promoter activity was not influenced by TGF-β stimulation. Interestingly, for both 
mouse and human promoters, TGF-β rather seemed to negatively regulate transcriptional activity 
in the presence of Treg-specific stimuli. This is consistent with the observed decrease of GARP 
expression on activated human Tregs after treatment with TGF-β (Zhou et al. 2013a). In addition, 
treatment of murine or human Tregs with a TGF-β inhibitor resulted in significant higher 
expression of GARP. Furthermore, Tregs isolated from T cell conditional TGF-β knock-out mice 
expressed GARP equivalent to Tregs from wildtype mice. This confirms studies where human 
Tregs continued to express GARP after siRNA-mediated knock-down of TGF-β (Tran et al. 
2009). Inhibiting TGF-β signaling in Tregs seems to upregulate GARP expression in both human 
and mouse. This is consistent with my observations that promoter activity of both human and 
murine genes is decreased after addition of TGF-β. One possible explanation is the existence of a 
negative feedback loop, where GARP-bound TGF-β gets activated and via autocrine signaling 
down-regulates GARP expression and thereby TGF-β activation on Tregs. This tight regulation 
of GARP and TGF-β signaling might be again a mechanism to control Treg-mediated effects in 
malignant or autoimmune processes. 
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4.2 MafF expression in Tconvs and iTregs  
The small Maf family of proteins consists of three members, MafF, MafG, and MafK. They can 
form homo- and heterodimers thereby regulating activation or repression of gene transcription 
(Blank et al. 1997). One member of the family, MafF, was found to be downregulated during the 
differentiation of iTregs, whereas this transcription factor was upregulated during the 
differentiation of effector T cells (Prots et al. 2011). In this thesis, I analyzed MafF protein 
expression in effector T cells. TCR/CD28 stimulation in the presence of IL-2 was able to 
temporarily increase MafF, whereas IL-4 impedes this effect (Figure 15). Interestingly, the pro-
inflammatory cytokines IL-1β and TNF are able to induce MafF transcript and protein levels in 
myometrial cells, but the expression of the highly homologous MafG and MafK genes is not 
modulated (Massrieh et al. 2006). IL-1β and TNF have been described as pro-inflammatory 
cytokines, whereas IL-4 rather exerts anti-inflammatory effects, suggesting a specific function of 
MafF in the inflammatory response (Yoshimura et al. 2003). Pro-inflammatory Th1 or Th17 cells 
secrete IFN-γ or IL-17 thereby enhancing macrophage functions by inducing the secretion of IL-
1β and TNF (Winer et al. 2009). In contrast, IL-4 producing Th2 cells or Foxp3+ Tregs influence 
macrophage differentiation in a way that they become IL-10-secreting macrophages (Odegaard et 
al. 2007; Tiemessen et al. 2007). However, IL-6 was not able to induce MafF expression 
(Massrieh et al. 2006). One possibility is that IL-1β and TNF can upregulate MafF by using 
similar signaling pathways. MafF was shown to function as a transcriptional activator or 
repressor depending on the dimerization partner (Marini et al. 2002; Ye et al. 2006). Furthermore, 
MafF is downregulated in diverse carcinoma cell lines (Amit et al. 2007). TGF-β produced by the 
tumor seems to mediate conversion of Foxp3+ Tregs (Moo-Young et al. 2009). In line with this, 
MafF overexpression is able to negatively influence Foxp3 during induction of Tregs (Figure 15). 
Foxp3 expression is not completely inhibited by MafF overexpression, but further upregulation 
by TGF-β and retinoic acid is attenuated suggesting that MafF negatively influences generation 
of iTregs. Concerning the inhibitory effect of MafF on Foxp3 expression, there might be a 
connection between MafF downregulation and increased abundancy of Tregs in tumors. Further 
experiments are necessary to show the molecular mechanisms underlying MafF-mediated 
inhibition of Foxp3. 
Overexpression of MafF was not able to inhibit Foxp3 expression in activated Tregs completely. 
Mouse studies could only show a mild if any phenotype after the knock-out of a single member 
of the small Maf family (Motohashi et al. 2000; Onodera et al. 1999; Shavit et al. 1998). 
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However, knock-out of all three small Mafs led to embryonic lethality (Katsuoka et al. 2005). 
Therefore, it was suggested that small Mafs have partial redundant functions, but lack complete 
functional redundancy. Supporting this, the three small Mafs exhibit distinct spatial and temporal 
expression profiles (Onodera et al. 1999; Onodera et al. 2000; Shavit et al. 1998). It is 
conceivable that also in T cells small Maf proteins might share some functions. More detailed 
studies of MafF in T cells might provide further insights into regulation and function of small 
Maf proteins in the adaptive immune response. 
4.3 GARP in RA 
4.3.1 Diminished GARP expression in RA-Tregs correlates with DNA demethylation 
Increased demethylation of the down-stream P1 promoter correlated with lower GARP expression 
in Tregs from patients with RA (Figure 16 and 17). In addition, we could observe that the 
methylation status of the Treg-specific demethylated intronic CNS at least partially correlated 
with GARP expression. The binding of transcription factors to the CNS and the P1 promoter 
could be demonstrated. Therefore, the binding of transcription factors to these regions might 
hinder the elongation from the up-stream promoter region. The usage of alternative promoters, 
regulation of alternative transcripts by DNA methylation, and as a result changes in transcription 
levels or tissue-specific expression of genes have been suggested to be involved in inflammatory 
processes and autoimmune diseases (Doig et al. 2014; Guthridge et al. 2014; Le Dantec et al. 
2015; Yan et al. 2004). Therefore, aberrant use of the alternative down-stream GARP promoter 
over the main up-stream promoter may contribute to altered GARP expression on Tregs in 
autoimmune diseases. GARP is implicated in Treg expansion in response to TCR activation and 
suppressive function (Wang et al. 2009; Zhou et al. 2013b). In addition soluble GARP is able to 
exert potent immunoregulatory activity by inhibiting effector functions of naïve T cells (Hahn et 
al. 2013). In this study, the addition of soluble GARP in differentiation cultures of naïve Th cells 
resulted in upregulation of Foxp3 and decreased cytokine production. Furthermore, it facilitated 
the generation of iTregs probably through TGF-β activation. In line with this, lowered GARP 
expression on Tregs from patients with RA might contribute to decreased function of Tregs and 
diminished peripheral tolerance. In this regard, we could demonstrate that Tregs from RA 
patients are prone to a pro-inflammatory phenotype (Zhou and Haupt et al. 2015). Thus, 
administration of soluble GARP or modulation of GARP expression on RA-Tregs might be 
useful for the treatment of RA. Interestingly, in the presence of the cytokines IL-6 and IL-23, 
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GARP was also able to promote Th17 cells (Edwards et al. 2013; Hahn et al. 2013). In the 
presence of IL-2, the induction of Tregs was favored. However, in a humanized mouse model it 
could be shown that soluble GARP is able to enhance the suppressive function of Tregs thereby 
preventing graft-versus-host disease. Recently, monoclonal antibodies against GARP were 
generated that could inhibit the immunosuppressive activity of human Tregs in vivo (Cuende et 
al. 2015). In this study, inhibition of TGF-β activation by anti-GARP antibodies was able to 
abrogate the Treg-mediated suppression of graft-versus-host disease. Thus, it can be assumed that 
GARP has some therapeutic potential. The application has to be tested in autoimmune disorders, 
but the observed decrease of GARP on RA-Tregs might indicate a positive outcome. In contrast, 
inhibition of GARP function on Tregs might be beneficial in other human diseases, such as 
cancer or chronic infections. 
In addition, it has been demonstrated that T cells from RA patients display global 
hypomethylation when compared to HCs (Richardson et al. 1990). In line with this, RA-Tregs 
were hypomethylated in the down-stream P1 promoter and the CNS. Compromised Treg function 
in patients with RA has been recently associated with diminished expression of the Treg 
signature gene, CTLA-4 (Cribbs et al. 2014). DNA methylation in an NFAT binding site inhibited 
binding of NFAT2 resulting in reduced CTLA-4 transcription. These results indicate that 
epigenetic changes in Treg signature genes in RA influence their expression thereby contributing 
to diminished Treg function. 
4.3.2 SNP alleles in the GARP gene locus are associated with RA 
GARP gene polymorphisms were analyzed regarding their potential to confer susceptibility to 
RA. Several risk genes are associated with the disease. For instance, one substitution in the 
CTLA-4 gene can result in diminished CTLA-4 export to the membrane (Lee et al. 2012). 
Furthermore, a genome-wide association study identified RA risk loci, such as REL, CTLA-4, and 
BLK (Gregersen et al. 2009). The REL locus encodes the NF-κB subunit c-Rel which has some 
distinct roles in the production of IL-12 and IL-23 subunits by macrophages and DCs and Th1 
immune responses (Grumont et al. 2001; Mason et al. 2004; Mise-Omata et al. 2007). In addition, 
alternative promoter variants in the BLK gene locus were recently associated with SLE 
(Guthridge et al. 2014). A risk allele (T) of rs922483 reduced the activity of the ubiquitous, 
proximal promoter and most likely removed attenuation from the up-stream, B-cell specific 
DISCUSSION   99 
promoter. However, analysis of SNP variants in the 5’UTR of the GARP gene locus revealed that 
none of the two SNPs in the GARP promoter region is associated with RA (Table 4 and 5). 
Interestingly, I found that an associated allele (G) of rs11236851 (SNP2) is located around 7.5 kb 
up-stream of the distal P2 promoter. It is conceivable that this region might have enhancer or 
repressor functions. In silico prediction revealed a κB binding site that is deleted upon the G 
substitution. Further analysis has to be done determining the function of this region in GARP 
regulation. However, it can be speculated that binding of NF-κB to this region might have 
enhancer function. This would be in line with the observed NF-κB-mediated regulation of GARP 
(Figure 6 and 7).  
Furthermore, two intronic SNPs were associated with RA. Studies have demonstrated that 
intronic polymorphisms can affect mRNA splicing, stability, and structure, as well as protein 
folding (Hunt et al. 2009). In addition, intronic regions can enhance or repress transcription (Han 
et al. 2012; Zhang et al. 2014). Higher frequency of the minor allele G of rs4944115 (SNP7) 
deletes a binding site for the basic helix-loop-helix (bHLH) E2A immunoglobulin enhancer-
binding factor E47. E47 has been shown to bind to the Foxp3 promoter and is implicated in 
Foxp3 transcription in Tregs (Maruyama et al. 2011). In addition, increased abundancy of the 
minor allele (G) of rs7944357 (SNP8) resulted in the formation of a binding site for the bHLH 
transcription factor Dec1. Dec1 is involved in the upregulation of CD25 expression and has been 
shown to bind to E47 (Miyazaki et al. 2010). Both intronic alleles result in the formation and 
higher prevalence of CpGs in the GARP gene locus in patients with RA. Interestingly, the 
methylation of a single intronic CpG can already mediate silencing of gene expression (Zhang et 
al. 2010). Thus, it is possible that other factors involved in the regulation of GARP expression or 
higher methylation within the GARP gene locus in Tregs promote the observed decrease of 
GARP expression in RA. The abundancy of a combination of several risk alleles might 
additionally promote the diminished GARP expression in Tregs of patients with RA thereby 
influencing Treg function and phenotype. In line with this, haplotype analysis revealed several 
haplotype distributions that are associated with a higher susceptibility to RA (Figure 19 and table 
7). 
4.4 Decreased expression of miR-146a in Tregs from patients with RA 
In the last part of my thesis, contribution of miR-146a expression to alterations in the Treg 
function and phenotype was assessed in the context of RA. Several studies demonstrated that 
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disturbed expression of miRNAs could lead to complex alterations in Treg function and 
phenotype, resulting in the development of autoimmune-like conditions (Cobb et al. 2006; Liston 
et al. 2008; Zhou et al. 2008). More specific, alterations in miR-146a expression were often found 
to be associated with autoimmune diseases (Tang et al. 2009; Yang et al. 2015). Using a miRNA 
microarray, it has been shown that miR-146a levels were not altered in naïve or memory Tregs 
from patients with RA (Smigielska-Czepiel et al. 2014). We demonstrated that miR-146a is 
decreased in Tregs from RA patients with active disease (Zhou and Haupt et al. 2015). MiR-146a 
expression levels negatively correlated with the DAS28. These opposing observations might 
result from different patient cohorts used in the studies. In the microarray analysis six patients 
were included, whereas we compared miR-146a expression levels in 61 patients. In addition, 
different Treg populations were used. In line with our results, it was consistently shown that miR-
146a expression is increased in Tregs compared to Tconvs (Lu et al. 2010; Smigielska-Czepiel et 
al. 2014). Induction of this miRNA is NF-κB dependent. Interestingly, miR-146a down-regulates 
TRAF6 and IRAK1, two of the signal transducers in the NF-κB pathway, leading to a negative 
feedback loop (Taganov et al. 2006). In line with this, TRAF6 and IRAK1 expression was 
elevated in RA patients with active disease (Zhou and Haupt et al. 2015). However, analysis of 
the NF-κB activity in Tregs revealed no differences between Tregs from RA patients and HCs 
suggesting that the NF-κB pathway is irrelevant for the observed defect of Tregs in RA (Figure 
20A). 
It is reported that miR-146a deficient Tregs fail to control Th1 responses which is most likely 
mediated by unrestrained expression and activation of STAT1 (Lu et al. 2010). In line with that, 
expression and phosphorylation of STAT1 protein was increased in Tregs from patients with 
active disease (Figure 20B). Tregs from patients with low disease activity showed comparable 
levels to HCs. Tregs from miR-146a deficient mice show impaired function and produced more 
IFN-γ which in turn might facilitate pathogenic Th1 responses (Lu et al. 2010). Here, we could 
show that increased STAT1 expression and phosphorylation correlated with higher production of 
pro-inflammatory cytokines, such as IFNγ, TNF, and IL-17 (Figure 21). Mir-146a was previously 
shown to negatively regulate TLR/IL-1R signaling in macrophages by targeting TRAF6 and 
IRAK1 (Hou et al. 2009; Taganov et al. 2006). In addition, Th17 differentiation and IL-17 
production seems to be facilitated by IL-1R signaling (Chung et al. 2009; Maitra et al. 2009). 
Therefore, it is conceivable that a decrease in miR-146a in Tregs from patients with RA results in 
higher expression of IL-17 in these cells. It seems that lower miR-146a levels mediate STAT1 
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expression and phosphorylation, as well as TRAF6/IRAK1 expression in Tregs. Thus, the pro-
inflammatory phenotype of Tregs in RA patients with active disease might be promoted by 
decreased miR-146a expression. Indeed, inhibition of miR-146a in Tregs from HCs using 
antagomirs led to increased STAT1 expression and phosphorylation (Figure 22). This was 
accompanied by augmented levels of pro-inflammatory cytokines. This study confirms the results 
obtained by Tregs isolated from miR-146a-deficient mice. MiR-146a seems to positively regulate 
the suppressive capacity of Tregs by targeting STAT1, TRAF6 and IRAK1. In summary, 
diminished miR-146a expression in Tregs from patients with RA seems to contribute to their 
altered phenotype observed in the disease by promoting the production of pro-inflammatory 
cytokines. 
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